Human genetic susceptibility to tuberculosis : the investigation of candidate genes influencing interferon gamma levels and other candidate genes affecting immunological pathways by Moller, Marlo
HUMAN GENETIC SUSCEPTIBILITY TO TUBERCULOSIS: 
THE INVESTIGATION OF CANDIDATE GENES 
INFLUENCING INTERFERON GAMMA LEVELS AND OTHER 
CANDIDATE GENES AFFECTING IMMUNOLOGICAL 
PATHWAYS. 
 
Marlo Möller 
 
 
 
 
 
 
 
Dissertation presented for the degree of Doctor of Philosophy in Medical Biochemistry 
at Stellenbosch University 
 
 
 
 
 
 
 
 
 
 
Promoter: Prof Eileen Hoal 
Co-promoter: Prof Paul van Helden 
December 2007 
DECLARATION 
I, the undersigned, hereby declare that the work contained in this dissertation is my own 
original work and that I have not previously in its entirety or in part submitted it at any 
university for a degree. 
 
 
Signature:  ___________________    
 M. Möller 
 
Date:  ___________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2007 Stellenbosch University 
All rights reserved
SUMMARY 
The infectious disease tuberculosis (TB) is one of the leading causes of death 
worldwide.  The idea that infectious diseases are the most important driving force in 
natural selection and that they sustain frequent polymorphisms in the human genome 
was formally suggested by Haldane in 1949.  This hypothesis implicated the human 
genetic component in the response to infectious disease.  Today the involvement of host 
genetics in TB has been proven unequivocally and, together with environmental factors 
(e.g. nutrition and crowding) and the causative bacterium, Mycobacterium tuberculosis 
(M.tuberculosis), may influence the outcome of disease.  As is evident, TB is a complex 
disease and the implication for studying genetic susceptibility is that a number of genes 
will be involved. 
 
Interferon gamma (IFN-γ) is the major macrophage-activating cytokine during infection 
with M.tuberculosis and its role has been well established in animal models and in 
humans. This cytokine is produced by activated T helper 1 (Th1) cells.  These Th1 
responses can best deal with intracellular pathogens such as M.tuberculosis.  We 
selected twelve candidate genes based on the hypothesis that genes which regulate the 
production of IFN-γ may influence TB susceptibility.  We also selected polymorphisms 
from 27 other candidate genes, which may affect immunological pathways involved in 
TB, to investigate as susceptibility factors based on the following hypotheses: 1) 
granulomatous diseases can share susceptibility genes; 2) gene expression studies done 
by DNA-array analysis experiments may reveal TB susceptibility genes; 3) genome-
wide linkage studies in TB can determine susceptibility loci and genes in this region are 
possibly susceptibility factors; and 4) functional susceptibility polymorphisms in genes 
involved in immune-mediated diseases other than TB may contribute to susceptibility to 
TB. 
 
This research tested the association of 136 genetic polymorphisms in 39 potentially 
important genes with TB in the South African Coloured population.  Well-designed 
case-control association studies were used and we attempted to replicate these findings 
in an independent sample set using family-based case-control designs (transmission 
disequilibrium tests (TDTs)).  In addition, haplotypes and linkage disequilibrium (LD) 
in the candidate genes were also investigated. 
 
During the case-control analyses we found significant associations for 6 single 
nucleotide polymorphisms (SNPs) in the following genes: SH2 domain protein 1A, toll-
like receptor 2, class II major histocompatibility complex transactivator, interleukin 1 
receptor antagonist, runt-related transcription factor 1 and tumour necrosis factor 
superfamily, member 1B.  Discrepant results were obtained during the TDT analyses.  
The number of families available was small and for this reason we cannot conclude that 
the case-control results were spurious.  We also tested the association of haplotypes 
with TB.  Haplotypes in the interleukin 12, beta (IL12B) and toll-like receptor 4 genes 
were nominally associated with TB in both the case-control and TDT analyses.  We 
observed strong LD for the genes in the South African Coloured population.  In total 17 
novel SNPs were identified and one novel allele was found for a microsatellite in 
IL12B.   
 
This research contributes to the increasing amount of information available on genes 
involved in TB susceptibility, which in the future may help to predict high risk 
individuals. 
OPSOMMING 
Die infektiewe siekte tuberkulose (TB) is wêreldwyd een van die hoofoorsake van 
menslike sterftes.  Die idee dat hierdie siektes die belangrikste dryfveer van natuurlike 
seleksie is en dat dit die rede is waarom polimorfismes in die menslike genoom 
voortbestaan, was in 1949 formeel voorgestel deur Haldane.  Volgens hierdie hipotese 
speel die mens se genetiese samestelling ‘n rol in die reaksie op infektiewe siektes.  Die 
betrokkenheid van die gasheer se genoom in TB is onaanvegbaar en saam met 
omgewingsfaktore (bv. voeding en oorbevolking) en die veroorsakende bakterium 
Mycobacterium tuberculosis (M.tuberculosis), kan dit die uitkoms van die siekte 
beïnvloed.  Die bydrae van al hierdie faktore maak TB ‘n komplekse siekte wat 
impliseer dat verskeie gene betrokke sal wees in die bestudering van genetiese 
vatbaarheid vir TB. 
 
Interferon gamma (IFN-γ) is die hoof makrofaag-aktiverende sitokien tydens infeksie 
met M.tuberculosis en die rol daarvan in dieremodelle en in die mens is bekend.  Die 
sitokien word geproduseer deur geaktiveerde T helper 1 (Th1) selle.  Hierdie Th1 
reaksies is die beste verdedigingsmeganisme teen intrasellulêre patogene soos 
M.tuberculosis.  Ons het twaalf kandidaatgene gekies gebaseer op die hipotese dat gene 
wat IFN-γ produksie reguleer TB vatbaarheid mag beïnvloed.  Ons het ook 
polimorfismes van 27 ander kandidaatgene, wat immunologiese paaie betrokke in TB 
kan affekteer, gekies gebaseer op die volgende hipoteses: 1) granulomateuse siektes kan 
vatbaarheidsgene deel; 2) geenuitdrukkingstudies kan TB vatbaarheidsgene voorstel; 3) 
genoomwye koppelingsanalise in TB kan vatbaarheidslokusse voorstel en gene in 
hierdie areas is moontlike vatbaarheidsfaktore; en 4) funksionele polimorfismes in gene 
betrokke in ander immuun-mediërende siektes kan bydrae tot vatbaarheid vir TB. 
 
Hierdie studie het die assosiasie van 136 genetiese polimorfismes in 39 kandidaatgene 
met TB in die Suid-Afrikaanse Kleurlingbevolking getoets.  Goedbeplande pasiënt-
kontrole assosiasiestudies is gedoen en familie-gebaseerde assosiasiestudies 
(transmissie disekwilibriumtoetse (TDT)) is gebruik om die resultate van die pasiënt-
kontrole studie te dupliseer in ‘n onafhanklike groep.  Ons het ook haplotipes en 
koppelings disekwilibrium (KD) in die kandidaatgene ondersoek. 
 
Tydens die pasiënt-kontrole assosiasiestudies het ons beduidende positiewe assosiasies 
vir 6 enkel nukleotied polimorfismes (ENPs) in die volgende gene gevind: SH2 domain 
protein 1A, toll-like receptor 2, class II major histocompatibility complex 
transactivator, interleukin 1 receptor antagonist, runt-related transcription factor 1 en 
tumour necrosis factor superfamily, member 1B.  Verskillende resultate is verkry tydens 
die TDT analises.  Die aantal families wat beskikbaar was vir studie, was relatief min en 
daarom kan ons nie aflei dat die resultate van die pasiënt-kontrole assosiasiestudies vals 
was nie.  Ons het ook die assosiasie van haplotipes met TB getoets.  Haplotipes in die 
interleukin 12, beta (IL12B) en toll-like receptor 4 gene was geassosieer met TB in 
beide die pasiënt-kontrole en TDT analises.  Ons het sterk KD vir die gene in die Suid-
Afrikaanse Kleurlingbevolking waargeneem.  In totaal is 17 nuwe ENPs geïdentifiseer 
en een nuwe alleel is gevind vir ‘n mikrosatelliet in IL12B. 
 
Hierdie navorsing dra by tot die toenemende hoeveelheid inligting beskikbaar oor gene 
betrokke in TB vatbaarheid, wat in die toekoms mag help om individue met ‘n hoë 
risiko om die siekte te ontwikkel te voorspel. 
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 CHAPTER 1 
INTRODUCTION 
1 
1.1. TUBERCULOSIS 
Tuberculosis (TB) is a common infectious disease in the developing world and can be 
fatal when left untreated.  The disease most frequently affects the respiratory system, 
but it can also affect bones, joints, the central nervous system, the lymphatic system, the 
circulatory system and the genito-urinary system.  Even though TB has been studied for 
centuries, it is still responsible for more human deaths than any other single infectious 
agent. The causative bacterium in humans is Mycobacterium tuberculosis 
(M.tuberculosis) and although the development of effective antibiotics during the 
twentieth century has reduced mortality rates in developed countries [1], TB continues 
to be a major threat to the world’s population.  In developing countries, such as South 
Africa, TB has been a public health problem of long standing.   
 
 
 
 
FIGURE 1. Estimated incidence of new tuberculosis cases in 2005 [2]. 
 
Worldwide, M.tuberculosis is thought to infect one new case every second [3] and one 
third of the global population is latently infected.   Only 10% of those infected will ever 
develop the active disease [4], while 90% will remain healthy.  It is estimated that in 
2005, 1.6 million people died of TB and approximately 8.8 million new cases (Figure 1) 
developed active disease [2].  The prevalence of TB is still increasing globally, 
especially in Africa, where the incidence of the disease parallels the spread of the 
human immunodeficiency virus (HIV) [4].   
 
1.1.1. The history of TB 
TB has been a human burden throughout the history of mankind and evidence of the 
bacterium has been found in several archaeological sites, ranging from the Greek and 
Roman empires to locations in Europe and ancient Egypt [5].  The disease was probably 
described in early written accounts from many cultures [6] and was documented as 
2 
phthisis by Hippocrates.  TB had several other attention-grabbing names, such as 
consumption, white plague, king’s evil and lupus vulgaris [5] and well known victims 
of the disease include John Keats, Emily and Charlotte Brontë, Lord Byron, Eleanor 
Roosevelt and Vivian Leigh [1].  The typical symptoms of TB, such as a thin and pale 
face, became signs of beauty during the nineteenth century as the disease was 
romanticised by artists and writers [1].  Aristotle (384-322 BC) was probably the first to 
suggest that TB was contagious, stating that “one takes the disease because there is in 
the air something disease-producing” [6].  Several other individuals also postulated the 
contagiousness of the disease, such as the Florentine physician Fracastorius (1546) [6], 
the Italian anatomist Valsalva (1666-1723) [6] and the British doctor Benjamin Martin 
(1790) [7].  Others considered TB to be hereditary, since the disease was often observed 
in many members of the same family.    However, the infectious nature of the disease 
was only convincingly proven in 1865 by Jean-Antoine Villemin [7].   
 
Robert Koch made the important discovery that demystified the cause of TB in 1882, 
namely, by isolating and culturing the infectious organism [5].  This discovery diverted 
attention to the significance of the pathogen and the importance of the host was ignored 
for many years thereafter.  In 1890 Koch produced a glycerine extract of the bacterium, 
named “old tuberculin”, which he presented as a cure to the disease [1].  This 
announcement proved to be false, since tuberculin did not protect against TB, but led to 
severe inflammatory reactions in individuals with active disease [8]. However, it was 
found that tuberculin could be used to distinguish between M.tuberculosis-infected and 
uninfected animals based on their reaction when inoculated with it [1].  Clemens 
Freiherr von Pirquet further investigated tuberculin and determined that children who 
did not have active TB, but had a positive tuberculin reaction, were latently infected 
with the bacterium [7].  Old tuberculin resulted in non-specific reactions and Florence 
Seibert developed purified protein derivate (PPD) [7]. This is still widely used as a 
diagnostic test.  Koch also developed staining methods for the identification of the 
bacterium.  These techniques were improved on by Paul Ehrlich, whose detection 
method was used to develop the Ziehl-Neelsen staining method, which is still an 
important TB diagnostic tool [1]. 
 
Treatment before the advent of antibiotics was based on rest, fresh air and a healthy 
diet.  These measures were implemented at sanatoriums dedicated to the treatment of 
TB [7].  South Africa, with a climate that was proclaimed as being beneficial to TB 
patients, was therefore promoted as health resort during the nineteenth century and 
numerous sanatoria were established [6].  Several therapies were employed in these 
institutions.  This included the collapse of lungs by removing part of the ribs 
(thoracoplasty) or by collecting air in the pleural space (pneumothorax).  The goal of 
these practices was the closure of TB cavities, which would hopefully result in sputum 
sterilisation and a decrease in the contagiousness of the TB patient [7].   
 
TB was one of the first diseases for which a vaccine was developed [8].  The first 
success in immunising against the disease was achieved by Albert Calmette and Camille 
Guérin [7].  They attenuated Mycobacterium bovis (M.bovis) for use as a vaccine, which 
was named bacillus Calmette-Guérin (BCG) [1].  Unfortunately, the BCG vaccine was 
not as effective in the developing world as in the developed countries, possibly at least 
partly due to the connection between M.tuberculosis, BCG and nonpathogenic 
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mycobacteria [8].  The development of an effective vaccine is still a priority today, 
more than 85 years after the development of BCG [9]. 
 
TB mortality rates started to decline, probably due to the improvement of socio-
economic circumstances, which includes diet, of the general population.  The isolation 
of streptomycin in 1944 [7], the first antibiotic and a chemical compound effective 
against M.tuberculosis, contributed to the lore that antibiotics would assist in reducing 
TB mortality rates.  The development of other antibiotics effective against the 
bacterium, such as isoniazid and rifampicin, fuelled the belief that TB would be 
eradicated.  However, drug-resistant isolates of M.tuberculosis were observed soon after 
the introduction of antibiotics [10].  This, together with the HIV pandemic (Section 
1.1.6.), the global population increase, poverty and the failure of many TB programmes 
[1] has led to an increase in the global incidence of TB.   The resurgence of TB was 
declared a global health emergency by the World Health Organization (WHO) in 2003, 
the first disease to be classified in this manner [1]. 
 
In the past, most of the understanding of M.tuberculosis resulted from animal studies 
and clinical and descriptive epidemiologic observations.  The development of molecular 
biology techniques enhanced the understanding of the biology of the bacterium [11].  
This included the complete genomic sequence [12,13] of the H37Rv M.tuberculosis 
laboratory strain, which facilitated the discovery of unique mycobacterial 
characteristics.  Several genotyping methods used to study the molecular epidemiology 
of TB have made their appearance in the literature, such as insertion sequence 6110 
(IS6110) restriction fragment length polymorphism analysis, spoligotyping and 
mycobacterial interspersed repetitive unit typing.  New diagnostic techniques for rapid 
detection of the bacterium have also been developed, for example polymerase chain 
reaction (PCR) methods and real-time PCR techniques. 
 
1.1.2. The pathogen 
The name of the genus of the TB pathogen, Mycobacterium, meaning fungus-bacterium, 
is a reference to the mould-like pellicles which are formed when the bacteria are grown 
in liquid media [14].  Infection by several members from the M.tuberculosis complex, 
which also includes M.bovis, M.microti and M.africanum, may result in TB [14].  
M.tuberculosis (Figure 2) however, is the main TB disease-causing bacterium in 
humans [15].  The mycobacteria are not only responsible for TB, but also for leprosy, 
where the causative bacterium is M.leprae.  The secret of the survival of M.tuberculosis 
in the host probably lies in the fact that it has evolved specialised strategies to persist 
and replicate within macrophages.  It is these characteristics that distinguish pathogenic 
and non-pathogenic mycobacteria from each other [16].  Firstly, the bacterium has the 
ability to block the delivery of the phagosome to the lysosome and can thus avoid 
instant destruction [17].  Secondly, the bacilli are able to inhibit the local immune 
responses that activate macrophages [18].  The cell wall of the tubercle bacillus contains 
high levels of lipids and the microbe is therefore not easily stained by Gram staining.  
However, it is considered to be Gram-positive [14].  After staining, dyes cannot be 
readily removed with acid-alcohol, and the bacteria are therefore also named acid-fast 
bacilli [19].  In sputum, or other samples, the bacilli can occur individually or in small 
clumps [15].   
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FIGURE 2. Scanning electron micrograph of M.tuberculosis (Courtesy: CDC). 
 
1.1.3. Pathophysiology  
Infection by M.tuberculosis is a complex, multistage process progressing from the first 
encounter with the bacterium.  For this reason a multistep course of disease has to be 
imagined (Figure 3) [20].  The consequences of mycobacterial infection are determined 
by two factors, namely the virulence of the infecting strain, as well as the resistance of 
the host [21].  TB is spread through the air by droplet nuclei containing M.tuberculosis 
from the lungs of individuals with active disease [5] to the respiratory tract of 
uninfected individuals.  These particles are 1-5 µm in size and can remain in the air for 
minutes to hours after release from diseased lungs [22].  The droplet nuclei are inhaled 
and move to the alveoli where the bacteria are phagocytosed by alveolar macrophages 
and also probably by dendritic cells [23], which have the activity to destroy most 
potential infectious microbes [16].  The phagocytosis of the bacterium invokes a strong 
host cellular immune response and a cascade of events is triggered that involves 
cytokines and chemokines [5].  In some cases the bacilli are immediately destroyed.      
 
Alternatively, the bacteria will begin to replicate in the intracellular environment and 
migrate to lymph nodes in the lung through the lymphatic system [24].  In the first 2-8 
weeks after infection, cell-mediated immunity will develop [22] and conversion to 
tuberculin reactivity takes place [24].  To limit the spread and replication of the bacilli, 
granulomas are formed by activated T lymphocytes and macrophages. The centres of 
these granulomas consist of dormant bacteria.  At this stage the immune system can 
contain the infection, but if this does not occur, the infection may progress to active 
disease [22].  In these cases, the bacteria continue to replicate and disease symptoms 
will start to appear.  Common symptoms of TB include persistent coughing, fever, 
coughing of blood, night sweats, weight loss and chest pain [22]. 
 
1.1.4. Current treatment 
The production of antibiotics, such as isoniazid and streptomycin played a role in the 
considerable decrease in TB mortality rates seen during the TB chemotherapy 
revolution [1].  Before the introduction of these medicines, 50% of patients with active 
TB died within two years [25].  The main goal of treatment is to ensure the elimination 
of the bacteria from the host, while preventing transmission of the disease, drug 
resistance and death [22].  Unfortunately, long-term treatment with a combination of 
drugs is needed to cure TB.  Most treatment regimens have two phases, namely 
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FIGURE 3. M.tuberculosis enters the host through the respiratory system. Three 
outcomes are possible. (i) Immediate clearance of the bacterium by the pulmonary 
immune system, (ii) infection progress to TB, (iii) infection does not progress to disease 
because the bacteria are controlled inside granulomas. From [23]. 
 
intensive and continuation [25].  A typical intensive phase lasts for two months and 
most patients receive first-line drugs [1], such as isoniazid, rifampicin, pyrazinamide 
and ethambutol.  After two weeks of treatment, the patient is no longer considered to be 
contagious.  During the continuation phase of four months, the therapy is continued 
with isoniazid and rifampicin [25].  In cases with multidrug-resistant TB (MDR-TB), 
the treatment period is extended and second-line drugs, such as ethionamide and 
kanamycin [26], are incorporated into the regimen.  Extreme cases with MDR or 
extensively drug-resistant (XDR) infections may be treated by surgical means, which 
involves the removal of granulomas [1]. 
 
1.1.5. Drug-resistant TB 
The appearance of the first drug-resistant strains of TB was noted soon after the 
introduction of antibiotics [10].  While anti-TB drugs kill susceptible M.tuberculosis 
they also select for drug-resistant bacteria, since these bacteria are resistant to the drugs 
[26].  One of the other contributing factors to drug resistance is the exceptional length of 
treatment (Section 1.1.4) which leads to the interruption of therapy by some patients.  
Drug-resistant TB is defined as resistance to at least one first-line drug [27].  During the 
early 1990’s an increased incidence of MDR-TB was observed [5].  These are 
M.tuberculosis strains that are resistant to at least isoniazid and rifampicin [26], two of 
the most effective first-line drugs [5].  The MDR-TB strains can be transmitted and the 
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most extensive MDR-TB outbreak reported to date was in the United States [28].  
Infections with MDR-TB are more difficult and expensive to treat and the rate of 
mortality ranges from 40 to 60%, which is similar to that of patients with untreated TB 
[29].   
 
Recently a new class of MDR-TB was defined and named XDR-TB.  These isolates are 
resistant to isoniazid, rifampicin, any fluoroquinolone and at least one of three injectable 
second-line drugs (capreomycin, kanamycin, and amikacin) [30].  Treatment success in 
XDR-TB is very difficult to achieve as few active drugs, if any at all, remain to combat 
the disease. 
 
1.1.6. HIV and TB 
The worldwide resurgence of TB is linked to the HIV pandemic and almost one-third of 
the 40 million HIV infected individuals in the world are co-infected with TB [31].  
Currently, HIV infection is the major cause of progression from latent TB to active 
disease.   
 
 
FIGURE 4. Estimated HIV prevalence in new TB cases, 2005 [2]. 
 
The production of stimulatory cytokines and the decrease in CD4 cells during TB 
infection also accelerates the progression of HIV to acquired immune deficiency 
syndrome (AIDS) [32].  The highest prevalence of HIV in new TB cases is found in 
Africa (Figure 4), with more than 50% [4] of new TB cases in South Africa estimated to 
be co-infected with both organisms.  TB also differs from other opportunistic infections 
observed in HIV positive patients, since the bacterium can be transmitted to HIV 
negative patients through the air [31].      
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1.2. HOST GENETIC SUSCEPTIBILITY TO TB  
Although infection with M.tuberculosis is required, it is not sufficient to cause TB in 
most humans.  This is substantiated by the observation that only 10% of infected people 
who are immunocompetent will ever develop the active disease, while the majority of 
the population control the bacterium effectively.  The genetic make-up of the host could 
determine the outcome after infection and several studies have proven that genetic 
factors contribute to the outcome of TB (Section 1.2.1.).  Before this finding was widely 
accepted, the misconception existed that other diseases, such as cardiovascular disease, 
cancer and diabetes were influenced by genetic factors, but that death from infection 
was due to unfavourable conditions or misfortune [33].  A classical epidemiological 
study on the premature death of adoptees in Denmark suggested that the genetic 
contribution to infectious disease is greater than for cancer or cardiovascular disease 
[34].  The explanation of the genetic control of susceptibility to TB is expected to 
provide new and more effective tools for prevention and control of this problematic 
disease.  However, up to the present day this field has achieved limited success and 
some of the genes and mechanisms which determine susceptibility to TB still remain 
unidentified.   
 
TB differs from Mendelian diseases, since disease in a family does not follow a 
Mendelian pattern and is polygenic and multifactorial.  Genetic susceptibility studies in 
TB are exceptionally complicated because of the presence of two different genomes and 
the influence their interaction can have on the disease.  Although several genes have 
been identified as susceptibility genes for TB (Section 1.2.3.), it is necessary to keep in 
mind that other genes, the environment (including socio-economic conditions) and 
M.tuberculosis itself can have an influence on the disease, this being the reason that no 
single major susceptibility gene has been identified for TB [35]. 
 
1.2.1. Evidence for a genetic influence in susceptibility to M.tuberculosis 
The idea that a genetic influence is present in susceptibility or resistance to TB has long 
been established and differences in susceptibility to TB in diverse populations were 
recognised even 100 years ago [33].  Before the discovery of M.tuberculosis, it was 
observed that TB frequently occurred in several members of the same family.  This 
convinced some scholars that the disease was hereditary.  However, the discovery of the 
bacterium led to the interpretation that host genetic factors were excluded from the risk 
of contracting TB and turned attention to the importance of the pathogen, while the host 
genome was largely ignored. 
 
The role of the host genome in TB has been suggested by several observations.  The 
inhabitants of the Qu’Appelle Indian Reservation serve as a first example.  When they 
were originally exposed to TB, almost 10% of the population died of the disease per 
annum.  The high prevalence of TB in this population was, in part, a consequence of the 
lack of “natural” resistance through the exposure to tubercle bacilli for many 
generations.  After 40 years more than half of the families were eradicated, but the death 
rate had fallen to 0.2%, a decrease that could be attributed to the strong selection against 
susceptibility genes for TB [36].  This is a very plausible explanation, since it has also 
been observed that Europeans have greater resistance to TB than populations from sub-
Saharan African descent, most likely due to the longer time that European populations 
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have been in contact with the bacterium [37].  These population differences are not only 
due to social factors, since a study in a nursing home in the USA determined that 
individuals from African descent were twice as likely (compared to individuals from 
European descent) to be infected with M.tuberculosis [38].  Another observation, one of 
the oldest and arguably the most important, is the wide range of responses seen in 
individuals exposed to M.tuberculosis.  Some individuals are never infected, some are 
infected but never develop clinical disease and others are infected and present with 
active TB.  A tragic example of this variable outcome of disease was provided in 1926 
by the inadvertent immunisation of children with a virulent strain of M.tuberculosis in 
Lübeck, Germany.  The same dose of bacteria was given to 251 children.  Of these 
children, 77 died, 127 had radiological signs of disease and 47 showed no evidence of 
TB [39]. 
 
Some of the most convincing evidence that host genes are important in TB 
susceptibility was provided by classical twin studies.  Monozygous and dizygous twins 
were compared to see how often both members develop the disease (concordance, Table 
1).  It was found that monozygous twins, who are considered to be identical in their 
genetic make-up, are more likely to show concordance for the development of TB than 
dizygous twins [40-42].  This indicated that genetic factors are involved in the 
progression of the disease, since twins share a similar environment.   
 
TABLE 1. Selected twin studies of TB, adapted from Cooke et al [43]. 
Country 
Concordance in 
monozygotes (%) 
Concordance in 
dizygotes (%) 
Reference 
UK 32 25 [40] 
USA 62 18 [41] 
 
 
Mendelian susceptibility to mycobacterial infection is a rare human syndrome and 
affected individuals are exceptionally susceptible to otherwise non-pathogenic 
mycobacteria, including BCG, and Salmonella.  Numerous studies have identified the 
mutations in these cases, mostly in genes that are vital for immunity against intracellular 
pathogens in the interleukin-12/interleukin-23/interferon-γ axis [44-50].  The existence 
of these individuals implies that the normal human genome could contribute to 
susceptibility to TB and the findings suggested candidate genes to investigate in the 
general population (Chapter 4).   
 
Studies in animal models of mycobacterial infections have also found evidence that a 
genetic component is involved in susceptibility to TB.  Several animal models for TB 
exist, such as the mouse, rabbit, guinea pig, fish and non-human primates [51].  
However, mice and rabbits are most often used in studies assessing the genetic 
component of TB susceptibility.  Rabbits are relatively resistant to TB [52], but Lurie et 
al [53] used the rabbit as an animal model and developed inbred resistant and 
susceptible strains (which were subsequently lost, unfortunately).  These strains were 
infected with aerosols of human and bovine TB.  More viable bacteria were present in 
the susceptible rabbits, and this was primarily due to the bactericidal effectiveness of the 
alveolar macrophages of the resistant strain [52].  Inbred strains of mice showed 
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different patterns of susceptibility after infection with M.tuberculosis.  Resistant mice 
can control bacterial replication, reduce lung injury and survive longer, while 
susceptible mice show more severe symptoms and die prematurely [54].  The use of the 
mouse model led to the identification of the first TB susceptibility gene, discussed later 
(Section 1.2.3.2). 
 
1.2.2. Approaches and study designs used in TB host genetics  
The ideal study design for evaluating genetic susceptibility in complex diseases such as 
TB would be based on the complete resequencing of the human genome in a large 
collection of cases and controls, since this would allow genotyping of all the variation, 
rare or common, in an individual’s genome [55].  However, at this stage, applying such 
a method would be time-consuming, expensive and impractical. Given this, several 
study designs and approaches have been devised and successfully used in complex 
disease genetics (Figure 5).  These include genome-wide linkage and candidate gene 
association analyses, which have been used in the majority of genetic susceptibility 
studies in TB.  All the susceptibility genes involved in TB will not be identified by 
applying a single study design, since all study approaches have limitations.  Two broad 
strategies exist to identify genes involved in a complex disease: 1) the experimental and 
2) hypothesis-driven approaches [56].  Experimental approaches, which include linkage 
analysis and genome-wide association analysis, can identify a region containing an 
unknown potential susceptibility gene. Candidate genes can also be selected by 
hypotheses which are based on the functions of putative susceptibility genes in animals 
or humans. This approach utilises association studies and screens for mutations or 
polymorphisms in the gene of interest.  Genetic nomenclature, also used in TB host 
genetics, are defined in Table 2. 
   
 
FIGURE 5. Methods and strategies for identifying susceptibility genes.  From [39].
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TABLE 2. Genetic nomenclature.  Adapted from [57]. 
Term Definition 
Locus A specific position in DNA. 
Polymorphism 
Variations in DNA that originated during evolution as a 
result of mutations. Indicates that a locus has more than one 
form in the population. Should occur with a frequency of 
greater than 1% in the population to be classified as such. 
Allele 
Refers to a particular form occuring at a locus. In humans, 
each individual will have a maximum of two forms, since it 
is possible that their parents differed from each other at this 
locus and that the individual inherited a different form from 
each parent. 
Genotype A description of the two alleles at a given locus. 
Single nucleotide 
polymorphisms  
A variation type in DNA where a single nucleotide has more 
than one allele in a population. Coding SNPs are found in 
genes and non-coding SNPs are present in promoters, 
introns, or intergenic regions.  Synonymous SNPs will not 
result in an amino acid change in the protein, while non-
synonymous SNPs will lead to a change of the amino acid at 
that position. (SNPs) 
Microsatellite repeat 
A more complex form of variation.  Consists of short 
nucleotide sequences (di-, tri-, tetra- or pentanucleotides) that 
are repeated several times in DNA. 
Insertion/deletion 
A polymorphism that consists of insertions or deletions. 
(indel) 
Haplotype 
A section of DNA on a single chromosome where certain 
alleles of different markers tend to be inherited as a unit. 
Linkage disequilibrium The non-random association of alleles at different loci. (LD) 
Haplotype tagging SNP 
A SNP that acts as an identifying marker for other SNPs 
through LD. Using haplotype tags reduces genotyping costs 
and redundancy. 
True association 
Association with the true causal variant. Also known as 
direct association. 
Association by LD 
Association with a marker in strong LD with the causal 
locus.  Also known as indirect association. 
False positive 
association 
Association due to confounding by stratification between 
cases and controls. Also known as confounded association. 
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Polymorphisms used in genetic studies can be selected from resequencing data, single 
nucleotide polymorphism (SNP) databases (such as dbSNP [58]) or from the 
International HapMap project [59].  Resequencing of genes, made possible by the 
elucidation of the complete human genome sequence [60,61], allows the identification 
of novel polymorphisms.  These novel polymorphisms may well be involved in genetic 
susceptibility to disease in particular populations and could therefore be used in 
association studies.  The dbSNP database, started in September 1998, is a public 
repository to deposit genetic variation.  The database is available freely [58] and 
contains more than 12 million sequence variations, as well as data from the International 
HapMap project and the Human Genome Project.   
 
The HapMap project attempts to determine the common arrangement of DNA variation 
in the human genome [59].  The goal of the first phase of the study was to genotype one 
common SNP (with an allele frequency greater than 5%) every 5 kilobases in 269 DNA 
samples from 4 populations [62].  Phase 2 will extend the project by typing another 4.6 
million SNPs in the HapMap samples.  The project proved the redundancy among SNPs 
located closely together (which enabled researchers to select haplotype tagging SNPs 
which represent the common variation in a genomic region, thereby optimising 
association studies) and made it possible to extract genomic variation information 
without resequencing. 
 
1.2.2.1. Linkage studies 
Linkage studies are used to trace chromosomal regions containing putative 
susceptibility genes, either by a genome-wide scan, which ensures that all major 
genomic regions involved in disease susceptibility are identified, or by concentrating on 
a candidate region.  This provides the opportunity to find new genes and pathways that 
might not previously have been thought to contribute to the disease studied.  This 
approach can be very successful in monogenic diseases, since it allows the fine-
mapping of the gene of interest.  However, this is not the case in complex disease 
studies, where (in general) several regions containing many genes may be identified.  
Linkage studies assume that chromosomal regions segregate non-randomly with the 
disease of interest in large affected families and aim to identify these regions [39].  
Model-based linkage analysis by the logarithm of odds (lod) score method needs a 
defined model that specifies the relationship between the phenotype and factors that 
may influence its expression.  The model is provided by segregation analysis.  Model-
free linkage studies are used when little is known about the relationship between the 
phenotype and the gene, which is generally the case with complex diseases.  Once 
evidence for linkage has been found, fine genetic and physical maps are constructed to 
narrow down the interval on the chromosome and allow gene identification by candidate 
gene selection (when the function of the gene is known) or by positional cloning (when 
the function is unknown) [63].   
 
A TB linkage study focused on the chromosome 17q11-q21 candidate region.  This 
region is syntenic to mouse chromosome 11 which was previously identified as a 
susceptibility region for another intracellular disease [64].  The results showed evidence 
that the chromosome 17q11-q21 region contained TB susceptibility genes and further 
evaluation of this region suggested that four genes contributed separately to 
susceptibility [65].   
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Genome-wide scans have been employed in TB genetics.  The first of these studies in 
TB was done using sibpairs from The Gambia and South Africa [66] and identified 
chromosome 15q and Xq as containing possible susceptibility genes.  Fine-mapping of 
chromosome 15q11-13 suggested that ubiquitin protein ligase E3A (human papilloma 
virus E6-associated protein, Angelman syndrome) (UBE3A) or a nearby gene may be 
involved in TB pathogenesis [67].  A linkage study in an extended family of aboriginal 
Canadians indicated chromosome 2q35 to be involved in disease [68].  Another study in 
Brazilians, which examined TB and leprosy families, suggested three regions 
(10q26.13, 11q12.3 and 20p12.1) [69].  A recent genome scan in Moroccan families 
recognized chromosome 8q12-q13 as containing a major dominant acting TB 
susceptibility gene [70].  A fifth study, using South African and Malawian populations, 
identified areas on chromosome 6 (Cooke et al, unpublished data).  The little overlap 
between susceptibility regions observed in these studies is probably because linkage of a 
genotype for a genetic marker to infectious disease may be unique to a specific family 
or population and thus impossible to identify in other studies [71].  These studies are 
also exquisitely sensitive to the phenotype definition. 
 
1.2.2.2. Association studies 
Association studies attempt to investigate the role of polymorphisms in candidate genes 
selected on the basis of their function or location [39] in humans or animals.  These 
studies have greater power than linkage analyses and can detect genes of smaller effect 
[72].  Traditionally association studies have a population-based case-control study 
design, but family-based association studies are also used and recently whole genome 
association studies have been successfully done.  Types of population-based association 
studies are given in Table 3. 
 
Association studies can be used to examine the influence of single polymorphisms, 
multiple polymorphisms in a candidate gene or the most common SNPs representing all 
variation in the complete genome.   When choosing a candidate gene to investigate in an 
association study, the influence of the gene on the development of TB and the 
functional effects of the particular polymorphism should ideally be taken into 
consideration to increase the likelihood that only true associations will be detected.  In 
the past, polymorphisms studied were frequently genetic markers and not necessarily 
polymorphisms that had a direct effect on the function of the gene product.  Due to 
technological advancements, such as the availability of the human genome sequence, it 
is now usually possible to choose a functionally important polymorphism in the gene.  
A genetic polymorphism is more likely to affect a function if it is associated with an 
amino acid substitution in the gene product, if it results in a frameshift mutation in the 
coding area or if it affects gene transcription, RNA splicing, mRNA stability or mRNA 
translation [71].   
 
A problem with population association studies using a single polymorphism or 
candidate gene approach is that not all polymorphisms in the candidate gene are 
examined for susceptibility or resistance.  Finding no association with an allele does not 
necessarily mean that the whole candidate gene is excluded as a susceptibility gene, 
only that a specific allele is disqualified [73].  Whole genome association studies 
promise to address this issue.  Association of an allele with TB is only a statistical 
finding and is not automatically a reflection of genetic linkage, since the associated 
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allele may be in linkage disequilibrium (LD) with the true susceptibility allele nearby, 
or can be a false positive.     
 
TABLE 3. Types of population association studies.  Adapted from [74]. 
Association study type Description 
Candidate 
polymorphism 
Individual polymorphisms that are likely to be involved in 
disease are investigated. 
Candidate gene 
Several polymorphisms (usually in the putative promoter, 
coding exons and possible splice sites) in a candidate gene 
are typed.  The gene is selected from a linkage study or on 
the basis of its homology with a gene of known function in 
a model organism. 
Haplotype tag SNPs 
A small subset of the SNPs which are sufficient to capture 
the full haplotype information of a gene (“tag” the gene) 
are genotyped.  This reduces genotyping costs. 
Fine mapping 
A study done in a candidate region, identified by a linkage 
study, genome-wide association study or admixture 
mapping.  This region may contain many genes. 
Genome-wide 
Thousands of common SNPs are genotyped throughout the 
whole genome to identify variants in LD with the causal 
variant.  In Europeans, 300 000 SNPs should be sufficient 
to cover the whole genome, while more SNPs would have 
to be genotyped in African populations.   
 
 
Another factor to consider when doing association studies is that multiple comparison 
testing may result in false positives, since random statistical fluctuations can occur [75].  
There are various ways to correct for multiple testing [76-80], but none have been 
deemed to be completely satisfactory (Sections 3.11.2 and 3.11.4) [75].   
 
a) Population-based case-control studies for polymorphisms and candidate genes 
In our case-control studies, allele frequencies of polymorphisms in candidate genes for 
TB susceptibility are compared in unrelated individuals with the disease, and healthy 
controls without TB.  In other words these studies identify an association between a 
particular polymorphism in a gene and the disease.  This study design is the most 
commonly used approach in association studies, since large study groups can be 
collected without the need to recruit the family members of the participants.  A well-
designed case-control study should have the cases and controls matched as closely as 
possible in terms of age, gender, ethnicity and geographical location i.e. they should 
ideally have an equal chance of contracting the disease. 
Usually allele frequencies are considered as a first approach in the analysis of case-
control studies.  There will be twice as many alleles as participants, since each 
individual has two alleles at any autosomal locus.  For this analysis to be valid, the cases 
and controls combined should be in Hardy-Weinberg equilibrium (HWE, section 
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3.11.1.).  However, the allelic analysis is questionable when interpreting the relative risk 
of a disease.  For this reason, genotypes are considered in the second analysis and this 
approach is preferred whenever possible.  It allows the comparison of individuals who 
do not carry a certain marker allele (AA) with individuals who carry a single copy of the 
gene (AB) and with those who are homozygous for the marker allele (BB).  HWE is 
only checked in the controls and the test provides the chance to test dominant or 
recessive allele effects [39].  
 
Like all study designs, the case-control study design has some disadvantages.  Many 
studies have reported positive associations that could not be replicated in other studies.  
In some cases the original study reported a false positive, but in other cases replication 
studies were underpowered to detect the original association [75].  Technical problems, 
such as methods used or genotyping cases and controls separately or on different days 
could also lead to false positive associations.  The biggest concern in case-control 
studies however is population stratification.  Bias may arise in these studies when there 
is admixture in the study population or when multiple subgroups that differ in disease 
prevalence are present in a sample set.  This may lead to overrepresentation of one or 
more of these groups in the diseased cases of the association study.  In this situation, a 
genetic marker with different allele frequencies in the various subgroups may show a 
false positive association with the disease [55].  However, there are methods available 
to correct for population stratification [81]. 
 
b) Family-based studies for polymorphisms and candidate genes 
The problem of population stratification in association studies is addressed by the use of 
a family-based study design.  This was the reason for the development of the 
transmission disequilibrium test (TDT) [82].  It was first used to control for population 
stratification while testing for linkage in the presence of association between a marker 
and a disease susceptibility locus.  The TDT essentially evaluates if a marker allele is 
transmitted from heterozygous parents to their affected children more often than 
expected, in other words the number of parents who transmit the marker to an affected 
child is compared with the number of parents who transmit the other allele.  This means 
that the transmission deviates from 50%, the expected Mendelian frequency when there 
is no linkage [83].   
 
Although the TDT was introduced to test for linkage in the presence of association, it 
can also be used to test for association in the presence of linkage, but only if the data 
consists of nuclear families with one affected child [84].  The TDT has been extended to 
accommodate several study designs.  These include the S-TDT (used when the 
genotypes from both parents are unavailable) [85], the 1-TDT (used when only one 
parent is available) [86] and a robust TDT that can handle incomplete genotypes for 
both parents and children without making assumptions about missing data [87].  
Acquiring sample sets for these tests can be difficult and time-consuming, because 
DNA samples from the parents and the affected children are needed.  This can be a 
problem if the parents are deceased, which is likely if the disease is late-onset [71].    
 
The TDT is often used as a second study approach to test for association with a disease, 
as all association findings need to be replicated in another population or sample set.  
Association of an allele with TB is only a statistical finding and is not necessarily a 
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reflection of genetic linkage, but as stated above, the TDT can be used to test for 
linkage.  For a TDT to have the same power as a case-control study, the number of 
families investigated should be equal to that of the unrelated cases [88].  A TDT is also 
more susceptible to technical errors than a case-control study [55]. 
 
c) Genome-wide association studies 
Genome-wide association (GWA) studies allow the genotyping of the most frequent 
genetic polymorphisms in the genome without making assumptions about the genomic 
location of the causal variants.  Since most of the genome is surveyed, it eliminates the 
disadvantages of the single polymorphism or candidate gene approach where only a few 
polymorphisms are investigated [55].  The completion of the human genome sequence, 
the deposition of SNPs into public databases, the rapid improvements in SNP 
genotyping methods (such as the development of microarray platforms) and the 
International HapMap Project have allowed the genetic association field to progress to 
this study design.  Previous studies [89-91] and the International HapMap project have 
shown that most common variation in the genome can be represented by approximately 
300 000 SNPs [74] in white populations.  African and other populations with greater 
variation and less LD will need more SNPs [55] to ensure coverage of the entire 
genome. 
 
GWA studies have the potential to identify many false associations and therefore 
replication in independent populations is essential [57].  However, these studies are very 
expensive.  In addition, the best approach to adjust for multiple comparisons in these 
studies has not been determined.  The proposed strategies to eliminate false-positive 
results are to use a two-step study design and to adopt strict rules for declaring 
significant associations.  A few individuals are genotyped genome-wide in the first 
stage of the study.  In the second stage, promising SNPs are genotyped in the remainder 
of the study population [74].  In cases where a significant association is determined, the 
results are verified in another population, preferably using another genotyping method 
to exclude technical artefacts [92].  These studies need a large sample size to ensure 
adequate power. 
 
Smaller scale GWA study designs involving extensive marker coverage have been 
employed in other complex diseases.  A study in Crohn’s disease tested 19 799 coding 
SNPs in 735 cases and 368 controls.  In the subsequent analysis, markers with p ≤ 0.01 
in the first analysis were evaluated in 380 Crohn’s disease family trios, 498 single cases 
and 1032 unrelated controls.  This study identified one novel association and three 
previously reported susceptibility variants for Crohn’s disease.  The novel finding was 
replicated in samples from the UK using another genotyping method [92].  Similar 
studies were done in myocardial infarction [89,93-95] and age-related macular 
degeneration [96].  A bigger GWA study in inflammatory bowel disease was done using 
more than 300 000 SNPs on the Illumina HumanHap300 Genotyping BeadChip and 
identified the interleukin-23 receptor gene as a susceptibility factor [97].  There are 
currently no reported GWA studies in TB or other infectious diseases, but such studies 
will probably be done in the future.  The Wellcome Trust Case-Control Consortium has 
initiated a study that will consider up to 2000 cases and 3000 controls for eight complex 
diseases such as TB and malaria using a GWA study design [57].   
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1.2.2.3. Haplotypes 
A haplotype is a section of DNA sequence on a single chromosome where certain 
alleles of different markers tend to be inherited as a unit.  Therefore, an individual’s 
genotypes at several strongly linked SNPs contribute to two haplotypes, each consisting 
of alleles from one parent [74].  If a susceptibility haplotype can be identified in a group 
of individuals with a disease, such as TB, typing alleles within the haplotype allows the 
identification of a conserved region, which may pinpoint the polymorphism contributing 
to the disease.   Haplotypes are mostly inferred by the use of statistical methods, such as 
Phase [98,99], Fastphase [100] and Cocaphase [101], since laboratory-based 
haplotyping or typing of family members to determine the unknown phase is expensive.  
However, true haplotypes are more informative than inferred haplotypes [74] and 
statistical methods can result in incorrect haplotype classification [102]. 
 
 
 
 
FIGURE 6. Illustration of LD blocks, recombination hotspots, haplotypes and haplotype 
tagging SNPs.  Four haplotypes, consisting  of 10 SNPs, are present in the LD block in 
the middle.  Since LD is present, coloured SNPs can predict the alleles present at other 
loci in the same colour.  Genotyping only one SNP from each colour will give 
information about all the other SNPs in that colour.  This means that the haplotype 
diversity of this block is depicted by four haplotype tagging SNPs.  Adapted from [75]. 
 
The diversity of haplotypes in the human genome is low and can lead to considerable 
associations of SNPs with neighbouring variants.  Therefore the genome can be divided 
into distinct blocks separated by recombination hotspots (Figure 6) [89,91,103].  This 
observation led to the generation of a haplotype map (HapMap) [62] of the human 
genome which offers the potential to extract extensive information without 
resequencing and allows the selection of haplotype tagging SNPs to optimise 
association studies, since redundant SNPs are excluded from genotyping.  However, 
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haplotype block structure can differ significantly between populations [91,104-107] if 
the block structure resulted due to selection, bottlenecks or admixture in the population 
history [91,108,109].  Consequently, when using information from the HapMap, it is 
important to determine that the data is applicable to the study population [110]. 
 
1.2.2.4. Linkage disequilibrium 
LD can determine disease susceptibility, reveal the history of human populations and 
supply the tools for understanding fundamental biological processes [110].  LD is the 
non-random statistical association of sequence variants at different positions along the 
chromosome as it occurs in gametes.  The fact that DNA mutations occur sporadically 
leads to linkage of SNPs along the chromosome.  This means that the presence of one 
allele at a certain SNP can give information about the presence of alleles at other 
variants [62].  LD can complicate association studies, because an apparently disease-
associated SNP may actually be in LD with the true disease-causing SNP (indirect 
association, table 2).  Therefore it is important to consider haplotypes (Section 1.2.2.3.) 
when investigating association with disease [111].  However, LD can also aid in the 
discovery of susceptibility variants, since the effect can be detected by genotyping 
SNPs.  This has been exploited in the HapMap and can assist in the selection of 
polymorphisms. 
 
LD between genetic markers can be used to identify functional genetic variants that 
influence human diseases. Several measures of LD exist, but Lewontin’s standardised 
disequilibrium coefficient D’ [112] and the square of the correlation coefficient between 
two loci, r
2
 [111,113], are the two most important.  The D’ value ranges from 0 to 1, 
where 0 indicates no LD and 1 indicates complete LD [113].  For example, consider two 
alleles at each of two loci, with A1 and A2 at locus A and B1 and B2 at locus B.  If only 
two out of four possible haplotypes are found in the population (A1B1 and A2B2), then 
these loci are in complete LD and D’ = 1 [111].  D’ is useful to assess the probability of 
historical recombination [114].  A disadvantage of D’ is that the estimate of this value is 
highly inflated in small samples [113]. This means that the value can indicate high LD, 
especially when one allele is very rare, even when the markers are in linkage 
equilibrium [113].  The r
2
-value reflects the statistical power to detect LD and is 
correlated to the D’ value.  In other words a low r
2
 will mean that a large sample size, n, 
is required to detect LD between the markers.  Thus, r
2
 = 1 when two SNPs evolved 
together and remained associated during recombination [62], in other words when only 
two haplotypes are present [115].  Since intermediate values of r
2
 can be easily 
interpreted [113] and r
2
 takes allele frequency differences into account [113], this value 
is more useful in association studies [114].  For example, assume two nearby loci where 
one is functionally associated with disease, while the other is a marker in LD with the 
susceptibility locus.  In order to have the same power to detect the association between 
the marker and disease, the sample size has to be increased by 1/r
2
 in comparison with 
the sample size needed to detect association with the true disease-causing locus [113]. 
 
1.2.3. Previous genetic susceptibility studies done in TB 
Several susceptibility genes for TB have been identified (Table 4), but some were not 
associated with every population examined (Table 5) or could not be replicated at all 
(Section 1.2.3.4.).  This emphasizes the complexities of characterising host 
18 
susceptibility in different ethnic populations living in diverse environments [113].  Even 
so, certain genes have consistently been associated with TB in diverse populations 
(Section 1.2.3.1).  From the susceptibility genes identified thus far, it seems that each 
gene makes a small contribution to the development of the disease, which can be 
expected since TB is a complex disease [113].  A few of the candidate genes previously 
investigated in a number of TB genetic susceptibility studies are discussed in sections 
1.2.3.1.-1.2.3.4.   
 
1.2.3.1. Human leukocyte antigen genes 
The human leukocyte antigen (HLA) region consists of approximately 200 genes, many 
of which are involved in antigen presentation.  Genes that are involved in protective 
immunity show greater variance than other genes [116].  This is also the case for the 
HLA region, which varies between populations and is highly polymorphic.  This is 
thought to be the effect of different selection pressures, such as infectious disease [117].  
The HLA class I and class II genes are involved in antigen presentation to T cells and 
each protein binds a different range of peptides [118].  There are three class I a-chain 
genes in humans, namely HLA-A, -B, and -C. There are four subclasses of genes in the 
HLA class II region, named HLA-DR, -DP, -DM and –DQ respectively. These sets of 
genes can give rise to four types of HLA class II molecules.  Genes in the HLA class III 
region encode, amongst others, heat shock proteins, complement proteins, tumour 
necrosis factor-α (TNF-α) and TNF-β [118].  HLA genes have been examined in several 
TB susceptibility studies (Tables 4 and 5) and were some of the first genes to be 
associated with the disease.  The HLA-DR subtypes, in particular, were consistently 
associated with TB and other mycobacterial diseases.   
 
1.2.3.2. Natural resistance associated macrophage protein 1 
The natural resistance associated macrophage protein 1 (NRAMP1, renamed solute 
carrier family 11A member 1 (SLC11A1)) was the first susceptibility gene to be 
identified from a mouse model of mycobacterial disease.  Resistance to several 
intracellular mycobacteria, including M.bovis (BCG) and M.lepraemurium [39], in 
inbred strains of mice is controlled by a single dominant gene, which was designated 
Bcg [119].  This gene, Nramp1, was isolated from the mouse genome by positional 
cloning and it was determined that a non-synonymous nucleotide substitution in codon 
169 led to an amino acid change (glycine to aspartic acid) which caused susceptibility to 
mycobacteria in mice [119,120].  Additional proof of the effect of Nramp1 was acquired 
when an Nramp1 knockout mouse strain and a mouse strain with the non-synonymous 
nucleotide substitution had identical phenotypes [121].  Nramp1 does not seem to affect 
susceptibility to M.tuberculosis in mice [122].  The human homologue of this candidate 
gene, derived from the mouse model, was named NRAMP1 and mapped to chromosome 
2q35 [123].  The protein product of NRAMP1 is a divalent cation transporter, which is 
recruited to the phagolysomal membrane when the macrophage is activated [124].  
Several TB association studies in different populations have considered NRAMP1 as a 
candidate gene (Tables 4 and 5).  Combined, these studies suggest that NRAMP1 is 
involved in M.tuberculosis susceptibility in humans. However, the effect of this gene is 
not strong enough to suggest that it is the major gene involved in TB.  
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1.2.3.3. Vitamin D Receptor 
The vitamin D receptor (VDR) gene mediates the effects of the active metabolite of 
vitamin D, 1,25-dihydroxyvitamin D3, which suppresses the growth of M.tuberculosis 
in vitro [125,126] by stimulating cell-mediated immunity and activating monocytes 
[127].  Conflicting results have been found in association studies of VDR in TB. The 
rare allele of codon 352 (“t”) was associated with protection against pulmonary TB in 
the Gambia [128], only associated with female TB patients from India [129] and 
associated with TB in the Gujerati population only when taking deficiency of serum 
vitamin D into consideration [130].  This polymorphism was not associated with TB in 
the Chinese-Han population, but the FokI polymorphism was associated with disease 
[131], while a case-control and family-based study in West African populations 
indicated a role for VDR haplotypes in susceptibility to TB [132].  Subsequent studies 
did not find any association between VDR polymorphisms and TB [133,134].  A meta-
analysis of studies indicated that results were inconclusive and that the studies were 
underpowered [135].  A recent study in South Africans [136], which attempted to 
replicate a previous study [137], determined that the ApaI “AA” genotype and “T”-
containing TaqI genotypes predicted a faster response to TB treatment, but did not 
detect an association with TB in a case-control analysis. 
 
1.2.3.4. SP110 nuclear body protein 
Recently, a mouse strain extremely predisposed to TB was used to identify a 
susceptibility region on chromosome 1 of the mouse.  This region was named 
susceptibility to TB 1 (sst1) and a candidate gene from this region, Intracellular 
pathogen resistance 1 (Ipr1), was found to mediate resistance to TB in mice [138].  The 
closest human homologue of Ipr1 is SP110b, a protein encoded by the SP110 nuclear 
body protein gene (SP110).  The initial association study in West Africa [139] identified 
three polymorphisms in the gene that possibly influenced genetic susceptibility to TB.  
However three large subsequent studies in Ghanian [140], Russian [141] and South 
African [142] populations failed to replicate this association.  Since a number of 
independent studies could not replicate the original finding, it is likely that this gene 
does not contribute to genetic susceptibility to TB in humans [142]. 
 
1.2.4. Genes investigated in this study 
Thirty-nine genes were chosen as candidate genes for this study according to their role 
in TB or other granulomatous diseases, or from DNA-array analyses, genome-wide 
linkage studies or genes known to be involved in other immune-mediated diseases 
(Section 2.2).  These genes will be discussed in more detail in the chapters to follow. 
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2.1. CANDIDATE GENE SELECTION 
Selection of a candidate gene for a genetic study can be based on two approaches as 
previously discussed (Section 1.2.2).  In this project both experimental means and 
hypotheses were used. 
 
2.2. MAIN HYPOTHESES 
1. Interferon gamma (IFN-γ) is the major macrophage-activating cytokine during 
infection with Mycobacterium tuberculosis (M.tuberculosis) and its role has been well 
established in animal models [266,267] and in humans [180,268-270].  Genes regulating 
the expression of interferon gamma (IFN-γ) may influence resistance or susceptibility to 
tuberculosis (TB) (Chapter 4). 
 
2. TB, sarcoidosis and Crohn’s disease (CD) are all granulomatous diseases.  
Because of this similarity, susceptibility genes in sarcoidosis and CD could also be 
candidate genes in TB susceptibility (Chapter 5). 
 
3. Gene expression studies previously performed by DNA-array analysis 
experiments [271] in our study population identified genes differentially expressed 
between TB cases and healthy controls.  These genes could determine the outcome of 
M.tuberculosis infection (Chapter 6).  
 
4. Genome-wide linkage studies can lead to the discovery of genes that influence 
disease susceptibility even where a function in disease might not have been suspected.  
Such a study, as yet unpublished, in the South African Coloured population has led to 
the identification of a novel susceptibility locus.  Genes in this region could therefore 
influence TB susceptibility (Chapter 7). 
 
5. Functional polymorphisms that influence susceptibility to immune-mediated 
diseases other than TB, such as arthritis, diabetes and Alzheimer’s disease, could 
influence susceptibility to TB (Chapter 8). 
 
2.3. AIMS OF THIS STUDY 
1. To identify novel polymorphisms in the South African Coloured population. 
 
2. To conduct case-control association studies in the South African Coloured 
population to test association of genetic markers with TB.  These markers can be 
novel (as derived from resequencing results using DNA from the South African 
Coloured population) or selected from previous studies. 
 
3. To test the findings from the case-control association studies by transmission 
disequilibrium test (TDT) analyses using families from the South African 
Coloured population. 
 
4. To evaluate haplotypes and linkage disequilibrium in the candidate genes. 
 
  
CHAPTER 3 
MATERIALS AND METHODS 
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3.1. REAGENTS AND EQUIPMENT 
The buffers and solutions, reagents, equipment, software and online resources used in 
this study are listed in the addendum. 
 
3.2. LABORATORY INFORMATION MANAGEMENT SYSTEM 
The Laboratory Information Management System (LIMS) used during this project is a 
public domain database system that allows the effective management of the laboratory 
workflow and the analysis of single nucleotide polymorphism (SNP) genotyping results 
[272,273].  Large-scale SNP studies require and generate huge amounts of information, 
such as patient data, sample data, plate data, assay information, experiments done and 
genotyping results.  It also requires the control of robots.  The LIMS of the Institute for 
Clinical Molecular Biology (IKMB, www.ikmb.uni-kiel.de), used in this study, is 
composed of a Standard Query Language Server Database and several Visual Basic and 
web-based tools. 
 
Patient data is entered and edited with the PatientTool program.  This data includes the 
population, pedigrees and disease status of individuals.  Each individual receives a 
unique number.  The SampleTool program is used to enter and edit sample data such as 
the concentration and amount of DNA available.  It is also used to design and name 96 
and 384-well plates (to track the DNA samples in specific plates).  All plates are 
labelled using a barcode system.  The Pipettor program is used to control the robots that 
sets up the plates.  The GenoTool program imports genotyping data into the database, 
checks the Mendelian inheritance in families and evaluates the quality of the genotyping 
by testing for Hardy-Weinberg equilibrium.  The program can also be used to export 
data into linkage files [272] for use in analysis programs.   
 
Assay information is stored in the database and comprises the genotyping method used, 
primers, assay conditions and variants typed.  Other programs from the LIMS used in 
this study are ProjectManager (used to track the experiment process) and AssayManager 
(used to manage the barcodes of the assay components) [273].  All the information for a 
specific sample from the different programs in the database is linked, enabling the 
integration of the data. 
 
3.3. STUDY PARTICIPANTS 
Samples for this study were collected in the Western Cape Province of South Africa, 
where the incidence of tuberculosis (TB) is greater than 500 per 100 000 population per 
year [274]; chiefly from Ravensmead/Uitsig and surrounding suburbs in the Cape Town 
metropolitan area.  In some of these suburbs the incidence of TB was 1340 per 100 000 
population in 1996 [275] and a low prevalence of HIV exists [276].    
 
3.3.1. Study population and stratification 
The population studied here, known as the South African Coloured population, has a 
mixed ancestry, dating back many generations, that includes San, Khoi, Malaysian, 
African black and European genetic contributions [277].  Since the study population 
was established through the mixing of racial ethnicities many years ago (even 
centuries), there was a possibility that population stratification existed which could bias 
 33 
any association results found.  Population stratification results when a case-control 
sample contains subgroups with allele-frequency differences.  These differences might 
then contribute to any association found and lead to false positive or negative results 
[75].  To test for population stratification in the South African Coloured population, 25 
unlinked SNP markers were genotyped in a previous investigation [176] using the 
population of the present study.  No significant stratification was observed (p = 0.26).  
Using admixed populations, such as the South African Coloured population, in disease 
association studies has advantages.  This group is a present-day homogenous population 
with a large degree of genetic diversity, since genetic input from several populations 
contributed to the group.  A high number of alleles and genotypes are therefore 
available to genotype.  Some of these polymorphisms may be present in certain 
populations (for example Europeans and Asians) and absent from other populations (for 
example African blacks).  For this reason, the South African Coloured population offers 
an unequaled opportunity to evaluate the association of unique markers with disease in a 
single population [278]. 
 
3.3.2. TB case-control sample set 
Large case-control sample sets are easier to collect than family-based samples and 
thought to be the most powerful method to identify modest risk variants in common 
diseases [75].  The samples from the case-control group were unrelated as reported by 
the participants.  The controls were healthy people older than 15 years with no history 
of TB who lived in the same high incidence community as the TB patients and were 
likely therefore to have been exposed to TB.  Recent surveys have shown a PPD 
conversion of ≥ 8% of individuals aged ≥ 5 [279].  Cases consisted of two groups: 
active TB patients (who had clinical symptoms and bacteriologically confirmed TB) and 
previous TB patients (who had received treatment and had no clinical symptoms at the 
time of sampling).  All TB cases were human immunodeficiency virus (HIV)-negative.  
The characteristics of the case-control samples used in this study are listed in Table 6. 
 
TABLE 6. Characteristics of the family-based and case-control samples. 
Characteristics Families Case-control 
Diseased individuals (n) 385 431 
% male 48 53 
Average age (years) 31 34 
Healthy individuals (n) 167 483 
% male 29 23 
Average age (years) 44 27 
Total individuals (n) 552 914 
Both parents and 2 or more children 30 - 
Trios (complete) 54 - 
Single parent and 1 or more children 101 - 
Total families (n) 185 - 
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3.3.3. Family-based study sample set 
Family-based studies have the advantage that population stratification is circumvented, 
since there is a common genetic background among the family members.  These studies 
can therefore ensure that an association found with a marker in a case-control study is 
not due to population stratification.  The samples for the family-based study were 
collected from the same community as the case-control group and were used to confirm 
associations observed in the case-control study in a smaller and independent sample set 
[280].  The group consisted of 185 families with 522 individuals.  Ideally the amount of 
families for a transmission disequilibrium test (TDT) should be equal to the number of 
cases in the case-control cohort, in order to achieve the same power [280], but it is more 
difficult to collect families than unrelated cases.  Both parents and one or more children 
were sampled in 84 families and single parents and one or more children were 
genotyped in 101 families.  Characteristics for the family-based samples used in this 
study are listed in Table 6. 
 
3.4. DNA SAMPLES 
3.4.1. DNA extraction from blood and quality testing 
Blood samples were collected with permission from the Ethics Committee of the 
Faculty of Health Sciences (Stellenbosch University, South Africa, Project registration 
number 95/072) and the DNA was purified using the Nucleon BACC3 Kit for blood and 
cell cultures (Amersham Biosciences, Buckinghamshire, UK).   
 
The concentrations of DNA samples were determined with a NanoDrop
®
 ND-1000 
Spectrophotometer and the NanoDrop
®
 v3.0.1 Software (Inqaba Biotechnology, 
Pretoria, RSA).  All genomic DNA samples were diluted to a final concentration of 
30ng/µl with autoclaved distilled water and stored in 0.5 ml tubes.  Samples were 
quality tested in order to determine suitability for whole genome amplification (WGA).  
All the samples from the family cohort, 64 randomly selected cases and 64 randomly 
selected controls were tested for quality on agarose gels (Figure 7).   
 
In order to ensure a high quality product after WGA, samples with a clear high 
molecular weight band and minimum degradation were used.  Five µl of each genomic 
DNA sample at 30 ng/µl , together with 5 µl of 2X loading buffer (0.25% bromophenol 
blue, 0.25% xylene cyanol FF, 30% glycerol in water) was loaded onto a 0.8% agarose 
gel (2.4 g of agarose, 300 ml TBE, 2.4 µl of ethidium bromide (10mg/ml, Invitrogen, 
Karlsruhe, Germany)).  Two µl of Hyperladder I (Bioline, Luckenwalde, Germany) was 
loaded as a molecular weight marker.   
 
The gel was electrophoresed at 110 V for 1 hour, analysed under UV light and 
photographed with the BioDoc Analyze Video Documentation System (Whatman 
Biometra, Goettingen, Germany).  In the case-control group only 2% of the tested 
samples were deemed to be unsuitable for WGA, and therefore no further testing was 
done. 
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FIGURE 7. A 0.8% agarose gel used for quality testing of the DNA samples, showing the 
low amount of DNA degradation present in the samples.  The molecular weight marker 
(Hyperladder I) was loaded in lane 1. 
   
3.4.2. Plate design 
The 96 well plate layouts were planned using the SampleTool program in the LIMS and 
contained 92 DNA samples.  These designs were used during WGA and TaqMan
® 
genotyping of the samples.  Each plate received a unique name.  Well C3 always 
contained a positive control with DNA from the Centre d’Etude du Polymorphisme 
Humain (CEPH), Paris, France and wells D3, D10 and H12 served as negative controls. 
For the SNPlex™ genotyping method and some TaqMan
® 
SNP Genotyping Assays, 384 
well plates were needed.  The 384 well plates were designed with the SampleTool 
program from the design of the 96 well plates for WGA and each received an unique 
name.  Each 384 well plate layout was prepared by merging four 96 well plates (Figure 
8).  Sixteen 96 well plates (plate names TBSA01 – TBSA16), and four 384 well plates 
(plate names XTBSA01-XTBSA04), were designed with the SampleTool program in 
the LIMS. 
 
 
FIGURE 8. Schematic representation of plate merging. 
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3.4.3. Whole genome amplification (WGA) 
The quantity of genomic DNA available for genetic studies is usually limited [281] and 
acquiring samples for these studies can be difficult [282].  This places restrictions on the 
type and number of genotyping methods that can be used [283].  The availability of high 
throughput genotyping methods has increased the demand for DNA, because of the 
increase in the number of potential genotyping experiments [284].  WGA can generate 
large amounts of DNA that are suitable for downstream applications [282].  Approaches 
to WGA can be either PCR-based or non-PCR based.  The use of PCR-based methods 
for WGA has been successful in some studies, but several disadvantages have been 
identified [283].  These include nonspecific amplification, the overamplification of 
certain regions and the production of short products [285], which may cause errors 
during SNP genotyping.  Non-PCR based methods are therefore more popular, because 
they preserve sequence representation, will not cause the preferential amplification of 
certain alleles and provide excellent coverage of the genome [283]. 
 
In this study, multiple displacement amplification (MDA), a non-PCR based method, 
was used for WGA (Figure 9).  This method uses the bacteriophage Phi29 DNA 
polymerase and random hexamer primers.  Phi29 DNA polymerase consists of a single 
subunit, has proofreading ability, will displace DNA strands and is very stable [286].  
The hexamer primers anneal to the denatured genomic DNA at several sites and Phi29 
starts replication at these sites.  As replication continues, the downstream DNA strands 
will be displaced by the polymerase and form new single-stranded DNA.  The hexamer 
primers bind to the new DNA, continuing the processes of priming and strand 
displacement to produce high molecular weight, double-stranded DNA. 
 
 
 
FIGURE 9. The multiple displacement amplification method used for whole genome 
amplification.  Adapted from [287]. 
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3.4.3.1. WGA Protocol 
Sixteen 96 well plates were used for WGA.  The GenomiPhi DNA amplification kit 
(Amersham Biosciences, Freiburg, Germany) was used for the process after a 
comparative test done by the host institution (IKMB).  This kit can produce 4-7 µg of 
product DNA from 10 ng of starting DNA.    
 
The workbench was cleaned with a 5% NaClO solution.  A 96-well plate was marked 
with the platename from the LIMS and the date.  The sample buffer from the WGA kit 
was vortexed and 9 µl was added to each well.  One µl of genomic DNA at 30ng/µl was 
added to the sample buffer.  In well C3, 1 µl of CEPH DNA was added to each 96 well 
plate to serve as positive control.  This sample was used to control for the possibility of 
preferential allele amplification during WGA.  No DNA was added to wells D3, D10 
and H12 and these blank wells were used to control for contamination during WGA.  
The plate was sealed with adhesive PCR film (Abgene, Epsom, UK).  The template 
DNA was heat denatured at 95°C for 3 minutes in a GeneAmp PCR system 9700 and 
cooled to 4°C on ice.  For each sample, 9 µl of reaction buffer and 1 µl of enzyme were 
combined on ice.  This enzyme mix was added to the plate, but not to D3, D10 and H12.  
All the other wells contained a volume of 20 µl.  The plate was sealed with an ALPS 
300 Platesealer (Abgene, Epsom, UK) and incubated at 30°C overnight (16-18 hours) 
for the amplification process.  After amplification, the enzyme was heat-inactivated at 
65°C for 10 minutes in a GeneAmp PCR system 9700 and the plate was cooled to 4°C.   
 
The WGA products were diluted with 1X TE in a 1:10 dilution using the 96-channel 
Robbins Scientific Hydra system.  The syringes of the Hydra were washed with 580 µl 
of 5% NaClO and rinsed with dH2O before adding the TE, to remove any contaminants.  
For the 1:10 dilution, 180 µl of 1X TE was added to the 20 µl WGA product and mixed.  
The 200 µl was divided into two 100 µl (per well) plates with the Hydra system and 
these were fragmented for 10 minutes at 95°C in a GeneAmp PCR system 9700 for use 
in the SNPlex™ genotyping system.  The plates were marked with a f to indicate that 
fragmentation was completed.  The sixteen 96-well plates were merged into four 384-
well SNPlex plates (as depicted in Figure 8) with the Tecan Genesis RSP 150 robot 
(Tecan Deutschland GmbH, Crailsheim Germany) for use in the SNPlex™ genotyping 
method (Section 3.9).  During the merging process, 5 µl of each sample was transferred 
to the 384 well plates and dried at 60°C.   
 
3.5. MUTATION DETECTION AND POLYMORPHISM SELECTION 
In order to determine the frequency of known polymorphisms and the presence of novel 
variants in some candidate genes, the coding exons and flanking regions of these genes 
were amplified and sequenced in at least 10 individuals.  Half of these individuals were 
healthy controls and the other half were tuberculosis cases.  The reason for selecting the 
samples for sequencing in this manner was to ensure that possible disease-causing 
polymorphisms (which may occur at a low frequency in healthy controls) were not 
missed.  Criteria that determined the selection of a SNP or repeat marker for genotyping 
from sequencing data were as follows: a minor allele frequency of at least 5% in the 
sequencing data and presence in a functional region of the gene i.e. in an exon, promoter 
or splice site.   
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Sequence data was aligned to the expected products with Sequencher v4.2 (Gene Codes 
Corporation, Michigan, USA).  Variations noted in this setup were automatically typed 
in all the sequenced samples with SGcaller [288].  In order to determine if 
polymorphisms were known or novel, the sequence containing the variation was aligned 
to the human genome with Blat (http://genome.ucsc.edu/cgi-bin/hgBlat).  Blat indicates 
the presence of a known SNP in a region by listing the rs-number for the SNP.  The rs-
number of a SNP is a unique record identifier for the Single Nucleotide Polymorphism 
Database (dbSNP), which was established by the National Human Genome Research 
Institute and The National Center for Biotechnology Information (NCBI).  These 
records can be found at http://www.ncbi.nlm.nih.gov/projects/SNP/.  If no rs-number 
could be found in dbSNP through Blat or in the literature, it was considered to be novel 
and submitted to the NCBI. 
 
3.5.1. Butyrophilin-like 2 gene  
The butyrophilin-like 2 gene (BTNL2) has eight coding exons.  These were amplified 
together with the putative promoter region in 48 individuals from the South African 
Coloured population. 
 
3.5.1.1 PCR primers 
Primers were designed as previously described [289]. The names, sequences and the 
expected product sizes for each primer pair are listed in Table 7. 
 
TABLE 7. The names, sequences and product sizes of the primers for BTNL2 [289]. 
Exon Primer name Sequence 
Size 
(bp) 
BTNL2_e1_F 5'-TGT CCT CTA AGG GCA AAA CAG C-3' 
1 
BTNL2_e1_R 5'-GTT TCC CCC TTT CCA AGA AAC TA-3' 
693  
BTNL2_e2_F 5'-CAA TGG AAG CCA TGG AGT GTG-3' 
2 
BTNL2_e2_R 5'-AAC GTG GTG CAA CCA CTG ATT-3' 
489  
BTNL2_e3_F 5'-CAT TTT GAC AGG CTG GAC ACC-3' 
3 
BTNL2_e3_R 5'-CCT CAA CTG TCA CAA AGC TTA CCA-3' 
511  
BTNL2_e4_F 5’-GTG ACA GCA TTT TTG TTG TGG AG-3’ 
4 
BTNL2_e4_R 5’-GGT GTC CAT CTG ATG CTC ACT G-3’ 
474  
BTNL2_e5_F 5'-GGT TTC TAA ACT CCA ATG GAG CTGTT-3' 
5 
BTNL2_e5_R 5'-CAA ATG TCA GAG AAA TTG TCC AGG A-3' 
527  
BTNL2_e6_F  5'-CCT GGC CGA AGT TAT TTT GT-3' 
6 
BTNL2_e6_R  5'-TAG AAT CCC TGG GTG TCC TG-3' 
738  
BTNL2_e7_F  5'-AGC AGG CCA ACT GCT TCC T-3' 
7 
BTNL2_e7_R  5'-ACT GAG CCT GGA TTG CAT GAT-3' 
402  
BTNL2_e8_F  5'-CTT GTC TTC CTG TTT GGC TGT TAA-3' 
8 
BTNL2_e8_R  5'-GGG AAG GTG TAG ATA GGG CAC TT-3' 
497 
 
 
 39 
3.5.1.2. PCR amplification 
PCR reactions were carried out in a total volume of 25 µl.  Each reaction contained 10 
ng of genomic DNA, 2.5 µl of 10X enzyme buffer (Applied Biosystems, Darmstadt, 
Germany), 0.5 µl of dNTPs (10 mM stock, Amersham Biosciences, Freiburg, 
Germany), 3 µl of MgCl2 (25 mM), 0.2 µl forward and reverse primers (20 µM stock) 
and 0.15 µl of AmpliTaq Gold DNA polymerase (Applied Biosystems, Darmstadt, 
Germany).  A GeneAmp PCR system 9700 was used with the following touchdown 
cycling program: 10 minutes of denaturation at 95˚C followed by 16 cycles of 30 
seconds at 95˚C, 45 seconds at 66˚C (dropping 0.5˚C per cycle) and 1 minute at 72˚C.  
This was followed by 20 cycles of 30 seconds at 95˚C, 45 seconds at 58˚C and 1 minute 
at 72˚C.  The reaction was terminated at 72˚C for 10 minutes.  Control for 
contamination was done by the inclusion of water blanks in every batch of samples 
amplified. 
 
3.5.1.3. Gel electrophoresis of BTNL2 PCR products 
To verify the success of each BTNL2 PCR reaction, agarose gel electrophoresis of the 
samples was performed.  A 2% agarose TBE gel was prepared with 2g of agarose, 
100ml of 0.5X TBE buffer and 0.8 µl of 10mg/ml ethidium bromide (Invitrogen, 
Karlsruhe, Germany).  Five µl of PCR product together with 5 µl of 2X loading buffer 
(0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol in water) were 
loaded in the gel.  Two µl of a 100 bp DNA ladder (Invitrogen, Karlsruhe, Germany) 
was electrophoresed with the samples as a molecular weight marker.  The samples were 
run for 1 hour at 110V and the gel was photographed with a BioDoc Analyze Video 
documentation system (Whatman Biometra, Germany) using UV light. 
 
3.5.1.4. Purification of BTNL2 PCR products 
PCR products were digested with Exonuclease I (to remove primers, Exo I, Amersham 
Biosciences, Freiburg, Germany) and Shrimp Alkaline Phosphatase (to remove 
unincorporated dNTPs, SAP, Amersham Biosciences, Freiburg, Germany).  Each 
reaction was carried out in a total volume of 10 µl with 0.3 µl of SAP, 0.15 µl of Exo I, 
1.55 µl of dH2O and 8 µl of PCR product.  The reactions were incubated in a GeneAmp 
PCR system 9700 at 37°C for 15 minutes, followed by 72°C for 15 minutes to 
deactivate the enzymes. 
 
3.5.1.5. Sequencing of BTNL2 PCR products 
Sequencing reactions were performed with BigDye Terminator v1.1 Cycle Sequencing 
Kit (Applied Biosystems, Darmstadt, Germany).  Each reaction was carried out in a 
total volume of 10 µl with 1 µl of Big Dye v1.1, 1 µl of primer (3.2 µM), 0.5 µl of 5X 
SB buffer, 5.5 µl of dH2O and 2 µl of purified PCR product.  The sequencing cycle was 
done in a GeneAmp PCR system 9700 with the following cycling program: 1 minute at 
96˚C followed by 25 cycles of 10 seconds at 96˚C, 5 seconds at 55˚C and 4 minutes at 
60˚C.  The sequencing products were purified with Sephadex columns and analysed on 
a 96-capillary 3730xl DNA analyzer (Applied Biosystems, Darmstadt, Germany).  To 
confirm the presence of SNPs, both the forward and reverse strands were sequenced. 
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3.5.2. Interleukin 12B gene 
The microsatellite D5S2941, in intron 2 of the interleukin 12B gene (IL12B), was 
amplified and sequenced to confirm the presence of a novel allele (Section 4.5.1.2.). 
 
3.5.2.1. PCR primers 
Primers from a previous study [290] were modified for sequencing purposes (Table 8). 
 
TABLE 8. The names, sequences and product sizes of the primers for IL12B. 
Region Primer name Sequence 
Size 
(bp) 
IL12msF 5'-GTT GGC CTC AGT ACG CTT CTT-3' 
Intron 2 
IL12msRu 5'-TCA CCA GTG GAG ATT TTC ATT C-3' 
133 
 
 
3.5.2.2. PCR amplification 
PCR reactions were carried out in a total volume of 25 µl.  Each reaction contained 100 
ng of genomic DNA, 2.5 µl of 10X enzyme buffer with 1.5mM MgCl2, 2 µl of dNTPs 
(1.25 mM stock, Bioline, Celtic Diagnostics, South Africa),  1.5 µl forward and reverse 
primers (10 µM stock) and 0.075 µl of Super-therm GOLD HotStart TAQ DNA 
polymerase (Southern Cross Biotechnology, South Africa).  An Eppendorf Mastercycler 
(Merck, South Africa) was used with the following cycling program: 10 minutes of 
denaturation at 95˚C followed by 35 cycles of 45 seconds at 94˚C, 45 seconds at 60˚C 
and 1 minute at 72˚C.  The reaction was terminated at 72˚C for 10 minutes and cooled at 
4˚C for 2 minutes.  Control for contamination was done by the inclusion of water blanks 
in every batch of samples amplified.  Gel electrophoresis, purification of PCR products 
and sequencing reactions were done as described in section 3.5.7. 
 
3.5.3. Interleukin 12 receptor, beta 2 gene 
A region from the putative promoter of the interleukin 12 receptor, beta 2 (IL12RB2) 
gene was sequenced to determine the presence of the known functional SNP rs3762317. 
 
3.5.3.1. Primer design 
Primers were designed from the genomic sequence of the IL12RB2 gene to amplify a 
723 bp product (Table 9). 
 
TABLE 9. The names, sequences and product sizes of the primers for IL12RB2. 
Region Primer name Sequence 
Size 
(bp) 
IL12RB2proF 5'-CTC AGC AAA CCT GTA CTG GGC-3' 
Promoter 
IL12RB2proR 5'-CCC AGC TCT TAC CAC ACC TGA-3' 
723 
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3.5.3.2. PCR amplification 
PCR reactions were carried out in a total volume of 25 µl.  Each reaction contained 100 
ng of genomic DNA, 2.5 µl of 10X enzyme buffer with 1.5mM MgCl2, 2 µl of dNTPs 
(1.25 mM stock),  1.5 µl IL12RB2proF and IL12RB2proR primers (10 µM stock) and 
0.075 µl of Super-therm GOLD HotStart TAQ DNA polymerase.  
 
An Eppendorf Mastercycler was used.  The PCR program used was as follows: 10 
minutes of denaturation at 95˚C followed by 35 cycles of 1 minute at 94˚C, 1 minute at 
60˚C and 2 minutes at 72˚C.  Control for contamination was done by the inclusion of 
water blanks in every batch of samples amplified.  Gel electrophoresis, purification of 
PCR products and sequencing reactions were done as described in section 3.5.7. 
 
3.5.4. Signaling lymphocytic activation molecule-associated protein  
A region from the putative promoter of the signaling lymphocytic activation molecule-
associated protein (SH2D1A) gene was sequenced in 10 individuals to determine the 
frequency of 3 promoter polymorphisms (rs990545, rs7357894, rs12164382) from the 
dbSNP database in the South African Coloured population. 
 
3.5.4.1. Primer design 
Primers were designed from the genomic sequence of the SH2D1A gene to amplify a 
695 bp product (Table 10). 
 
3.5.4.2. PCR amplification 
PCR reactions were carried out in a total volume of 25 µl.  Each reaction contained 100 
ng of genomic DNA, 2.5 µl of 10X enzyme buffer with 1.5mM MgCl2, 2 µl of dNTPs 
(1.25 mM stock),  1.5 µl of SAPproF and SAPproR primers (10 µM stock) and 0.075 µl 
of Super-therm GOLD HotStart TAQ DNA polymerase.  An Eppendorf Mastercycler 
was used with the following cycling conditions: 10 minutes at 95˚C followed by 35 
cycles of 1 minute at 94˚C, 1 minute at 60˚C and 2 minutes at 72˚C.  The reaction was 
terminated at 72˚C for 10 minutes and cooled at 4˚C for 2 minutes.  Control for 
contamination was done by the inclusion of water blanks in every batch of samples 
amplified.  Gel electrophoresis, purification of PCR products and sequencing reactions 
were done as described in section 3.5.7. 
 
TABLE 10. The names, sequences and product sizes of the primers for SH2D1A. 
Region 
Primer 
name 
Sequence 
Size 
(bp) 
SAPproF 5'-GAA AGG TGG GCC CTG TAC AC-3' 
Promoter 
SAPproR 5'-TAG TAG CTT GGT TCG ATC GAG C-3' 
695 
 
 
3.5.5. Testis expressed sequence 264 
The five coding exons of the testis expressed sequence 264 (TEX264) gene were 
sequenced in 14 individuals to determine the presence of new SNPs and the frequencies 
of known SNPs. 
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3.5.5.1. Primer design 
Primers were designed from the genomic sequence of TEX264 to amplify regions for 
sequencing (Table 11). 
 
3.5.5.2. PCR amplification 
PCR reactions were carried out in a total volume of 25 µl.  Each reaction contained 100 
ng of genomic DNA, 2.5 µl of 10X enzyme buffer with 1.5mM MgCl2, 2 µl of dNTPs 
(1.25 mM stock),  1.5 µl of forward and reverse primers (10 µM stock) and 0.075 µl of  
 
Super-therm GOLD HotStart TAQ DNA polymerase.  An Eppendorf Mastercycler was 
used with the following cycling conditions: 10 minutes at 95˚C followed by 30 cycles of 
45 seconds at 94˚C, 45 seconds at the Tm of the primer and 1 minute at 72˚C.  The 
reaction was terminated at 72˚C for 10 minutes and cooled at 4˚C for 2 minutes.  The 
Tm used for each exon is listed in Table 11.  Control for contamination was done by the 
inclusion of water blanks in every batch of samples amplified.  Gel electrophoresis, 
purification of PCR products and sequencing reactions were done as described in 
section 3.5.7. 
 
TABLE 11. The names, sequences and product sizes of the primers for TEX264. 
Exon Primer name Sequence 
Size 
(bp) 
Tm 
(˚C) 
TEXEx1.1F 5'-AGG CTC CGT AAC CGA ACC CT-3' 
TEXEx1.1R 5'-GAG GGC GGA AGG ACT ATG GAG-3' 
559 64.0 
TEXEx1.2F 5'-GCT AAA TCA ACC TCA GCA ACC G-3' 
1 
TEXEx1.2R 5'-CCA GTG GGT ATG CCT CTC CT-3' 
316 61.1 
TEXEx2F 5'-GGC ACA TTG TCA GAG TAG GCT AC-3' 
2 
TEXEx2R 5'-CAG GCT AAA TCT GGA AGG TGC-3' 
508 60 
TEXEx3F 5'-CCT GAT CTG GCA CAG TCC CA-3' 
3 
TEXEx3R 5'-GGA TAT GCT CCG GCT TCC A-3' 
522 63.3 
TEXEx4F 5'-GCT CTG TGA GAC CAG TGC CTT-3' 
4 
TEXEx4R 5'-GCA TAG CCT GAC ACC CAC AGT-3' 
618 62.2 
TEXEx5.1F 5'-AGT GCA CTG CGT GCT GAG TT-3' 
TEXEx5.1R 5'-GTG CAG GCC ATG GGT TAC TC-3' 
392 62.2 
TEXEx5.2F 5'-AGC ACA GCT ACA GCG AGT CAG-3' 
5 
TEXEx5.2R 5'-CCA GCC TAT CTG TAC AGC CAT C-3' 
541 61.1 
 
 
3.5.6. Toll-like receptor 2 
The GT repeat in intron 2 of the toll-like receptor 2 (TLR2) gene was sequenced in 14 
individuals to determine the spectrum of repeats present in the South African Coloured 
population. 
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3.5.6.1. Primer design 
The forward primer was designed according to a previous study [291], but was modified 
for sequencing.  The reverse primer was designed from the genomic sequence of TLR2 
(Table 12). 
 
3.5.6.2. PCR amplification 
PCR reactions were carried out in a total volume of 25 µl (100 ng of genomic DNA, 2.5 
µl of 10X enzyme buffer with 1.5mM MgCl2, 2 µl of dNTPs (1.25 mM stock), 1.5 µl 
TLR2msF and TLR2msRu primers (10 µM stock) and 0.075 µl of Super-therm GOLD 
HotStart TAQ DNA polymerase amplified with the following cycling program: 10 
minutes at 95˚C followed by 35 cycles of 1 minute at 94˚C, 1 minute at 62˚C and 1 
minute at 72˚C in an Eppendorf Mastercycler.  The reaction was terminated at 72˚C for 
10 minutes and cooled at 4˚C for 2 minutes).    Control for contamination was done by 
the inclusion of water blanks in every batch of samples amplified.  Gel electrophoresis, 
purification of PCR products and sequencing reactions were done as described in 
section 3.5.7. 
 
TABLE 12. The names, sequences and product sizes of the primers for TLR2. 
Region Primer name Sequence Product size 
TLR2msF 5'-GCA TTG CTG AAT GTA TCA GGG A -3' 
TLR2 
TLR2msRu 5'-GAT TCT TCC TTG GAG AGG CTG-3' 
292 bp 
 
 
3.5.7. Gel electrophoresis, purification of PCR products and sequencing reactions 
All PCR products from IL12B, IL12RB2, SH2D1A, TEX264 and TLR2 were 
electrophoresed, purified and sequenced using the following protocol: 
 
A 2% agarose sodium boride (SB) gel was prepared with 2g of agarose, 100ml of 0.5X 
SB (Addendum A.1) buffer and 5 µl of 10mg/ml ethidium bromide (Sigma-Aldrich, 
South Africa).  Five µl of PCR product together with 5 µl of 1X Orange Loading Dye 
Solution (Fermentas, Inqaba Biotechnology, South Africa) were loaded on the gel.  Five 
µl of a 100 bp DNA ladder (Promega, Whitehead Scientific, South Africa) was 
electrophoresed with the samples as a molecular weight marker.  The samples were run 
for 30 minutes at 150V and the gel was photographed with a Syngene G box (Vacutec, 
South Africa) using UV light. 
 
Purification of the PCR products prior to sequencing was done with ExoSAPit (AEC 
Amersham, South Africa).  Each reaction was carried out in a total volume of 19.2 µl 
with 7.2ul of enzyme and 12 µl of PCR product.  The reactions were incubated in an 
Eppendorf Mastercycler at 37°C for 15 minutes followed by 72°C for 15 minutes to 
deactivate the enzymes. 
 
Sequencing reactions were performed with BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems, South Africa).  Each reaction was carried out with 1.5 µl of 
Big Dye v3.1, 0.5 µl of DMSO, 5 µl of the primers used for the PCR (1.1 µM), and 5 µl 
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of purified PCR product.  A GeneAmp PCR system 9700 was used with the following 
cycling program: 5 minutes at 95˚C followed by 35 cycles of 45 seconds at 95˚C and 4 
minutes at 58˚C.  The sequencing products were purified with Centri-Sep 96 well plates 
(Princeton Separations, Adelphia, New Jersey) and analysed on a 16-capillary 3130xl  
DNA analyzer (Applied Biosystems, South Africa).  To confirm the presence of SNPs, 
both the forward and reverse strands were sequenced with the respective forward and 
reverse primers. 
 
3.5.8. Selection of remaining polymorphisms 
Remaining polymorphisms were selected from the literature and the Hapmap project 
(Section 1.2.2., http://www.hapmap.org/).  The markers chosen were either previously 
found to be functional in mycobacterial or related diseases or had a minor allele 
frequency greater than 5%. 
 
3.6. AMPLIFICATION REFRACTION MUTATION SYSTEM-POLYMERASE CHAIN REACTION  
The amplification refraction mutation system-polymerase chain reaction (ARMS-PCR, 
Figure 10) method allows the genotyping of samples by PCR and agarose gel 
electrophoresis only.  It is a simple and reliable system which makes it possible to 
distinguish between heterozygotes and homozygotes at a certain allele.  
  
 
 
FIGURE 10. The concept of the ARMS.  Adapted from [293]. 
 
Two PCR reactions are carried out for each sample.  The one primer will be the same in 
both reactions, while the second primer will be unique to each reaction.  The only 
difference between these unique primers will be that their 3’ ends correspond to one of 
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the two alleles of the polymorphism of interest.  In theory these allele-specific primers 
will anneal only to DNA with a complementary base at that allele.  To enhance allele-
specificity a deliberate mismatch at position -3 bases from the 3’ end is incorporated 
into these primers.  The presence of a DNA fragment on an agarose gel will indicate 
which base is present at the locus. Control primers are included to amplify another 
sequence in the genome and are used to check that the PCR reaction has worked [292]. 
 
An adaptation of the ARMS method, the tetraprimer ARMS-PCR [294] (Figure 11), 
simplifies this technique even further by reducing the number of PCR reactions per 
sample to one.  This minimises costs and is time-saving.  Two sets of allele-specific 
primers (four primers) are designed for each reaction.  One allele-specific (or inner) 
primer is designed in the sense direction, while the other allele-specific primer is 
designed in the anti-sense direction.  The counterparts (or outer primers) are designed to 
amplify different sized allele-specific PCR products when combined with the inner 
primers.  The PCR product sizes must be different enough to be distinguished by gel 
electrophoresis.  The PCR product from the outer primers also serves as an internal 
control to verify the success of the PCR reaction.  When using this technique, the 
shorter and allele-specific products will have a lower amplification efficiency than the 
largest product and non-specific amplification of the shorter products might take place 
[295].  These problems are resolved by lowering the concentration of the outer primers 
and by adjusting the PCR program [294]. 
 
 
FIGURE 11. The concept behind the tetraprimer ARMS-PCR.  Adapted from [294]. 
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3.6.1. ARMS protocol 
The ARMS technique was used to genotype the rs3762317 SNP in the promoter of the 
IL12RB2 gene.  Allele-specific and common primers were designed as previously 
described [296] and a mismatch was incorporated three bases from the 3’ end of the 
allele-specific primers.  SAPproF and SAPproR (Table 13) were used as internal control 
primers to amplify a 695 bp product from the promoter in SH2D1A.  The allele-specific 
primers IL12-G and IL12-A together with the common IL12-R primer amplified the 
region surrounding the SNP of interest. 
 
PCR reactions for the ARMS-PCR were carried out in a total volume of 25 µl.  Each 
reaction contained 60 ng of genomic DNA, 2.5 µl of 10X enzyme buffer with 1.5mM 
MgCl2, 2 µl of dNTPs (1.25 mM stock), 0.3 µl of SAPproF and SAPproR primers (the 
control primers, 10 µM stock), 1.5 µl of the common primer IL12-R, 1.5 µl of the allele-
specific IL12-G or IL12-A primers (10 µM stock) and 0.075 µl of Super-therm GOLD 
HotStart TAQ DNA polymerase.  An Eppendorf Mastercycler and touchdown PCR 
program was used as follows: 10 minutes of denaturation at 95˚C followed by 10 cycles 
of 45 seconds at 94˚C, 1 minute at 70.3˚C (dropping 1˚C per cycle) and 1 minute at 
72˚C.  This was followed by 35 cycles of 45 seconds at 94˚C, 45 seconds at 60.3˚C and 
1 minute at 72˚C.  The reaction was terminated at 72˚C for 10 minutes and cooled at 
4˚C for 2 minutes.  Control for contamination was done by the inclusion of water blanks 
in every batch of samples amplified.  To verify the success of each PCR reaction 
agarose gel electrophoresis of the samples was performed on a 2% SB gel as described 
in section 3.5.7.   
 
TABLE 13. Primers used for genotyping the rs3762317 SNP in IL12RB2. 
Primer name Sequence Product size 
SAPproF 5'-GAA AGG TGG GCC CTG TAC AC-3' 
SAPproR 5'-TAG TAG CTT GGT TCG ATC GAG C-3' 
695 bp 
IL12-G 5'-ACT AGC GCA TAA ATA ATG GTG TG-3' 
IL12-A 5'-ACT AGC GCA TAA ATA ATG GTG TA-3' 
IL12-R 5'-CTC TGC ACC GCC CAG CTC TTA-3' 
494bp 
 
 
3.6.2. Tetraprimer ARMS-PCR protocol 
The tetraprimer ARMS-PCR technique was used to genotype a promoter SNP, G-631A 
(rs990545), in the SH2D1A gene.  Outer and inner primers (Table 14) for the reaction 
were designed from the genomic sequence of the gene.  The sizes of the resulting PCR 
products were selected in such a way that the differences in size could be easily 
visualised on an agarose gel.  Homozygotes would have the 695 bp product and either a 
450 or 296 bp product, while heterozygotes would have all three products. 
 
PCR reactions for the tetraprimer ARMS-PCR were carried out in a total volume of    
25 µl.  Each reaction contained 100 ng of genomic DNA, 2.5 µl of 10X enzyme buffer 
with 1.5mM MgCl2, 2 µl of dNTPs (1.25 mM stock), 0.5 µl of SAPproF and SAPproR 
primers (the outer primers, 10 µM stock), 5 µl of SAP-631G and SAP-631A primers 
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(the inner primers, 10 µM stock) and 0.075 µl of Super-therm GOLD HotStart TAQ 
DNA polymerase.   
 
An Eppendorf Mastercycler and touchdown PCR program was used as follows: 10 
minutes of denaturation at 95˚C followed by 12 cycles of 45 seconds at 95˚C, 1 minute 
at 72˚C (dropping 1˚C per cycle) and 1 minute at 72˚C.  This was followed by 22 cycles 
of 45 seconds at 95˚C, 1 minute at 60˚C and 1 minute at 72˚C.  The reaction was 
terminated at 72˚C for 10 minutes and cooled at 4˚C.  Control for contamination was 
done by the inclusion of water blanks in every batch of samples amplified.  Gel 
electrophoresis was done as described in section 3.5.7. 
 
TABLE 14. Primers used to genotype the rs990545 SNP in SH2D1A. 
Primer 
name 
Sequence Size (bp) 
SAPproF 5'-GAA AGG TGG GCC CTG TAC AC-3' 
SAPproR 5'-TAG TAG CTT GGT TCG ATC GAG C-3' 
695 
SAP-631G 5'-GGA GAA GAA GAA CTT GCC TAG-3' 450 
SAP-631A 5'-AAT CAG ACA TAG TAG ATG AAC AGT GAA TTT-3' 296 
 
 
3.7. CAPILLARY ELECTROPHORESIS OF FLUORESCENTLY LABELLED PCR PRODUCTS 
Roughly 94-95% of the human genome is made up of repeated sequences.  Eukaryotic 
and prokaryotic genomes contain many repetitive DNA sequences and these are present 
in all sizes [297].  Short tandem repeats (STRs), or microsatellites, are defined as 
tandemly repeated regions of DNA that consist of 1-6 base pair long motifs [298].  
These markers, that can be polymorphic, are primarily used for genetic mapping [299] 
and have been reported to be associated with several diseases, such as a (CA)n repeat in 
the interferon-γ gene that was correlated with the production of interferon-γ and 
associated with pulmonary TB [300,301].  However, the manner by which these STRs 
influence disease are still not clear [302].   
 
STRs can be genotyped using capillary electrophoresis and fluorescently labelled PCR 
products (Figure 12).  The fluorescent dye is linked to a PCR primer and this is 
incorporated into the amplified region during PCR.  Multiple regions can be 
simultaneously amplified using a multiplex PCR and uniquely labelled primers that 
amplify differently sized regions. These products are separated according to size using 
capillary electrophoresis and the results are represented by peaks on an 
electropherogram.   
 
3.7.1. Capillary electrophoresis protocol 
The TLR2 (GT)n and IL12B (ATT)n (D5S2941) microsatellites were amplified using a 
multiplex PCR and fluorescently labelled primers (Table 15).  Primers were designed by 
modifying previously described primers [290,291] or from the genomic sequence of the 
genes.  Each reaction was done in a total volume of 10 µl and contained 1 µl of WGA-
DNA, 1 µl of 10X enzyme buffer with 1.5mM MgCl2, 0.8 µl of dNTPs (1.25 mM 
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stock), 0.2 µl of each of the TLR2msF, TLR2msRl, IL12msF and IL12msRl primers 
and 0.03 µl of Super-therm GOLD HotStart TAQ DNA polymerase.   
 
 
 
FIGURE 12. Graphical representation of capillary electrophoresis of fluorescently 
labelled primers. 
 
TABLE 15. Primers used during the multiplex PCR prior to capillary electrophoresis. 
Region Primer name Sequence Size (bp) 
TLR2msF 5'-GCA TTG CTG AAT GTA TCA GGG A -3' 
TLR2 
TLR2msRl 5' HEX-GAT TCT TCC TTG GAG AGG CTG-3' 
292 
IL12msF 5'-GTT GGC CTC AGT ACG CTT CTT-3' 
IL12B 
IL12msRl 5' FAM-TCA CCA GTG GAG ATT TTC ATT C-3' 
133 
 
 
An Eppendorf Mastercycler was used for amplification and the following cycling 
conditions were used: 10 minutes at 95˚C followed by 25 cycles of 1 minute at 94˚C, 1 
minute at 60˚C and 1.5 minutes at 72˚C.  The reaction was terminated with 10 minutes 
at 72˚C and cooled at 4˚C for 2 minutes. 
 
After amplification, samples were prepared for capillary electrophoresis.  One µl of 
fluorescently labelled PCR product, 10 µl of HiDi™ Formamide (Applied Biosystems, 
South Africa) and 0.5 µl of the Genescan™ – 500 LIZ™ size standard (Applied 
Biosystems, South Africa) were mixed.  The samples were denatured for 5 minutes at 
94˚C in a GeneAmp PCR System 9700 and placed on ice to preserve the single-stranded 
DNA conformation.  Samples were electrophoresed in a 36 cm capillary array using the 
3130 Performance Optimized Polymer 7 (Applied Biosystems, South Africa) on a 
3130xl DNA analyzer.  Following data collection, samples were analysed with the 
Genemapper version 3.7 software program (Applied Biosystems, South Africa).  
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3.8. TAQMAN
®
 GENOTYPING 
TaqMan
® 
SNP Genotyping Assays [303], done in a single-step PCR reaction (Figure 
13), use the 5’ to 3’ exonuclease activity of Taq DNA polymerase [304].  Each assay 
contains 2 locus-specific PCR primers that surround the SNP of interest and two 
TaqMan
®
 probes (Figure 14).  Every probe consists of an allele-specific oligonucleotide 
labelled with a fluorescent reporter dye at the 5’ end.  The 3’ end of the probe is unable 
to extend [304] and is labelled with a non-fluorescent quencher and a minor groove 
binder.  The minor groove binder stabilises the double-stranded probe structure and 
therefore increases the melting temperature (Tm) of the probe without increasing the 
length of the probe.  This enhances allelic discrimination.  The quencher diminishes the 
fluorescence emitted by the fluorescent dye [303].    
 
 
 
FIGURE 13. The TaqMan
®
 platform.  Photos from http://www.ikmb.uni-kiel.de. 
 
The two probes are labelled with different fluorescent reporter dyes to discriminate 
between the two alleles of a SNP in a single reaction [305].  During the PCR, the probes 
and primers are allowed to hybridise to the target DNA (Figure 14). If no hybridisation 
occurs, the probe will remain intact and will not emit a detectable fluorescent signal 
when excited, due to the presence of the quencher molecule.  If hybridisation does 
occur, the 5’ nuclease activity during each cycle of the PCR reaction cleaves the probe 
thus leading to the release of the reporter dye from the quencher and a fluorescent signal 
can be detected [306].   
 
The results of a SNP TaqMan
®
 Genotyping Assay are read at the PCR endpoint, as 
opposed to TaqMan
®
 assays designed for gene expression which are read in realtime 
[303].  Genotype calls are done by plotting the normalised intensity of the fluorescent 
reporter dyes on a cluster plot (Figure 15) using the data analysis software.  For a 
diallelic SNP, a maximum of three clusters would be expected, with two of these 
representing the homozygotes of each allele and the third representing heterozygotes.  
An additional cluster in the vicinity of the cross of the x- and y-axis would represent the 
control samples without any DNA.  Several pre-designed and validated assays [307] are 
available from Applied Biosystems and these were used during this project.  The 
TaqMan
®
 Genotyping Assays offer the following advantages:  a single enzymatic 
reaction is required followed by PCR and endpoint reading using the closed tube, 
universal reactions and PCR conditions are used, the location of the primers and probes 
around the SNP of interest is flexible and insertion or deletion polymorphisms can be 
typed [303]. 
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FIGURE 14. Graphical representation of the TaqMan
®
 SNP Genotyping method.  
Adapted from [303]. 
 
 
 
FIGURE 15. Cluster plot used during genotype calling.  The top left block represents the 
plate layout. 
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3.8.1. TaqMan
®
 protocol 
TaqMan
®
 Genotyping Assays were used to genotype the following SNPs: rs2857654 
from CCL2, rs2243250 from IL4 and rs557077 from WNT5A (Table 16).  R702W 
(rs2066844), G908R (rs2066845) and 1007fs (rs2066847) from CARD15 were 
genotyped using the TaqMan assays and protocols of Hampe et al [308,309].  Both 96-
well and 384-well plates were used for genotyping SNPs with the TaqMan
®
 Genotyping 
Assays.  Pipetting was done with the Tecan Genesis Workstation 150 (Tecan 
Deutschland GmbH, Crailsheim, Germany).  For each 5 µl reaction, 2.5 µl of TaqMan® 
Universal PCR Master Mix (Applied Biosystems, Darmstadt, Germany), 0.25 µl of the 
20X TaqMan® SNP Genotyping Assay Mix (Applied Biosystems, Darmstadt, 
Germany) and 2.5 ng of dried DNA were used.  PCR reactions were completed in either 
a Biometra T1 Thermocycler (Whatman Biometra, Goettingen, Germany) or in a 
GeneAmp PCR system 9700 with the following cycling program: 10 minutes at 95˚C 
followed by 40 cycles of 15 seconds at 92˚C and 1 minute at 60˚C.  The plates were 
read in the 7900 HT Sequence Detection System (Applied Biosystems, Darmstadt, 
Germany) and the fluorescence analysed with the SDS 2.0 software.  
 
TABLE 16. TaqMan
®
 Genotyping Assays used during this project. 
Gene SNP Applied Biosystems Assay ID 
CCL2 rs2857654 C_16134900_10 
IL4 rs2243250 C_16176216_10 
WNT5A rs557077 C_3214537_10 
 
 
3.9. SNPLEX™ GENOTYPING SYSTEM  
The SNPlex™ Genotyping System (Applied Biosystems, Darmstadt, Germany) allows 
high-throughput genotyping and up to 48 SNPs can be genotyped in one reaction [303]  
(Figure 16).  The method relies on the oligonucleotide ligation assay (OLA) and 
multiplex PCR to discriminate between alleles and to amplify the target [310].  The 
products are hybridised with universal fluorescently labeled Zipchute probes and 
separated and detected with Applied Biosystems 3130xl or 3730xl DNA analysers 
[303].  The traditional OLA makes use of two adjacent oligonucleotides.  The 5’ probe 
is biotinylated and the 3’ probe is the reporter sequence.  The two probes will anneal to 
the target DNA sequence and the DNA ligase will covalently bind it if there is perfect 
complementarity.  The 5’ probe is captured on streptavidin and analysed for the 3’ 
reporter [311].   
 
In the SNPlex Genotyping System, three unlabeled oligonucleotides are used to detect a 
SNP during OLA.  Two of these are allele-specific oligonucleotides (ASOs) and will 
correspond to the 2 alleles of the SNP.  They contain unique ZipCode sequences.  Each 
of the ASOs have a linker that contains an internal spacer, a partial Zipcode sequence, 
the forward primer site and a hairpin structure that is complimentary to the Zipcode 
sequence of its ASO.  In a 48-plex reaction there are 96 ASO linkers.  The third 
oligonucleotide is the locus-specific oligonucleotide (LSO), which contains the reverse 
primer site.  The LSO linker is universal for the reaction, i.e. there is only one LSO 
linker in a 48-plex [310].   
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FIGURE 16. Graphical representation of the SNPlex™ genotyping system.  Adapted 
from [303]. 
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The linkers and probes are activated by phosphorylation before the OLA step. During 
the SNPlex OLA process, the ASO that corresponds to the base present at the SNP will 
anneal to the DNA together with the LSO.  The ASOs and LSO at a particular SNP will 
be ligated to their specific linkers and to each other.  After ligation, the unused probes, 
linkers and genomic DNA are removed by digestion with the exonuclease I and λ-
exonuclease enzymes [303].  The products are diluted before the multiplex PCR 
reaction with universal primers.  One of the PCR primers is labelled with biotin and 
after PCR this will lead to biotinylated amplification products.  The labelled amplicons 
are captured on streptavidin-coated microtiter plates and non-biotinylated amplicons are 
removed [310].   
 
ZipChute probes (Figure 17) are used to report the genotypes during SNPlex 
genotyping.  Each probe corresponds to one of the unique ZipCode sequences of the 
ASOs, which is incorporated into the amplification product.  The ZipChute probes also 
contain varying numbers of mobility modifiers, so that size separation of the different 
probes is possible during capillary electrophoresis.  The fluorescent label is detected by 
the 3730xl DNA analyser.  Each SNP has two ZipChute probes, one for each allele of 
the SNP and each probe pair is labelled with the same fluorescent marker.  Both the size 
and the colour of the ZipChute probes are therefore used to discriminate between SNPs 
and their alleles [303].  The universal ZipChute probes are added to the wells of the 
microtiter plates where the biotinylated amplicons are captured.  After hybridisation and 
washing steps, the ZipChute probes are released from the amplification products by 
incubating the plate at 37°C.  The plates are loaded onto the 3730xl DNA analyser. 
 
 
 
FIGURE 17. Graphical representation of a ZipChute probe.  Adapted from [303]. 
 
The resulting sample files are analysed with the GeneMapper Analysis Software v3.5.1 
[310].  This software can be used for automatic allele calling of the SNPs genotyped.  
Electrophoretic mobility bins are assigned to each marker, two bins for each ZipChute 
pair.  In order to perform the allele calling, the peaks in the mobility bins are compared 
relative to an internal size standard.  To correct for variability that might occur during 
different runs, an allelic ladder that contains all the ZipChute probes are also analysed.  
The signal intensities of the peaks are used by a clustering algorithm to determine the 
genotype of a sample and the results are presented as cluster (Figure 18) or polar plots 
[303].  The resulting genotypes can be exported as comma-separated value files or as 
text delimited files for use in other programs such as Microsoft Excel or a LIMS. 
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3.9.1. SNPlex pool design 
The SNPs selected for genotyping were submitted online at the myScience Environment 
of Applied Biosystems (http://myscience.appliedbiosystems.com) for assay design.  A 
list of the selected SNPs was compiled and uploaded and either specified the SNP IDs 
from NCBI’s dbSNP or the SNP-containing sequence as prescribed [312].  The list was 
submitted to the automated high-throughput pipeline (Figure 19) that designs multiplex 
pools from the submitted SNP information.  Every genotyping method has some 
limitations and in the case of the SNPlex Genotyping System, it is not possible to design 
assays for all SNPs.  There are several reasons for this: 1) The SNP may be present in a 
region that is homologous to another in the genome, for example in duplications or 
repeats, and this could lead to non-specificity of the assay, 2) other SNPs in the region 
may influence probe binding and 3) certain oligonucleotides in the same pool 
 
 
 
FIGURE 18. Cluster plots used during the analysis of SNPlex™ results. 
 
 
 
FIGURE 19. The SNPlex™ automated high-throughput pipeline for designing a 
multiplex pool.   Adapted from [303]. 
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might interact with each other [312].  The pipeline controls for all these issues and will 
reject any SNP that does not fulfill these criteria.  For this reason it is desirable to target 
more than 48 SNPs per pool during the design phase, so that an optimised design can be 
made. 
 
3.9.2. SNPlex protocol 
3.9.2.1. Phosphorylation and activation 
The SNPlex System Phosphorylation Kit was used to phosphorylate the 5’ ends of the 
SNPlex ligation probes and linkers.  The kit consists of SNPlex kinase, SNPlex kinase 
buffer, SNPlex enhancer, 10X deoxyadenosine triphosphate (dATP) and SNPlex 
universal linkers.  The pooled SNPlex ligation probes were ordered separately.  The 
phosphorylation master mix was prepared with 0.1 µl of  pooled ligation probes, 0.05 µl 
of universal linkers, 0.125 µl of nuclease free water, 0.05 µl of kinase buffer, 0.025 µl of 
kinase, 0.1 µl of enhancer and 0.05 µl of dATP for a total volume of 0.5 µl per reaction.  
The mix was incubated at 37°C for 1 hour.  After incubation the activated ligation probe 
pool was diluted 1:1 with 0.1X TE buffer, pH 8. 
 
3.9.2.2. OLA  
The SNPlex System Ligation Kit contains SNPlex ligase and SNPlex ligase buffer.  The 
kit was used to prepare the OLA master mix with 3.475 µl of nuclease free water, 0.5 µl 
of ligation buffer and 0.025 µl of ligase per reaction.  A total of 4 µl of the OLA master 
mix was pipetted with the Tecan Genesis RSP 150 (Tecan Deutschland GmbH, 
Crailsheim, Germany) to each well of the 384-well plate at 4°C, followed by 1 µl of the 
activated SNPlex ligation probe pool.  The plates were sealed and transferred from the 
ice to a GeneAmp PCR system 9700 at 90°C.  The cycling consisted of 3 minutes at 
90°C followed by 30 cycles of 90°C for 15 seconds, 60°C for 30 seconds and 51°C for 
30 seconds with a 2% ramp.  This was followed by 10 minutes at 99°C and incubation 
at 4°C.  The OLA plates were centrifuged after thermal cycling. 
 
3.9.2.3. Purification 
The SNPlex System Purification Kit was used to create the exonuclease reaction mix.  
The mixture for one 5 µl reaction contained 4.2 µl of nuclease-free water, 0.5 µl of 
SNPlex exonuclease buffer, 0.2 µl of SNPlex lamba exonuclease and 0.1 µl of SNPlex 
exonuclease I and was pipetted to the 384-well plates with the Tecan Genesis RSP 150 
(Tecan Deutschland GmbH, Crailsheim, Germany).  The plates were vortexed, 
centrifuged and sealed with a heat-seal cover.  The thermal cycler was pre-heated to 
37°C and the program consisted of 90 minutes at 37°C followed by 10 minutes at 80°C 
and incubation at 4°C.  The plates were centrifuged and 15 µl of nuclease free water 
was added to each well. 
 
3.9.2.4. Amplification 
The SNPlex System Amplification kit containing the SNPlex amplification master mix 
(2X) and SNPlex amplification primers (20X) were used to perform the amplification 
reaction.  Each reaction contained 2.42 µl of nuclease free water, 5 µl of the 
amplification master mix, 0.5 of the amplification primers and 2.08 µl diluted OLA 
products.  The plates were sealed and transferred to the thermal cycler.  The PCR 
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program consisted of 10 minutes at 95°C followed by 30 cycles of 15 seconds at 95 °C, 
1 minute at 63°C and incubation at 4°C. 
 
3.9.2.5. Hybridisation 
The components of the SNPlex System Hybridisation kit are SNPlex hybridisation 
plates, SNPlex hybridisation wash buffer, SNPlex hybridisation binding buffer, SNPlex 
ZipChute dilution buffer and the SNPlex System ZipChute kit, 48-plex (SNPlex 
denaturant, positive hybridisation control and SNPlex ZipChute mix, 48-plex).   
 
The hybridisation plates containing the streptavidin were washed with 100 µl of 
hybridisation wash buffer (diluted 1:10).  This was repeated three times and was 
performed with the Power Washer 384 (Tecan Deutschland GmbH, Crailsheim, 
Germany).   The plates were shaken upside down on a paper towel to remove the excess 
water.  The PCR plates from the amplification reaction were vortexed and centrifuged.  
For each reaction, 17.491 µl hybridisation binding buffer and 0.009 µl of the positive 
hybridisation control were combined in a master mix.  Of this, 17.5 µl was pipetted to 
each well of the PCR plate with the Tecan robot.  The mixture was pipetted to the 
hybridisation plates and the plates were sealed with Thermowell sealing plates (Corning 
Incorporated Costar, Corning, USA).  The plates were placed on the TiMix control 
shaker (Edmund Bühler Labortechnik, Tübingen, Germany) and incubated for 1 hour at 
600 rpm after which they were centrifuged to collect the contents in the bottom of the 
wells.  The contents of the wells were aspirated and the plates were washed with 100 µl 
of SNPlex hybridisation buffer in the Power Washer 384 and this was repeated three 
times.  The excess water was shaken from the plates by hand and 50 µl of NaOH was 
added to each well.  The plates were incubated without a seal on the TiMix control 
rotary shaker (Edmund Bühler Labortechnik, Tübingen, Germany) for 10 minutes at 
800 rpm.  The supernatant was removed from the wells, each well was washed five 
times and the excess water was removed by draining the plates upside down on paper 
towels. 
 
3.9.2.6. Elution 
The ZipChute hybridisation mix was prepared with 0.05 µl SNPlex ZipChute mix, 
11.25 µl SNPlex denaturant and 13.7 µl SNPlex ZipChute dilution buffer per reaction.  
The ZipChute mix is light-sensitive and was therefore stored in the dark.  A total of 25 
µl of ZipChute hybridisation mix was pipetted to each well with the Tecan Te-Mo 
robot.  The plates were incubated for 1 hour at 37°C at 800 rpm on the TiMix control 
rotary shaker with a TH15 incubator hood (Edmund Bühler Labortechnik, Tübingen, 
Germany)  after which the supernatant was aspirated.  The plates were washed with 100 
µl of SNPlex hybridisation buffer in the Power Washer 384 and this was repeated four 
times.  The plates were centrifuged upside down at 1000 rpm for 1 minute to remove all 
buffer solution. 
 
3.9.2.7. Detection 
The Sample loading master mix was prepared with the SNPlex System Assay Standards 
Kit.  The total volume of 17.5 µl per reaction consisted of 0.54 µl of SNPlex size 
standard and 16.96 µl of SNPlex sample loading reagent.  This master mix was pipetted 
to the plates with the Tecan Te-Mo robot and the plates were sealed with foil. The plates 
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were incubated at 37°C for 30 minutes at 800 rpm on a TiMix control rotary shaker with 
a TH15 incubator hood.  The plates were centrifuged and 7.5 µl of the eluted ZipChutes 
were pipetted to new 384 well PCR plates.  One µl of allelic ladder was pipetted to the 
control wells.  The plates were loaded onto the 3730xl DNA analyser for analysis of the 
ZipChute fluorescence. 
 
3.9.2.8. Automated allele calling 
After the analysis of the ZipChute fluorescence, the .fsa output files were evaluated with 
the GeneMapper Analysis Software v3.5.1 (Applied Biosystems Darmstadt, Germany).  
Alleles were automatically called.  The results were verified by looking at the 
distribution of the “clouds” for each SNP in the cluster plots and by checking that the 
genotypes for the positive CEPH controls were the same on all the plates for the same 
assay.  A maximum of three clustered clouds had to be visible on the plot.  In order to 
ensure genotyping of high quality, the logarithm of the intensity of the fluorescence for 
a sample had to be greater than 3.  The genotypes were exported from Genemapper in 
tab delimited files.  These files were imported into the LIMS for further analysis. 
 
3.10. CLONING OF THE SH2D1A GENE PROMOTER 
3.10.1. In silico promoter analysis 
Sequencing of the putative promoter of SH2D1A did not reveal any novel SNPs, but 3 
known variants were present in this region, namely G-631A (rs990545), G-494A 
(rs7357894) and C-347T (rs12164382).  The polymorphisms were in complete linkage 
disequilibrium (LD, D’ = 1 and r
2
 = 1) as assessed by Haploview (Section 3.11.4) [313].  
The SNPInspector program [314] (www.genomatix.de/products/SNPInspector) was 
used to determine the potential effects of the SNPs on the SH2D1A sequence.  Only G-
631A created 2 putative transcription factor binding sites (for CCAAT enhancer binding 
protein, beta (C/EBP-β) and pregnane X receptor (PXR), respectively). 
 
3.10.2. Cloning into pGEM
®
-T Easy vector system 
3.10.2.1. Amplification and purification of promoter fragment 
The 731bp promoter fragments from two male DNA samples, one containing the A-
allele (SAP A) and the other containing the G-allele (SAP G) of the G-631A SNP, were 
PCR amplified.  Primers (Table 17) were designed to incorporate endonuclease 
recognition sites for the KpnI and XhoI restriction enzymes in the amplification product 
with three base overhangs to facilitate binding of the specific restriction enzymes during 
later stages of the experiment. 
 
PCR reactions were carried out in a total volume of 25 µl.  Each reaction contained 100 
ng of genomic DNA, 2.5 µl of 10X enzyme buffer with 1.5mM MgCl2, 2 µl of dNTPs 
(1.25 mM stock),  1 µl forward and reverse primers (10 µM stock) and 0.075 µl of 
Super-therm GOLD HotStart TAQ DNA polymerase.  An Eppendorf Mastercycler was 
used with the following cycling program: 10 minutes of denaturation at 95˚C followed 
by 35 cycles of 45 seconds at 94˚C, 45 seconds at 61˚C and 1 minute at 72˚C.  The 
reaction was terminated at 72˚C for 10 minutes and cooled at 4˚C for 2 minutes.  
Control for contamination was done by the inclusion of water blanks in every batch of 
samples amplified. 
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TABLE 17. The names, sequences and product sizes of the primers used for SH2D1A 
promoter cloning.  The endonuclease recognition site of KpnI (5’-GGTAC↓C-3’) and 
XhoI (5’-C↓TCGAG-3’) are indicated in red bold type.  The three base overhangs, 
which were added to facilitate restriction enzyme binding, are underlined. 
Primer name Sequence Size 
SAP_KpnI 5’-AGG GGT ACC AAG ATG ACT GCG TGA GGT AGA-3’ 
SAP_XhoI 5’-CCG CTC GAG CTC GCC GGT TTC CCT GCT-3’ 
731 bp 
 
 
The PCR products were purified by vacuum using the Wizard SV Gel and PCR Clean-
up System (Promega, Whitehead Scientific, South Africa).  From each sample, ten PCR 
reactions were pooled (250 µl) and mixed with an equal volume of membrane binding 
solution.  The SV minicolumn was placed into the adapter of the vacuum manifold. The 
prepared PCR product was transferred to the minicolumn and incubated for 1 minute.  
The vacuum was applied to pull the liquid through the minicolumn after which 600 µl 
of Membrane Wash Solution was added to the minicolumn.  The vacuum was applied 
and the wash step was repeated.  The minicolumn was transferred to a collection tube 
and centrifuged (Eppendorf centrifuge 5415 D, Merck, South Africa) at full speed for 5 
minutes.  The minicolumn was transferred to a clean 1.5 ml microcentrifuge tube and 50 
µl of nuclease-free water was added to the minicolumn.  After a 1 minute incubation 
step the minicolumn and microcentrifuge tube was centrifuged for 1 minute at full speed 
to elute the DNA.  The DNA concentration was determined with the NanoDrop
®
 ND-
1000 Spectrophotometer and the NanoDrop
®
 v3.0.1 Software.    
 
3.10.2.2. Ligation to pGEM
®
-T Easy vector 
The amplified promoter fragments were each ligated to the pGEM
®
-T Easy vector using 
the T4 DNA ligase and 10X buffer (Promega, Whitehead Scientific, South Africa).  
This is possible, because the Super-therm GOLD HotStart TAQ DNA polymerase adds 
adenosine bases to the 3’ ends of the amplified fragments, which enables ligation to the 
3’ tyrosine overhangs of the pGEM
®
-T Easy vector.  The ligation was done in a 10 µl 
reaction with 1 µl of pGEM
®
-T Easy vector, 1 µl of 10X ligation buffer, 3 µl of PCR 
product and 1 µl of T4 DNA ligase.  The ligation reactions were incubated overnight at 
4˚C.  Purification of the ligation reactions were done by ethanol precipitation.  Briefly, 
90 µl of dH2O were added to the ligations.  The diluted ligation reactions were added to 
100 µl of 24:1 chloroform: isoamylalcohol, mixed and centrifuged (Eppendorf 
Centrifuge 5415, Merck, South Africa) at 14 000 rpm for 30 minutes at 4˚C.  The top 
layer was aspirated and added to 2 volumes of ethanol, after which the centrifugation 
step was repeated.  The ethanol was aspirated and the tubes were incubated at 65˚C until 
all ethanol had evaporated.  The DNA was dissolved in 10 µl of dH2O.  
 
3.10.2.3. Transformation 
The purified ligation products were used for transformations with competent 
Escherichia coli (strain DH5-α) cells.   For each transformation, 2 µl of ligation product 
and 50 µl of competent cells were transferred to a cuvette and electroporated (Bio-Rad 
Gene pulser, capacitance = 125 µfD, resistance = 1000 Ω, 250 V).  After 
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electroporation, 1 µl of SOC (Addendum A.1.) medium were added to the cells.  This 
was incubated in a shaker (Orbital shaker incubator LM-530, Yih Der, Japan) at 37˚C 
for 1 hour.  From each transformation reaction 50, 100 and 150 µl were plated onto LB 
agar plates supplemented with 100 mM ampicillin, 40 µg /ml X-gal and 0.2mM IPTG.  
The plates were incubated overnight at 37˚C to allow colony formation. 
 
3.10.2.4. Clone selection 
After overnight incubation, blue and white colonies were visible on the plates.  White 
colonies, which indicated vectors containing inserts, were selected with a pipette tip and 
swirled in a 25 µl PCR reaction.  This screening PCR (Section 3.10.2.1.), with the 
SAP_KpnI and SAP_XhoI primers, were used to determine if the selected colonies 
contained the insert.  The remainder of the single colony on the tip was inoculated in 20 
µl of LB and placed on a shaker at 37˚C until the results from the screening PCR were 
available.  One µl of this 20 µl culture was used to inoculate 11ml of LB medium with 
11 µl of ampicillin if the colony showed amplification of the desired insert.  The 50ml 
tubes were incubated overnight at 37˚C in a shaker.   
 
3.10.2.5. Small-scale plasmid extraction (Miniprep) 
After overnight growth, glycerol stocks were prepared by collecting 850 µl of the 
bacterial culture and mixing it with 150 µl of 100% glycerol.  This was stored at -80˚C.  
The Wizard Plus SV Miniprep Kit (Promega, Whitehead Scientific, South Africa) was 
used for plasmid extraction.  The remaining 10ml of bacterial culture was centrifuged 
for 10 minutes at 3000rpm and the supernatant was discarded.  The cell pellet was 
resuspended in 300 µl of cell resuspension solution by pipetting vigorously.  The 
resuspended cells were transferred to a 2ml tube to which 350 µl of cell lysis solution 
was added and was gently rotated.  The cells were resuspended by adding 10 µl of 
alkaline protease and incubating for 5 minutes.  After incubation, 450 µl of 
neutralisation solution was added and the contents of the tube were flicked to the top of 
the tube to create a homogenous solution.  This was centrifuged at 13.2 rpm for 10 
minutes.  The clear top layer was transferred to the minicolumn and centrifuged for 1 
minute.  The columns were washed with 600 µl of column wash solution and 
centrifuged for 5 minutes at 13.2 rpm.  This step was repeated.  The plasmid DNA was 
eluted with 25 µl of nuclease-free water at 65˚C and the concentration was determined 
with the NanoDrop
®
 ND-1000 Spectrophotometer and the NanoDrop
®
 v3.0.1 Software.  
The resultant constructs were named pGEM(SAP G) and pGEM(SAP A) and were 
sequenced with the Sp6 and T7  primers (Table 18) to verify the nucleotide sequence 
and orientation of the inserts. 
 
TABLE 18. The names and sequences of the primers used for sequencing of the 
pGEM(SAP G) and pGEM(SAP A) constructs.   
Primer name Sequence 
Sp6 5’-TAT TTA GGT GAC ACT ATA G-3’ 
T7 5’-TAA TAC GAC TCA CTA TAG GG -3’ 
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3.10.3. Subcloning into pGL4 luciferase reporter vector 
3.10.3.1. Digestion and purification 
The pGEM(SAP_G) and pGEM(SAP_A) constructs and the luciferase-reporter vector, 
the pGL4.10[luc2] plasmid (Promega, Whitehead Scientific, South Africa), were double 
digested using the KpnI and XhoI restriction enzymes.  The digestion of the pGEM 
constructs were done in a total volume of 40 µl using 8 µg of plasmid each, 20 µl of 
10X buffer (SuRE/cut buffer L, Roche, South Africa), 5 µl of KpnI (10 U/µl, Roche, 
South Africa), 0.5 µl of bovine serum albumin (BSA) and 5 µl of XhoI (10 U/µl, Roche, 
South Africa).  The pGL4.10[luc2] plasmid was digested in a total volume of  30 µl 
using 4 µg of plasmid, 10 µl of 10X buffer (SuRE/cut buffer L), 2 µl of KpnI, 0.3 µl of 
BSA and 2 µl of XhoI (10 U/µl, Roche, South Africa).  The reactions were incubated 
overnight at 37˚C.   To prevent recircularisation of the digested pGL4.10[luc2] plasmid 
during ligation, the 5’ ends were dephosphorylated using 1 µl of SAP.  This was 
incubated at 37˚C for 1 hour and the enzyme was inactivated by incubation at 65˚C for 
15 min. 
 
The reactions were resolved on a 1% agarose gel at 150 V for 1 hour.  The fragments 
were excised from the gel under UV light with a sterile scalpel.  Membrane binding 
solution was added to the gel slices as determined by its weight (10 µl of solution for 
every 10 mg of gel) and placed at 65˚C to melt before proceding with the Wizard SV 
Gel and PCR Clean-up System (Promega) as described in section 3.10.2.1.  The DNA 
was eluted with 20µl of nuclease-free water.  The DNA concentration was determined 
with the NanoDrop
®
 ND-1000 Spectrophotometer and the NanoDrop
®
 v3.0.1 Software. 
 
3.10.3.2. Ligation and ethanol precipitation 
The digested promoter fragments were each ligated to the pGL4.10[luc2] luciferase 
reporter vector using T4 DNA ligase and 10X buffer (Promega, Whitehead Scientific, 
South Africa).  The ligation was done according to the manufacturer’s protocol which 
recommends that a 3:1 vector: insert DNA ratio should be used.  The digested SAP A, 
SAP G and pGL4.10[luc2] products had concentrations of 16.8, 12.1 and 61.6 ng/µl 
respectively.  To achieve the 3:1 ratio, 3 and 4 µl of each of SAP A and SAP G were 
used in a 10 µl reaction with 1.6 µl of digested pGL4.10[luc2], 1 µl of 10 ligation buffer 
and 1 µl of T4 DNA ligase.  The ligation reactions were incubated overnight at 4˚C.   
 
Purification of the ligation reactions were done by ethanol precipitation.  Briefly, 90 µl 
of dH2O were added to the ligations.  The diluted ligation reactions were added to 100 
µl of 24:1 chloroform: isoamylalcohol and centrifuged (Eppendorf Centrifuge 5415) at 
14 000 rpm for 30 minutes at 4˚C.  The top layer was aspirated and added to 2 volumes 
of ethanol, after which the centrifugation step was repeated.  The ethanol was aspirated 
and the tubes were incubated at 65˚C until all ethanol had evaporated.  The DNA was 
dissolved in 10 µl of dH2O.  
 
3.10.3.3. Transformation 
The purified ligation products were used for transformations with competent DH5-α 
Escherichia coli cells.   This was done as described in section 3.10.2.3.  From each 
transformation reaction 100, 150 and 300 µl were plated onto LB agar plates 
 61 
supplemented with 100 mM ampicillin and 40µg/ml X-gal.  The plates were incubated 
overnight at 37˚C to allow colony formation. 
 
3.10.3.4. Clone selection 
After overnight incubation, white colonies which contained the vector, were visible on 
the plates.  Clones were screened by PCR as described in section 3.10.2.4.  Positive 
reactions for each of the SAP A and SAP G fragments were selected and 1 µl of these 
reactions were inoculated into 50 ml LB medium with 50 µl of ampicillin. The cultures 
were incubated overnight at 37˚C in a shaker for use in an endotoxin-free plasmid 
extraction. 
 
3.10.3.5. Endotoxin-free plasmid extraction (Midiprep) 
After overnight incubation, glycerol stocks were prepared as described in section 
3.10.2.5.  The remainder of the bacterial cultures were used for plasmid extractions with 
the endotoxin-free PureYield™ Plasmid Midiprep system (Promega, Whitehead 
Scientific, South Africa) using an adjusted protocol of the manufacturer.  The cells were 
pelleted using centrifugation (Eppendorf Centrifuge 5810 R) at 2000 x g for 15 minutes 
and the supernatants were discarded.  The pellets were resuspended in 3 ml of Cell 
Resuspension Solution until dissolved.  After resuspension, 3 ml of Cell Lysis Solution 
were added to each reaction and the tubes were gently inverted 5 times. This solution 
was incubated for 3 minutes at room temperature and 5 ml of Neutralization Solution 
were added to the lysed cells.  This solution was mixed by inverting the tubes 5 times.  
The lysates were incubated in an upright position for 3 minutes to allow a white 
precipitate to form. 
 
Two blue lysate clearing PureYield™ Clearing Columns were placed into 50 ml Falcon 
plastic tubes.  The lysates were added to the column and incubated for 2 minutes to 
allow the cellular debris to rise to the top.  The columns were centrifuged at 1500 x g 
for 5 minutes.  The filtered lysates were transferred to the white DNA binding 
PureYield™ Binding Columns in new 50 ml Falcon tubes and centrifuged at 1500 x g 
for 3 minutes.  After the first centrifugation step, 5 ml of Endotoxin Removal wash 
solution were added to the columns and centrifuged at 1500 x g for 3 minutes.  The 
flowthroughs were discarded and 20 ml of Column Wash Solution were added.  The 
columns were centrifuged at 1500 x g for 5 minutes.  The flowthroughs were discarded 
and the columns centrifuged for an additional 10 minutes to ensure the removal of the 
Column Wash Solution.  The tips of the columns were tapped on a paper towel to 
ensure that all the Column Wash Solution had been removed.  The columns were 
transferred to clean 50 ml tubes and the DNA was eluted with 600 µl of nuclease-free 
water by centrifuging at 1500 x g for 5 minutes.  The filtrates were collected and 
transferred to 1.5 ml tubes.   
 
The DNA concentrations were determined with the NanoDrop
®
 ND-1000 
Spectrophotometer and the NanoDrop
®
 v3.0.1 Software.  The correct nucleotide 
sequences of the inserts were verified by DNA sequence analysis with the Rvprimer3 
(Promega, Whitehead Scientific, South Africa) and SAP_XhoI primers.  The resultant 
pGL4 luciferase constructs were named pGL4(SAP A) and pGL4(SAP G). 
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3.11. STATISTICAL ANALYSIS 
3.11.1. Quality checking of the genotype data 
Allele frequencies can be used to predict genotype frequencies in a stable population if 
there is no mutation, migration, natural selection or non-random mating present.  This is 
the Hardy-Weinberg model [315,316] and it is valid for most human populations [317].  
If the assumptions of this model are true for a population, the genotype and allele 
frequencies will remain constant over consecutive generations, and the population is 
considered to be in Hardy-Weinberg equilibrium (HWE).  The model allows the 
comparison of a population’s actual genetic structure with the genetic structure expected 
if the population were not evolving.  If genotype frequencies differ from those expected 
under equilibrium, it can be assumed that one or more of the model’s assumptions are 
violated.  In case-control association studies a departure from HWE can indicate 
genotyping error [318], population stratification or, sometimes if found in disease cases, 
an association of the marker with the disease [317].  
 
The model consists of two equations: one that calculates allele frequencies and one that 
calculates genotype frequencies.  The p + q = 1 equation describes allele frequencies for 
two alleles of a marker and if the frequency for one allele is known, the other can be 
calculated.  The 1 = p
2
 + 2pq + q
2 
equation is used to calculate the expected genotype 
frequencies from known allele frequencies, where p and q are the proportions of alleles.  
p
2
 and q
2
 are the proportions of the homozygotes pp and qq, while pq is the proportion 
of the heterozygotes.  To calculate the expected number of pp genotypes, the equation 
p
2
 x n was used, where p refers to the allele frequency of p and n is the total number of 
samples examined in the population.  The same calculation would be used to determine 
the expected number of qq and pq genotypes.  Once the expected values have been 
calculated, the chi-square test (χ
2
, section 3.10.2.1.) is performed to determine if the 
population is in HWE.  This value must be less than 3.84 for the population not to be 
significantly out of HWE, because the test has one degree of freedom. 
The basic principles of inheritance were described by Gregor Mendel in 1866.  
According to Mendel’s law of segregration, alleles separate during meiosis and one 
allele of each parent is inherited by their descendant [319].  These principles can be 
applied in pedigrees, since the 4 parental alleles of a bi-allelic marker can only result in 
certain combinations of alleles in the offspring.  Deviations from these expected 
genotypes, called Mendel errors, could indicate non-paternity or errors in the 
genotyping method. 
 
The quality of genotyping was verified by checking for conformance with HWE in the 
control population and by Mendel checking in families.  Mendel checking was done 
with the Genotool program in the IKMB LIMS [272,273].   
 
3.11.2. Genotype distributions of SNPs 
Contingency tables were drawn up to determine significant differences in the 
distribution of genotypes (2 x 3 table) between cases and controls.  Only genotypes 
were considered, since allelic tests are more prone to results in false positive 
associations.  The two-tailed chi-square test or the Fisher’s exact test (depending on the 
data analysed, sections 3.10.2.1 and 3.10.2.2.) was done to establish whether the results 
were significantly different between the genotype data.  Prism version 4.02 was used to 
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calculate the odds ratios and p-values as reported.  When a significant result was found, 
Bonferroni corrections for multiple testing were done by considering the number of 
independent linkage disequilibrium (LD) blocks (Section 1.2.2.4.) and the number of 
independent SNPs [76] in each gene.  
 
3.11.2.1. The chi-square test 
The chi-square (χ
2
) test is a statistical test that determines if observed frequencies are 
significantly different from expected frequencies.  A null hypothesis (H0: there is no 
significant difference between the observed and expected frequencies) and an 
alternative hypothesis (H1: there is a significant difference between the observed and 
expected frequencies) is stated. [320]  The value for χ
2
 is calculated by the following 
equation:  
χ
2
 = ∑
−
number expected
2
number) expectednumber (observed
  
The chi-square tests were done with Prism version 4.02. 
 
3.11.2.2. The Fisher’s exact test 
This test must be used for small sample sizes and when the expected number in any cell 
of a contingency table is less than six [321] and calculates the exact p-value.  In this 
study the test was done using Prism version 4.02.  Prism always uses this exact test for 2 
x 2 contingency tables. For genotype data, which consists out of 2 x 3 tables, the two 
smallest genotype numbers in a group are added together and then compared to the 
remaining data. 
 
3.11.3. Transmission disequilibrium test 
In this study, a transmission disequilibrium test (TDT, discussed in section 1.2.2.2.) was 
done to confirm results found in the case-control studies.  If TDT results suggested that 
there was proof of linkage, it could be deduced that LD exists between the marker allele 
and the disease allele.  The TDTs in the family sample set were analysed with 
Haploview v3.3 [313].  Single markers and haplotypes were evaluated.  Power 
calculations for TDTs were done with the Genetic Power Calculator [322]. 
 
3.11.4. Haplotypes and linkage disequilibrium 
Haplotypes and LD (discussed in sections 1.2.2.3. and 1.2.2.4.) in the case-control 
cohort were analysed with Haploview v3.3 [313].  Pairwise LD was analysed in terms 
of D’.  The D’ value ranges from 0 to 1, where 0 indicates no LD and 1 indicates 
complete LD.  Haploview automatically selects haplotype blocks according to a 
commonly used block definition from Gabriel et al [89].  This block definition 
calculated the 95% confidence levels for the D’ values and the comparisons are labelled 
as strong LD, uncertain or strong recombination.  If 95% of the comparisons are 
labelled as strong LD, a block will be created.  Markers with a minor allele frequency of 
less than 0.05 are ignored in this algorithm.  With this definition, several overlapping 
blocks can be found, therefore the program sorts the list of possible blocks, starts with 
the largest and keeps adding the blocks until they overlap with an already declared 
block [89,313]. The chi-square test was used by Haploview to determine any significant 
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differences between the two groups.  In addition, we tested global significance for these 
haplotypes using the Cocaphase program in the Unphased suite [101] and permutation 
testing in Haploview, since haplotypes in a haplotype block is not independent and 
Bonferroni correction is too conservative in this instance. Using the Cocaphase 
program, 10 000 permutation replicates were done for each block.  In Haploview, 10 
000 or 100 000 permutation replicates were done, depending on the distribution graph 
generated by the program.  The “global” (empirical) p value from Cocaphase and 
Haploview represents the total significance when the observed versus expected values 
of all of the haplotypes are analysed together.   
 
3.11.5. Microsatellite analysis  
The numbers of repeats from the microsatellite markers were determined by direct 
counting and plotted as a distribution graph.  The distribution of the peaks on this graph 
(either bi- or trimodal) determined the number of subclasses (two (S or L) or three (S, M 
or L)) into which the alleles were divided.  This methodology was previously described 
by studies in the analysis of microsatellite polymorphisms [291,323-325].  To evaluate 
the genotypic effect on the development of TB, the genotype classes (three (S/S, S/L, 
L/L) or six (S/S, S/M, S/L, M/M, M/L, L/L)) resulting from this classification were 
divided into two subgroups depending on the presence or absence of the S allele.  
Possible associations between the disease groups and classes of alleles were analysed 
for significance by the chi-square test.  Distribution graphs were prepared with 
Microsoft Excel and the chi-square tests were done with Prism version 4.02. 
 
3.11.6. Power calculations 
Our case-control studies had the power to detect an odds ratio of 2.15 with 95% 
confidence given an allele frequency of at least 5% based on the sample size available 
(Epi Info 2000, CDC).  The TDTs had 68% power to detect the same odds ratio as the 
case-control studies given an allele frequency of at least 5% [322].  In order to have 
95% power 409 family trios would be needed for the TDT analysis. 
 
 
 
  
CHAPTER 4 
CANDIDATE GENES WHICH INFLUENCE 
INTERFERON GAMMA LEVELS 
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4.1. INTRODUCTION 
Interferon gamma (IFN-γ) is a member of the interferon family.  These cytokines play a 
crucial role in resistance to pathogens [326] and were first identified as agents that 
interfere with viral replication [327].  IFNs are classified into type 1 and type 2 
depending on receptor specificity and sequence homology.  IFN-γ is the only type 2 IFN 
[328] and was first identified in lymphocyte supernatants as a unique lymphocyte 
antiviral activity.  The cytokine is produced not only by natural killer (NK) cells [329], 
CD4+ and CD8+ T cells [330,331], but also by γδ T cells [332], NK T cells [333], B 
cells, myeloid cells [334] and type II alveolar epithelial cells [335].   
 
There has been a great deal of interest in IFN-γ since its discovery, because the 
macrophage, an important target cell of IFN-γ, plays a central role in the immune 
system.  The IFN-γ/macrophage system is vital in natural and acquired resistance to 
infection and defects in the system may lead to inflammatory and autoimmune disease 
[336].       
 
The T helper 1 (Th1) cell response, which is required to contain Mycobacterium 
tuberculosis (M.tuberculosis) infection, is largely characterised by IFN-γ production.  
Production of IFN-γ is essential for the effectiveness of the innate immune system 
against M.tuberculosis.  However production of this cytokine alone is not sufficient to 
protect against disease [337].  Even so, convincing evidence for its importance in the 
control of mycobacterial infections have been found in both experimental and clinical 
studies.  Mice with a disrupted IFN-γ gene show increased susceptibility to tuberculosis 
(TB) [338-340] and replacement of the gene into the lung confers resistance [341].   
 
Humans with mutations in genes of the interleukin-12 (IL-12)/interleukin-23 (IL-
23)/IFN-γ axis (Figure 20), such as interleukin-12, beta (IL12B) [50,342,343], 
interleukin-12 receptor, beta 1 (IL12RB1) [45,46,344-346], IFN-γ receptor-1 (IFNGR1) 
[268,347-349], IFN-γ receptor-2 (IFNGR2) [350] or signal transducer and activator of 
transcription-1 (STAT1) [351], have an increased susceptibility to even non-pathogenic 
mycobacteria.  These mutations are all associated with the rare human syndrome known 
as Mendelian susceptibility to mycobacterial disease (MSMD, Online Mendelian 
Inheritance in Man #209950).  The affected patients are also susceptible to 
M.tuberculosis and Salmonella, but not to other infections.   
 
In addition to these experimental and clinical studies, genetic association studies have 
also suggested that this cytokine is important in protecting against mycobacterial 
infection.  The functional 874A→T polymorphism, a common variant in the IFN-γ 
gene, has been associated with TB in the South African Coloured population [180].  
This polymorphism is also associated with TB in Spanish [179], Sicilian [181], Turkish 
[182], Colombian [354] and Hong Kong Chinese [183] populations, but not in 
Malawians [133], Croatians [185] and Americans from Caucasian, African or Hispanic 
descent [248]. 
 
In most TB patients the production of M.tuberculosis-induced IFN-γ by peripheral 
blood mononuclear cells is reduced at the time of diagnosis [355].  During and after 
successful treatment, these levels increase significantly [356].  It is also known that the  
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FIGURE 20. Simplified overview of the interleukin-12/interleukin-23/IFN-γ axis.  
Proteins encoded by genes mutated in patients with MSMD are underlined.  IFN-γ and 
IL-12 may induce genes with response elements (RE) for these cytokines.  IL-23 is not 
represented in this scheme, but may be involved in protective immunity against 
M.tuberculosis.  Adapted from [352] and [353]. 
 
IFN-γ concentrations in sputum and bronchoalveolar lavage fluid can be used as an 
estimate of disease activity [357,358].  Currently, experimental data propose that IFN-γ 
is the best correlate of protective immunity against TB [359,360].  However, it is known 
that M.tuberculosis modulates the anti-mycobacterial action of IFN-γ by adopting 
various mechanisms, such as inhibiting the response of macrophages to IFN-γ 
[361,362].  A recent study indicated that the bacterium accomplished this by 
downregulating the stimulating protein 1, which in turn was responsible for 
downregulating IFN-γR1 and altering the cells sensitivity of the cells to IFN-γ [363]. 
 
IFN-γ has been considered as an immunotherapy to treat TB [364-367] and certain 
studies using aerosolized IFN-γ as a treatment have reported favourable results when 
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using this approach [368,369].  However administering IFN-γ subcutaneously to 
patients with chronic TB and advanced multidrug-resistant (MDR)-TB found that this 
treatment did not affect the disease parameters [360].  The authors concluded that 
treatment with aerosolised IFN-γ might be useful in treating MDR-TB in patients that 
respond poorly to treatment. 
 
Given the clinical and experimental evidence showing a crucial role of IFN-γ in host 
defence against TB, we investigated polymorphisms in candidate genes which could 
potentially modulate expression levels of this vital cytokine. 
 
 68 
4.2. C-C CHEMOKINE LIGAND-2 
Chemokines play an important role in the development of immune responses against 
TB.  The C-C chemokine ligand-2 gene (CCL2) encodes monocyte chemoattractant 
protein-1 (MCP-1), a protein which is essential for the recruitment of monocytes, T 
lymphocytes [370] and NK cells [371] to the site of mycobacterial infection.  It may 
also take part in the localisation of TB in the lungs by contributing to granuloma 
formation [370] and possibly have a role in T cell differentiation [372].  Mice deficient 
in CCL2 are more susceptible to TB during the early stages of the infection [373].   
 
It is known that MCP-1 production is promoted by IFN-γ [374].  In turn, MCP-1 attracts 
antigen-specific IFN-γ-secreting T cells to the site of infection [373].  Since MCP-1 is 
responsible for the recruitment of immune cells to the infection site, it is possible that 
levels of this chemokine will determine the initial cellular immune response at the site 
of disease and will therefore indirectly influence IFN-γ levels.  MCP-1 also inhibits 
production of IL-12p40, a key player in the IL-12/IL-23/IFN-γ pathway [175].  For this 
reason it is likely that the clinical presentation of TB and its outcome will be partially 
regulated by MCP-1, which could conceivably have a major effect on disease 
progression.   
 
It is well documented that polymorphisms in the promoter region of a gene can affect its 
expression levels.  This is also true for CCL2, where the expression of the gene seems to 
be controlled by two sections in the 5’ regulatory region.  The proximal regulatory 
region, located approximately 150 bp upstream [375] of the transcriptional start site, 
responds to various cytokines and contains several putative transcription factor binding 
sites [376-378].  In addition, a distal regulatory region, which contains two binding 
sequences for nuclear factor-κβ and other unknown cis-acting regulatory elements 
[376,379,380], is located 1.8 to 2.7 kb upstream [375] of the transcriptional start site. 
 
The functional [381-383] CCL2 promoter polymorphism rs1024611 (named MCP-1-
2518 [381] or MCP-1-2578 [384] in the respective studies) was associated with 
increased susceptibility to pulmonary TB in Mexicans and the finding was replicated in 
Koreans [175].  Patients with a GG genotype had a higher risk of progression to disease.  
Monocytes from these individuals with a GG genotype were stimulated with 
M.tuberculosis antigens and produced higher concentrations of MCP-1 and lower 
concentrations of IL-12p40 than monocytes from individuals with the AA genotype 
[175].  This polymorphism was not associated with TB in a smaller study of Brazilians 
[65].  In addition, the T allele of the rs1024610 single nucleotide polymorphism (SNP, 
named MCP-2136 [384] or MCP-1-2076 [385]) may also influence MCP-1 levels [384].  
The rs1024610 and rs1024611 SNPs were in complete linkage disequilibrium (LD) in 
previous studies [384,385], but both polymorphisms contributed separately to increased 
MCP-1 levels in patients [384].    
 
The rs1024611 CCL2 polymorphism (Table 19) was investigated in the South African 
Coloured population to test the possible association of the gene with TB based on a 
previous association study which found an association between it and disease [175].  In 
addition six other SNPs from this gene were genotyped to elucidate the LD structure of 
the region in this unique South African population.  Both a case-control study design 
and a transmission disequilibrium test (TDT) were used.   
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TABLE 19. Polymorphisms genotyped in the CCL2 gene. 
Polymorphism Class Location Genotyping method 
rs2857654 SNP Promoter TaqMan 
rs1024611 SNP Promoter SNPlex 
rs1024610 SNP Promoter SNPlex 
rs3760399 SNP Promoter SNPlex 
rs3760396 SNP Promoter SNPlex 
rs4586 SNP Exon 2, synonymous SNPlex 
rs2530797 SNP 3' UTR
a
 SNPlex 
a
 untranslated region (UTR) 
 
4.2.1. Results 
4.2.1.1. Single-point statistical analysis 
All of the SNPs genotyped in CCL2 were in Hardy-Weinberg equilibrium (HWE) in the 
control population.  The threshold for significance was set at p = 0.025 after Bonferroni 
correction, since 6 of the 7 genotyped SNPs were in LD with each other. Under this 
criterion, none of the analysed SNPs reached statistical significance.  The functional 
[381-383] promoter polymorphism rs1024611 was not associated with TB in our case-
control study (p = 0.24, Table 20) or TDT (p = 0.59, Table 21), a finding similar to a 
previous study considering Brazilian TB patients [65].  However, it was previously 
associated with increased susceptibility to pulmonary TB in Mexicans and in Koreans 
[175].  These contradictory results suggest an ethnic-specific role of CCL2 
polymorphisms in TB.  The other SNP with a known functional effect, rs1024610, was 
also not associated with TB in the South African Coloured population.  None of the five 
remaining SNPs, which included the synonymous SNP rs4586 and the functional distal 
promoter polymorphism rs2857654 [375], were associated with disease in the case-
control or TDT analyses. 
 
TABLE 20.  Single-point statistical analysis in the CCL2 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs2857654 A C 0.10 0.43 0.47 0.11 0.43 0.46 0.90 
rs1024611 G A 0.06 0.33 0.61 0.08 0.36 0.56 0.24 
rs1024610 A T 0.01 0.16 0.83 0.02 0.19 0.79 0.17 
rs3760399 C T 0.01 0.11 0.88 0.01 0.11 0.88 0.62 
rs3760396 G C 0.01 0.11 0.88 0.01 0.11 0.88 0.89 
rs4586 T C 0.20 0.52 0.28 0.24 0.48 0.28 0.26 
rs2530797 G A 0.06 0.37 0.57 0.05 0.4 0.55 0.82 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 70 
TABLE 21. Single-point statistical analysis in the CCL2 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs2857654 C 53 : 47 0.36 0.55 
rs1024611 G 45 : 40 0.29 0.59 
rs1024610 A 20 : 12 2 0.16 
rs3760399 C 8 : 6 0.29 0.59 
rs3760396 G 17 : 13 0.53 0.47 
rs4586 T 57 : 53 0.15 0.70 
rs2530797 G 42 : 41 0.01 0.91 
 
 
4.2.1.2. Haplotype analysis 
The Haploview program [313] was used to identify haplotype blocks (Figure 21) for the 
markers genotyped in CCL2 in the control samples.  Strong LD exists across the CCL2 
gene in the South African population.  The promoter polymorphisms and exonic SNP 
were part of a single haplotype block, while the 3’UTR SNP (rs2530797) was not 
included in this block.  Since no additional information on the haplotype block 
containing the 3’UTR SNP was available, it was not considered in the statistical 
analysis of haplotypes with TB. 
 
 
FIGURE 21. Plot of LD between all markers of CCL2 analysed in control individuals of 
South African Coloured descent, generated by Haploview v3.3.  The 5’- and 3’- ends of 
the gene are indicated.  D’-values (%) are indicated on the squares.  The colours of the 
squares represent LD strength, with red being strong, and blue weak.  Haplotype blocks 
are outlined in black.   
 
Seven haplotypes were determined for the case-control samples in the haplotype block 
(Table 22).  Haplotype 1 was the most frequent haplotype in controls, while haplotype 2 
had the highest frequency in cases.  Haplotype 5 had a nominally significant difference 
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between cases and controls (p = 0.02).  To test the global significance of the haplotypes, 
we did 10 000 permutations using Haploview [313].  According to the calculation of the 
program, 1154 out of these 10 000 permutations exceeded the best observed χ² 
(haplotype 5, χ² = 5.79, p = 0.02).  This means that there is a 12% chance that the 
significant nominal p value of haplotype 5 was observed due to chance alone.  
Haploview also identified the same single haplotype block for the markers genotyped in 
CCL2 for the samples from the TB families.  None of the estimated haplotypes were 
significantly associated with TB before or after permutation testing using the haplotype 
TDT analysis in Haploview (Table 23). 
 
TABLE 22. CCL2 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b
 
1 A-G-T-T-C-C 0.22 0.26 2.99 0.08 0.45 
2 C-A-T-T-C-T 0.24 0.24 0.01 0.93 1 
3 C-A-T-T-C-C 0.22 0.20 1.78 0.18 0.73 
4 C-A-A-T-C-T 0.09 0.11 2.78 0.10 0.50 
5 A-A-T-T-C-C 0.09 0.06 5.78 0.02 0.12 
6 C-A-T-T-G-C 0.07 0.07 0.16 0.69 1 
7 C-A-T-C-C-T 0.07 0.06 0.23 0.63 1 
a
 The order of the SNPs in each block corresponds to Figure 21. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
 
TABLE 23. CCL2 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p value p valuePermutation
b
 
1 C-A-T-T-C-T 25.0 : 33.0 1.11 0.29 0.80 
2 A-G-T-T-C-C 30.0 : 26.6 0.20 0.65 1 
3 C-A-T-T-C-C 21.6 : 20.7 0.02 0.90 1 
4 C-A-A-T-C-T 13.0 : 10.5 0.27 0.60 1 
5 C-A-T-T-G-T 11.0 : 9.3 0.13 0.71 1 
6 A-A-T-T-C-C 6.0 : 8.4 0.40 0.53 0.99 
7 C-A-T-C-C-T 6.0 : 4.0 0.40 0.53 0.98 
a
 The order of the SNPs in each block corresponds to Figure 21. 
b 
Permutation test p values were calculated from 100 000 permutations in Haploview. 
 
4.2.1.3. Comparison of allele frequency and LD between different populations 
We compared the allele frequencies of rs1024611 between populations to evaluate the 
distribution of the SNP in 4 different populations, namely South African Coloureds, 
Mexicans [175], Koreans [175], African Americans [375] and Caucasians [375] (Table 
24).  Allele frequencies of control samples from each study were considered.  The allele 
frequencies of the South African Coloureds, African Americans and Caucasians were 
similar, and the G allele was the minor allele in these 3 populations.  The G allele was 
also the minor allele in the Koreans, but it was the major allele in Mexicans.  Spanish, 
Amerindian and African populations contributed to the admixture in the Mexican 
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population [175]. The A allele is the major allele in African Americans, suggesting that 
the G allele was probably the major allele in the Spanish or Amerindian ancestors of the 
Mexican population.   
 
TABLE 24.  Comparison of allele frequencies of rs1024611 between populations. 
Allele 
South 
African 
Mexican 
[175] 
Korean [175] 
African 
American [375] 
Caucasian [375] 
A 0.78 0.49 0.64 0.78 0.71 
G 0.22 0.51 0.36 0.22 0.29 
 
 
We also compared the LD structure (Figure 22) of CCL2 between the South African 
Coloured control population (n = 482) and a community-based cohort from 
Framingham, New England, namely the Framingham Offspring Study (n = 1797) 
[386,387], in which an association between CCL2 polymorphisms and MCP-1 levels 
and myocardial infarction was found [384].  Both the present study and the Framingham 
Offspring Study genotyped 7 SNPs from CCL2, of which 6 corresponded.  McDermott 
et al [384] included the intronic rs2857657 and we included the synonymous rs4586.  In 
both studies strong LD was found across the CCL2 region.  The 3’UTR SNP was not 
part of the haplotype block determined by Haploview in the South African Coloured 
population, but it was part of the single haplotype block determined by McDermott et al 
[384]. 
 
 
FIGURE 22. Comparison of LD between the South African Coloured control population 
(n = 482) and the Framingham Offspring Study (n = 1797) [384,386,387].  Six of the 7 
SNPs genotyped in both studies corresponded.  The 3’UTR SNP rs2530797 was 
included in the haplotype block of the Framingham Offspring Study, but not in that of 
the South African Coloured population.  Squares are coded in the same manner as in 
Figure 21. 
 73 
4.2.2. Discussion 
CCL2 encodes the MCP-1 protein, a chemokine which recruits immune cells to the site 
of TB infection.  MCP-1 levels are influenced by IFN-γ production and it could possibly 
also regulate IFN-γ levels in return since it determines the migration of IFN-γ producing 
cells to the disease site.  This study in the South African Coloured population did not 
find an association between TB susceptibility and polymorphisms in CCL2.  This is 
similar to the finding of Jamieson et al [65] in a Brazilian population, but differs from 
the association result of Flores-Villaneuva et al in Mexicans and Koreans [175]. 
 
We did not observe any association between the genotypes of the three functional SNPs 
(rs2857654, rs1024610 and rs1024611) and TB susceptibility in the case-control or 
TDT studies.  None of the four remaining SNPs showed any indication of association 
either.  We also tested for an association between TB and the estimated haplotypes.  
One haplotype in the case-control group had a nominally significant p value, but this 
was lost after correcting for multiple testing and is unlikely to be a true reflection of 
association with this region. 
 
In addition, we compared allele frequencies of the rs1024611 SNP between populations.  
The South African Coloureds, African Americans [375] and Caucasians [375] had 
similar frequencies and shared the same major allele (A).  The alternate allele (G) was 
the major allele in Mexicans [175].  Since this is the allele previously associated with 
TB susceptibility in Mexicans and Koreans [175], the lower frequency of the allele in 
the South African Coloured, African American and Caucasian populations suggest that 
it is not the cause of TB susceptibility in these populations, but probably an ethnic-
specific susceptibility factor. 
 
LD analysis of the CCL2 region in the South African Coloured population confirmed 
the strong LD observed in other populations for this region.  However, where another 
study found one haplotype block in this region [384], the results from this study suggest 
that two haplotype blocks are present in the South African Coloured population, 
dividing the gene in 5’ and 3’ segments.  The rs1024610 and rs1024611 SNPs were in 
complete LD in the South African Coloured population, as in previous studies 
[384,385].  
 
In summary, polymorphisms in CCL2 are not associated with TB in the South African 
population and the gene is probably an ethnic-specific susceptibility factor. 
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4.3. INTERLEUKIN-4 
Interleukin-4 (IL-4) is traditionally a T helper 2 (Th2) cytokine and can be produced by 
a variety of cell types, such as T cells, NK cells, eosinophils, basophils and some 
antigen-presenting cells (APCs) [388].  During the early stages of the Th1 response, IL-
4 can promote the associated reactions, but it may downregulate the Th1 response 
during later phases [388].  In addition, IL-4 has a regulatory influence on the alternative 
activation of mouse macrophages [389], a process where an increased expression of, 
and phagocytosis by, the mannose receptor is observed.  M.tuberculosis makes use of 
the mannose receptors to enter the macrophages without hindrance.  IL-4 enhances this 
process due to its anti-inflammatory properties [390]. 
 
Contradictory results as to the importance of IL-4 in TB have been observed in 
genetically deficient IL4
-/-
 mice infected with mycobacteria [390-395].  It has been 
argued that IL-4 does not play an important role in all mouse models of TB [391] as 
these studies differed in the mouse strain used and in the dosage of mycobacteria 
administered [390].  In two studies, where mice with C57BL/6 [395] and B6129 [393] 
genetic backgrounds were used, inactivation of IL4 did not affect the disease.  In 
contrast, M.tuberculosis-infected IL4/IL13
-/-
 mice on a C57BL/6 background generated 
significantly higher levels of IFN-γ mRNA than wild type mice on day 50 after 
infection [394].  BALB/c mice normally have an increased expression of IL-4 during 
TB, as do humans.  When IL4 was disrupted, IFN-γ levels remained high [391], as 
opposed to IL4
+/+
 BALB/c mice, where IL-4 also had unfavourable effects on the Th1 
response. 
 
Contrasting effects of IL-4 are also observed during TB disease in humans.  IFN-γ 
production is favoured during mild disease, while IL-4 levels increase in advanced 
stages of TB with a simultaneous decrease in IFN-γ production and the Th1 immune 
response [195].  These seemingly contradictory effects of IL-4 could be explained by 
the presence of the competitive IL-4 antagonist, IL-4δ2.  IL-4δ2 is a splice variant of 
IL4, lacking exon 2 of the gene, and displays Th1-like properties by inhibiting the 
actions of IL-4 [396,397].  Individuals with latent TB infection, but who remain healthy, 
have high levels of this variant mRNA [398].  During TB chemotherapy IL-4δ2, but not 
IL-4 levels, increased in HIV positive and negative patients [399].  In addition, there is a 
difference in the stability of the two IL4 mRNA products in TB patients, with IL-4 
being more stable than IL-4δ2 [400].  Therefore the ratio of IL-4 and IL-4δ2 may play a 
role in disease progression and outcome [400].     
 
Polymorphisms in the IL4 promoter could influence the transcription levels of the gene.  
Several such polymorphisms in IL4 have been identified previously.  Specifically, a 
functional SNP (rs2243250, IL-4-C589T), located 589 bp upstream of the translational 
site, has been associated with increased promoter strength, stronger binding of 
transcription factors and with different levels of IL-4 activity [401,402].  The CC 
genotype of this polymorphism was previously associated with protection against 
pulmonary TB in a South Indian population [195], but not in Gambians [403].  The 
rs2243250 SNP, together with rs2070874, was also associated with asthma and total IgE 
levels in white Americans [404].  No linkage was found between the chromosome 5q 
region, which contains IL4, and TB in Brazilian families [405,406].   
 75 
TABLE 25. Polymorphisms genotyped in the IL4 gene in the South African Coloured 
population. 
Polymorphism Class Location Genotyping method 
rs2243248 SNP Promoter SNPlex 
rs2243250 (-589) SNP Promoter TaqMan 
rs2070874 (-33) SNP Promoter SNPlex 
rs2243251 SNP Exon 1, synonymous SNPlex 
rs2243291 SNP 3' UTR SNPlex 
 
 
IL4 polymorphisms (Table 25) were investigated in the South African Coloured 
population to test the possible association of the gene with TB and to attempt replication 
of the previous association found with rs2243250 in the South Indian TB population 
[195].  In addition, several other SNPs from this gene were genotyped to elucidate the 
LD structure of the region in this unique South African population.  Case-control and 
family-based association studies were employed.   
 
4.3.1. Results 
4.3.1.1. Single-point statistical analysis 
All SNPs were in HWE for the control population.  The threshold for significance was 
set at p = 0.025 after Bonferroni correction, using the methodology of Nicodemus et al 
[76], since 4 of the 5 genotyped SNPs were in strong LD with each other.  Under this 
criterion, none of the analysed SNPs (Tables 26 and 27) were associated with TB. 
 
TABLE 26.  Single-point statistical analysis in the IL4 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs2243248 G T 0.13 0.47 0.40 0.11 0.41 0.48 0.08 
rs2243250 C T 0.28 0.49 0.23 0.24 0.53 0.23 0.37 
rs2070874 C T 0.35 0.45 0.20 0.36 0.50 0.14 0.05 
rs2243251 A G 0.54 0.38 0.08 0.61 0.31 0.08 0.08 
rs2243291 C G 0.32 0.47 0.21 0.28 0.51 0.20 0.37 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
The rs2243250 SNP has a known functional effect on IL4 transcription, but was not 
associated with TB in the South African Coloured population in the case-control (p = 
0.37) or TDT (p = 0.088) analyses.  This SNP was also not associated with TB in a 
Gambian population [403], but was associated with disease in a South Indian population 
[195].  The rs2070874 SNP had the smallest p value (p = 0.05) of the polymorphisms 
studied, but this was not considered to be statistically significant, because of the 
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adjusted threshold (p = 0.025) for significance.  None of the other SNPs were associated 
with disease either. 
 
TABLE 27. Single-point statistical analysis in the IL4 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs2243248 G 51 : 48 0.091 0.76 
rs2243250 T 58 : 41 2.9 0.088 
rs2070874 T 64 : 54 0.85 0.36 
rs2243251 G 41 : 33 0.87 0.35 
rs2243291 C 54 : 42 1.5 0.22 
 
 
4.3.1.2. Haplotype analysis 
Haplotype and LD analysis for IL4 was done with the Haploview program.  The 
program identified one haplotype block consisting of 4 SNPs.  Strong LD exists in this 
block (Figure 23).  The rs2243248 SNP, which was not included in this block, is in the 
distal promoter region.   
 
 
FIGURE 23.  Plot of LD between IL4 markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  Squares are coded in the same 
manner as in Figure 21. 
 
In both the case-control (Table 28) and TDT (Table 29) samples eight haplotypes were 
present in the single haplotype block identified.  Haplotype 7 had the highest frequency 
in both the cases and controls.   Haplotype 1 had a nominally significant p value of 0.02 
in the case-control study.  The empirical p value (p valuePermutation) represents the 
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number of times the observed data would be expected to occur in the data set analysed.    
During permutation testing in the case-control samples, p values less than 0.02 were 
observed on 1107 out of 10 000 occasions (11%).  These permutation results imply that 
there is an 11% chance that the significant difference between cases and controls with 
the rare haplotype 1 is likely to be due to random variation in the selection of the SNPs. 
 
Similarly, permutation testing in the TDT resulted in the observation of p values less 
than 0.05 on 28933 out of 100 000 occasions (29%).  These permutation results suggest 
that the significant difference in the transmission of the rare haplotype 5 from parents to 
their affected children is likely to be the result of random variation in the selection of 
the SNPs and not a reflection of a true association. 
 
TABLE 28. IL4 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b
 
1 T-T-G-G 0.03 0.02 5.40 0.02 0.11 
2 T-T-G-C 0.16 0.13 4.10 0.04 0.22 
3 T-T-A-C 0.20 0.22 1.17 0.28 0.91 
4 T-C-G-C 0.07 0.09 2.04 0.15 0.65 
5 T-C-A-C 0.06 0.05 0.62 0.43 0.98 
6 C-T-A-C 0.02 0.02 0.43 0.51 0.99 
7 C-C-A-G 0.41 0.44 2.06 0.15 0.64 
8 C-C-A-C 0.04 0.03 0.64 0.42 0.98 
a
 The order of the SNPs in each block corresponds to Figure 23. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview.  
 
TABLE 29. IL4 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p value p valuePermutation
b
 
1 T-T-G-G 3 : 5 0.58 0.45 1 
2 T-T-G-C 18 : 16 0.09 0.77 1 
3 T-T-A-C 27 : 21 0.87 0.35 1 
4 T-C-G-C 13 : 7 1.80 0.18 0.73 
5 T-C-A-C 11 : 11 0.01 0.94 1 
6 C-T-A-C 7 : 5 0.54 0.46 1 
7 C-C-A-G 29 : 39 1.46 0.23 0.82 
8 C-C-A-C 1 : 6 3.75 0.05 0.29 
a
 The order of the SNPs in each block corresponds to Figure 23. 
b 
Permutation test p values were calculated from 100 000 permutations in Haploview. 
 
4.3.1.3. Comparison of allele frequency of rs2243250 between different populations 
We compared the allele frequency of rs2243250 (Table 30) between five different 
populations, namely the South African Coloureds from this study, Indians [195] and the  
populations from the HapMap [59] (Section 4.9), namely Han Chinese from Beijing, 
Japanese from Tokyo, Yoruba Nigerians from Ibadan and individuals of European 
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descent from Utah.  The T allele was the major allele in the South African Coloured, 
Asian and Yoruba Nigerian populations, while the C allele was the major allele in the 
Indians and Europeans, who also shared similar allele frequencies.  The intermediate 
frequency of the C allele (0.47) in the South African Coloureds controls reflects the 
genetic contribution of a number of parental populations. 
 
TABLE 30.  Comparison of allele frequencies of rs2243250 between populations. 
Allele 
South 
African 
Indian [195] 
Asian, 
Beijing and 
Tokyo [59] 
Yoruba 
Nigerians [59] 
Europeans, 
Utah [59] 
C 0.47 0.89 0.27 0.17 0.84 
T 0.53 0.11 0.73 0.83 0.16 
 
 
4.3.2. Discussion 
In this study, polymorphisms in IL4 were tested as susceptibility factors in TB.  
Promoter polymorphisms of the gene have previously been shown to influence 
transcription of IL4.  We did not find any association with the SNPs studied and TB in 
cases and controls or families from the South African Coloured population.   
 
The rs2243250 SNP has a known functional effect on IL4 transcription [401,402] and 
the CC genotype was previously associated with TB in a South Indian population by 
Vidyarani et al [195].   We, and a study in The Gambia [403], did not find an 
association with this polymorphism and TB.  We also did not see any association with 
the other SNPs or haplotypes and TB susceptibility.  We have determined that the allele 
frequency of rs2243250 differed significantly between the South African Coloureds and 
other populations. 
 
The discrepancies reported in association studies with TB for polymorphisms in IL4 
could be the result of differences in allele frequencies and the extent of LD in the 
various populations studied.  However, it is also possible that previous studies reporting 
an association with IL4 may reflect the common problem of an initial association which 
proves to be a false positive.  Another possibility is that alternative splicing, and not 
increased expression of the IL4 gene, is the actual regulatory mechanism in the 
production of IL-4, since the product of alternative splicing of IL4, namely IL-4δ2, is a 
competitive antagonist of IL-4.  The apparent exclusion of a significant genetic effect of 
this gene in TB susceptibility is therefore not an indication that the cytokine is not 
important in TB disease. 
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4.4. INTERLEUKIN-10 
Interleukin-10 (IL-10) is a powerful Th2 regulatory cytokine and plays an essential role 
during the latent TB stage, where increased production of this cytokine promotes 
reactivation of disease [407] and suppression of cell mediated immunity against the 
intracellular infection.  This is mediated via inhibition of MHC-restricted cytotoxicity 
against infected macrophages [408].  In mice, this cytokine inhibits the production of 
IFN-γ [409,410].  IL-10 may also downregulate interleukin-12 (IL-12) responses [411-
413] and thereby influence IFN-γ levels [413,414] (Section 4.5.).  The multifunctional 
IL-10 also inhibits the replication of macrophages and lymphocytes and the secretion of 
other inflammatory cytokines [415].  Individuals innately susceptible to TB after 
infection with M.tuberculosis produce more IL-10 in response to lipopolysaccharides 
(LPS) than those who are resistant [218].   
 
The three most frequently investigated polymorphic variants (rs1800872, rs1800871 and 
rs1800896) in IL10, studied in numerous diseases and disorders such as brucellosis 
[416], psoriasis [417] and TB [171,179,194,418], are located in the proximal promoter.  
These SNPs are linked and in most cases three haplotypes (CCG, ATA and CCA) are 
observed [419].  The haplotypes and individual SNPs have been shown to correlate with 
IL-10 production, transcriptional activity and nuclear-binding activity [419-422].  The 
rs1800896 SNP has previously been associated with TB in Cambodians [190], Sicilians 
[171] and Turkish [189], but not in Korean [418], Gambian [194] or Spanish 
populations [179].  The rs1800872 SNP is in complete LD with rs1800871 and these 
SNPs were associated with TB in Koreans [418], but not in Gambians [194].  A 4 SNP 
haplotype of IL10, which consisted of rs1800896, rs1800871, rs1800872 and 
rs3024496, were also associated with TB in the Koreans [418].  Polymorphisms in the 
distal region of the IL10 promoter, such as rs1800895, may also affect IL-10 production 
[423].  IL10 variants (Table 31) were investigated to test the possible association of the 
gene with TB and to attempt replication of previous association studies in different 
population groups.  The selected polymorphisms included three frequently studied 
functional markers, namely rs1800896, rs1800871 and rs1800872, as well as a SNP in 
the distal promoter region (rs1800890).  In addition other SNPs from this gene were 
genotyped to elucidate the LD structure of the region in the South African Coloureds.     
 
TABLE 31. Polymorphisms genotyped in IL10 in this study. 
Polymorphism Class Location Genotyping method 
rs1800890 (-3575) SNP Promoter SNPlex 
rs1800893 (-1330) SNP Promoter SNPlex 
rs1800896 (-1082) SNP Promoter  SNPlex 
rs1800871 (-819) SNP Promoter SNPlex 
rs1800872 (-592) SNP Promoter SNPlex 
rs3024490 SNP Intron 1 (HapMap) SNPlex 
rs3790622 SNP Intron 1 (HapMap) SNPlex 
rs3024496 (+117) SNP 3' UTR SNPlex 
rs3024498 SNP 3' UTR SNPlex 
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4.4.1. Results 
4.4.1.1. Single-point statistical analysis 
All polymorphisms were analysed in the case-control and family samples and were in 
HWE for the control samples.  Since all nine genotyped SNPs were in strong LD with 
each other, the threshold for significance was set at p = 0.05.  We found no association 
between the functional promoter rs1800896 SNP and TB in the case-control (Table 32) 
or TDT (Table 33) analysis.  The frequently studied rs1800872 and rs1800871 promoter 
polymorphisms were not associated with TB either.  The rs1800890 SNP in the distal 
region of the promoter was also not associated with disease.  None of the other SNPs 
genotyped in IL10 were associated with TB susceptibility. 
 
TABLE 32.  Single-point statistical analysis in the IL10 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs1800890  T A 0.05 0.38 0.58 0.06 0.34 0.60 0.34 
rs1800893 A G 0.16 0.53 0.31 0.16 0.46 0.37 0.12 
rs1800896 G A 0.09 0.46 0.45 0.11 0.42 0.47 0.43 
rs1800871 T C 0.09 0.43 0.48 0.11 0.48 0.42 0.15 
rs1800872 A C 0.09 0.43 0.48 0.11 0.48 0.42 0.16 
rs3024490 T G 0.11 0.41 0.48 0.13 0.46 0.42 0.14 
rs3790622 T C 0 0 1 0 0.01 0.99 0.17 
rs3024496  C T 0.23 0.53 0.24 0.24 0.48 0.29 0.21 
rs3024498 G A 0.01 0.24 0.75 0.01 0.19 0.80 0.17 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
TABLE 33. Single-point statistical analysis in the IL10 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs1800890  A 37 : 36 0.01 0.91 
rs1800893 G 58 : 48 0.94 0.33 
rs1800896 A 48 : 41 0.55 0.46 
rs1800871 C 47 : 39 0.74 0.39 
rs1800872 C 47 : 40 0.56 0.45 
rs3024490 G 46 : 34 1.80 0.18 
rs3790622 - - - - 
rs3024496  C 51 : 41 1.09 0.30 
rs3024498 A 18 : 11 1.69 0.19 
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4.4.1.2. Haplotype analysis 
Haplotypes in IL10 have previously been investigated in TB susceptibility.  We 
analysed LD and haplotypes with the Haploview program, which identified a single 
haplotype block, consisting of all 9 SNPs genotyped in this gene region (Figure 24).  
The SNPs were mostly in strong LD. Only the rs3790622 and rs3024498 variants 
displayed weak LD (D’ value = 5%).  This could be explained by the extremely low 
allele frequency of rs3790622, which was hardly polymorphic in the South African 
Coloured population. 
 
 
 
FIGURE 24. Plot of LD between IL10 markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  Squares are coded in the same 
manner as in Figure 21. 
 
Eight haplotypes (Table 34) were estimated in the case-control samples for the single 
haplotype block of IL10, while ten haplotypes were estimated in the family samples 
(Table 35).  Haplotypes 3 and 9 (Table 35) were present in the family samples, but not 
in the case-control group, possibly due to their low frequencies.  The most frequent 
haplotype in the cases and controls was haplotype 8 (Table 34).  This haplotype was 
also the most frequent in the TDT analysis.  Haplotype 1 was nominally associated (p = 
0.05) in the case-control group, but permutation results implied that this was due to 
random variation in the selection of the SNPs (Table 34).  Haplotype 2 (Table 35) in the 
family samples had a nominally significant p value of 0.0048 and was transmitted more 
frequently to affected offspring than expected.  After permutation calculations, this 
association remained significant, with an empirical p value of 0.01, implying that the 
result is true.  However, this association was not observed in the case-control analysis, 
where the haplotype had a low frequency (Table 34, haplotype 2).  None of the other 
haplotypes were associated with TB. 
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TABLE 34. IL10 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 A-C-C-G-C-C-A-A-A 0.10 0.08 3.71 0.05 0.30 
2 A-C-C-G-C-C-A-G-A 0.09 0.10 0.16 0.69 1 
4 A-C-C-G-C-C-G-A-A 0.07 0.07 0.01 0.93 1 
5 A-C-C-G-C-C-G-A-T 0.10 0.12 2.23 0.14 0.61 
6 A-T-C-G-C-C-A-G-A 0.17 0.15 0.97 0.32 0.96 
7 A-T-C-G-C-C-G-A-A 0.02 0.02 0.06 0.80 1 
8 A-T-C-T-A-T-A-G-A 0.31 0.34 2.27 0.13 0.60 
10 G-C-C-G-C-C-G-A-T 0.12 0.10 3.43 0.06 0.40 
a
 The order of the SNPs in each block corresponds to Figure 24. 
b 
Permutation test p values were calculated from 100 000 permutations in Haploview. 
c
 p values less than 0.05 were observed on 30 018 out of 100 000 occasions (30%)  
 
TABLE 35. IL10 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p pPermutation
b, c
 
1 A-C-C-G-C-C-A-A-A 13 : 18 0.78 0.38 1 
2 A-C-C-G-C-C-A-G-A 17 : 3 9.75 0.0048 0.01 
3 A-C-C-G-C-C-A-G-T 2 : 1 0.33 0.56 1 
4 A-C-C-G-C-C-G-A-A 9 : 5 1.14 0.29 0.93 
5 A-C-C-G-C-C-G-A-T 12 : 15 0.33 0.56 1 
6 A-T-C-G-C-C-A-G-A 21 : 15 1 0.32 1 
7 A-T-C-G-C-C-G-A-A 1 : 5 3.54 0.061 0.34 
8 A-T-C-T-A-T-A-G-A 29 : 33 0.26 0.61 1 
9 A-T-C-T-C-C-G-A-A 1 : 4 2.86 0.088 0.58 
10 G-C-C-G-C-C-G-A-T 9 : 13 0.73 0.39 1 
a
 The order of the SNPs in each block corresponds to Figure 24. 
b 
Permutation test p values were calculated from 100 000 permutations in Haploview. 
c
 p values less than 0.048 were observed on 624 out of 100 000 occasions (0.6%)  
 
TABLE 36. IL10 three SNP  haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b,c
 
1 C-C-A 0.37 0.34 2.71 0.10 0.22 
2 A-T-A 0.31 0.34 3.26 0.07 0.16 
3 C-C-G 0.32 0.32 0.02 0.90 0.99 
a
 The order of the SNPs is rs1800872, rs1800871 and rs1800896. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.16 were observed on 624 out of 10 000 occasions (16%)  
 
We also considered a 3 SNP haplotype, previously associated with TB in Gambians, 
Spanish, Sicilians and Koreans [171,179,194,418] (Table 36, rs1800872, rs1800871 and 
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rs1800896), but it was not significantly associated with disease in the South African 
Coloured case-control study population.  As in previous studies of the 3 SNP haplotype, 
rs1800896, rs1800871 and rs1800872 were linked and only 3 haplotypes, namely CCA, 
ATA and CCG were observed [419].   
 
The estimation of a 4 SNP haplotype, previously associated with TB in Koreans [418] 
(Table 37, rs3024496, rs1800872, rs1800871 and rs1800896), indicated that 5 
haplotypes were present in the South African Coloured population.  The Korean study 
inferred 4 haplotypes containing these SNPs [418] and found that the second most 
frequent haplotype in their study (TCCA, haplotype 4 in Table 37) was associated with 
disease.  This was not the case in our study, where the haplotype was not as frequently 
observed (0.16 in controls) and also not associated with TB.  
 
TABLE 37. IL10 four SNP haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 T-A-T-A 0.30 0.34 2.93 0.09 0.27 
2 C-C-C-G 0.30 0.29 0.03 0.85 1 
3 C-C-C-A 0.20 0.18 1.61 0.20 0.66 
4 T-C-C-A 0.17 0.16 0.62 0.43 0.94 
5 T-C-C-G 0.03 0.03 0.03 0.88 1 
a
 The order of the SNPs  is rs30224496, rs1800872, rs1800871, rs1800896. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.09 were observed on 2707 out of 10 000 occasions (27%).  
 
4.4.1.3. Comparison of allele frequencies and haplotypes of IL10 between populations 
Three promoter polymorphisms and a 3’UTR SNP have been studied extensively in 
diverse populations.  We collected allele frequency information for rs1800896, 
rs1800871, rs1800872 and rs3024496 from previously published studies 
[171,179,183,189,190,194,418,424,425,425,426] and compared the results with that of 
the South African Coloured population (Table 38).  In the South African Coloured 
population the major A allele of rs1800896 had similar allele frequencies to the 
Cambodian and Gambian populations (66-68%).  The respective Chinese studies, as 
well as the Korean study indicated that rs1800896 was not a highly polymorphic SNP in 
those populations, with the A allele being the major allele and having frequencies higher 
than 90%.  The UK white, Spanish and Sicilian populations also had the A and G alleles 
at approximately equal frequencies (A allele frequency = 0.52, 0.56 and 0.45 
respectively).  The G allele was the major allele only in Brazilians.   
 
Four populations, namely the South African Coloureds, Brazilians, Gambians and 
Turkish had allele frequency data for rs1800871.  The T allele of this SNP was the 
major allele only in the South African Coloured population.  The Brazilian and Turkish 
allele frequencies were the inverse of the South African Coloureds, with the C allele as 
major allele.  Allele frequencies of rs1800872 were available in five populations.  The 
South African Coloureds shared the same minor allele (A) and similar allele frequencies 
with the Turkish.  The Koreans were the only population with the A allele as major 
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allele.  Only two studies had allelic information for rs3024496.  This SNP was highly 
polymorphic in the South African Coloured population, but not in Koreans. 
 
TABLE 38.  Comparison of allele frequencies of IL10 markers between populations. 
rs1800896 rs1800871 rs1800872 rs3024496 
Population 
A G T C A C C T 
South African Coloured 0.68 0.32 0.66 0.34 0.34 0.66 0.48 0.52 
Cambodian  [190] 0.67 0.33 - - - - - - 
Brazilian  [424] 0.31 0.69 0.34 0.66 - - - - 
Chinese  [425] 0.96 0.04 - - - - - - 
Gambian  [194] 0.66 0.34 0.47 0.53 0.47 0.53 - - 
Hong Kong Chinese  [183] 0.96 0.04 - - - - - - 
Korean  [418] 0.92 0.08 - - 0.67 0.33 0.04 0.96 
Sicilian  [171] 0.45 0.55 - - - - - - 
Spanish  [179] 0.56 0.44 - - - - - - 
Turkish  [189] 0.77 0.23 0.33 0.67 0.33 0.67   
Ugandian  [426] - - - - 0.42 0.58 - - 
UK white [425] 0.52 0.48 - - - - - - 
 
 
We also compared frequencies of the 3 SNP haplotype consisting of rs1800872, 
rs1800871 and rs1800896 (Table 39).  This haplotype has been studied repeatedly in 
numerous populations and in most cases only 3 haplotypes, namely CCA, ATA and 
CCG were observed [419].  This is also true for the South African Coloured population.  
All three of these haplotypes were present at approximately the same frequencies in the 
South African Coloureds (0.32-0.34).  The minor haplotype in Koreans and Hong Kong 
Chinese was CCG, two populations which also differ markedly in the allele frequencies 
of the other polymorphisms in IL10 when compared to the rest.  The GTA haplotype is 
rarely identified in populations and was present in Estonian whites [417]. 
 
TABLE 39.  Comparison of 3 SNP haplotype frequencies of IL10 between populations. 
1 2 3 4 
Population Ref 
C-C-A
a
 A-T-A C-C-G G-T-A 
South African Coloured 0.34 0.34 0.32 - 
Estonian whites [417] 0.26 0.28 0.45 0.01 
Hong Kong Chinese [183] 0.92
b
 0.08 - 
Koreans [418] 0.23 0.70 0.07 - 
Kwazulu-Natal [427] 0.28 0.34 0.38 - 
Spanish [416] 0.37 0.27 0.36 - 
Turkish [189] 0.44 0.33 0.23 - 
a
 The SNPs are listed in the following order: rs1800872, rs1800871 and rs1800896. 
b
 Frequency of combined CCA and ATA. 
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4.4.2. Discussion 
Polymorphisms in IL10 have been studied in various diseases, including TB.  However, 
association results from these TB studies have been conflicting.  We attempted to 
replicate previous association studies in other populations and to elucidate the LD and 
haplotype structure of this gene in the South African Coloured population. 
 
We found no association between the rs1800896 SNP, which has previously been 
shown to influence IL-10 production, and TB susceptibility in the case-control or TDT 
analysis.  This result is similar to findings in Korean [418], Gambian [194] and Spanish 
populations [179], even though the polymorphism was previously associated with TB in 
Cambodians [190], Sicilians [171] and Turkish [189].  The rs1800871 and rs1800872 
SNPs, also previously associated with TB disease, were not susceptibility factors in this 
study either.  However, these SNPs were in complete LD with each other in the South 
African Coloured population, as was found in other populations [194,418].  None of the 
remaining SNPs were associated with disease in the case-control or TDT analysis. 
 
Haplotype analysis of the SNPs genotyped in IL10 showed a single association with one 
haplotype in the TDT analysis.  This association remained significant after permutation 
testing.  However, this haplotype was not associated with disease in the case-control 
study.  This seemingly conflicting result could be explained by the smaller sample size 
available for the family-based association test.  Since the case-control association study 
had a bigger sample size, and therefore higher power than the TDT, it is probable that 
this association is not true and that, given the availability of more TB families to 
genotype, it would disappear. 
 
Since a three SNP haplotype of IL10 was previously associated with TB, we also tested 
this in the South African Coloured population.  In contrast to studies done in Gambians, 
Spanish, Sicilians and Koreans [171,179,194,418], there was no association evident in 
the South African Coloured population.  The CCG haplotype has previously been 
associated with higher, and the ATA haplotype with lower, IL-10 production [428].  A 
four SNP haplotype, previously associated with TB in Koreans [418], was also not 
associated with disease in this study.  Our comparison of allele frequencies and 
haplotypes of IL-10 in different populations highlights the genetic diversity that exists 
between populations. 
 
In conclusion, our results suggest that IL10 polymorphisms and haplotypes are not 
susceptibility determinants for TB in the South African Coloured population. 
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4.5. MEMBERS OF THE INTERLEUKIN-12 FAMILY AND THEIR RECEPTORS 
Interleukin-12 (IL-12, IL12-p70), IL-12(p40)2 (IL12p80) and interleukin-23 (IL-23) are 
all dimeric members of the IL-12 family [429].  The heterodimers IL-12 and IL-23 
share the p40 chain (encoded by the interleukin-12, beta (IL12B) gene [430]), but each 
cytokine also contains a unique subunit, namely p35 [431] and p19 [432] respectively, 
while the homodimer IL-12(p40)2 is composed of two p40 chains [433,434] (Figure 25).  
In order for these cytokines to have any biological activity, they need to bind to their 
specific receptors.  The high affinity interleukin-12 receptor complex (IL-12R) [435] 
consists of two subunits, namely interleukin-12 receptor, beta 1 (IL-12Rβ1) and 
interleukin-12 receptor, beta 2 (IL-12Rβ2) [435], encoded by the IL12RB1 [436,437] 
and IL12RB2 [438] genes respectively.  IL-23 also binds to IL-12Rβ1, but not 
measurably to IL-12Rβ2 [432], and attaches to the IL-23R subunit instead [439].  The 
respective heterodimeric receptors of IL-12 and IL-23 share the IL-12Rβ1 chain and it 
is likely that IL-12(p40)2 may also bind to it [440].  Even though IL-12, IL-12(p40)2 and 
IL-23 all utilise these cytokine and receptor subunits [441] (Figure 25), each cytokine 
has specific and diverse functions. 
 
 
 
FIGURE 25. Selected members of the IL-12 family and their receptors.  Adapted from 
[429]. 
 
IL-12 is a key promoter of the Th1 immune responses and plays a vital role in the 
protective cell-mediated immunity against M.tuberculosis as part of the IL-12/IL-
23/IFN-γ pathway [442].  This cytokine is released from macrophages after 
phagocytosis of the bacterium and induces IFN-γ production by Th1 lymphocytes, 
which in turn will activate macrophages (Figure 20).  A positive feedback loop is 
therefore created which will enhance the antimicrobial activity of the macrophages and 
increase killing of the mycobacterium [443,444].  IFN-γ production is reduced in the 
absence of IL-12 [445].  It has been shown in mice that deficiency of the p35 chain is 
less detrimental to host response against TB than the lack of p40 [446,447].  IL-
12(p40)2 can not induce IFN-γ production in T cells, is an antagonist of IL-12 that binds 
to IL-12Rβ1 and blocks the IL-12p70 activation of T cells [443].  It is also a 
chemoattracttant for macrophages [448], and may induce tumor necrosis factor-α [449] 
and nitric oxide synthase [450].  IL-12(p40)2 binds to the IL-12R, but this interaction 
does not result in a biological response [433,434,451].  It has been shown that IL-
12(p40)2 is sufficient to ensure the M.tuberculosis-induced maturation of pulmonary 
dendritic cells to that of a T cell activating phenotype, but it is not known through which 
receptor it acts [452].   
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IL-23 was first thought to have similar functions to IL-12, since it induced the 
production of IFN-γ in human T cells and activated signal transducer and activator of 
transcription 4 (STAT4) [432,439].  However IL-23 can induce interleukin-17 
production in T cells, something which IL-12 cannot [453].  The IL-23 p19 subunit has 
a negligible effect on TB progression in both early and chronic M.tuberculosis infection 
[453].  It can however reduce the severity of TB infection and may promote granuloma 
formation when IL-12 is absent [441].   
 
MSMD (as discussed in 4.1.) is a rare syndrome and affected individuals are usually 
predisposed to clinical disease which is caused by normally nonpathogenic 
mycobacteria, but they are also susceptible to M.tuberculosis and Salmonella.  
Mutations in IL12B [50,342,343] and IL12RB1 [45,46,344-346] of these patients are 
often the cause of this disease.  More common polymorphisms in these genes may have 
an effect on the genetic control of M.tuberculosis in the general population [454].  
Considering this hypothesis, the importance of the p40 and IL-12Rβ1 subunits in TB, 
their effects on IFN-γ production and the conflicting findings of previous association 
studies done in other populations [191,444,454-457], IL12B and IL12RB1 were selected 
to study as susceptibility factors for TB.   
 
TABLE 40. Polymorphisms genotyped in the IL12B, IL12RB1 and IL12RB2 genes in the 
South African Coloured population. 
Polymorphism Class Location Genotyping method 
IL12B 
rs730691 SNP 5’ UTR SNPlex 
rs3212217 SNP 5’ UTR SNPlex 
rs3212220 SNP 5’ UTR SNPlex 
D5S2941 ((ATT)n) STR
a
 Intron 1 Capillary electrophoresis 
rs3213096 SNP Exon 3, non-synonymous SNPlex 
rs2288831 SNP Intron 3, HapMap SNPlex 
rs2853696 SNP Intron 5, HapMap SNPlex 
rs3212227 (+1188/1159) SNP 3' UTR SNPlex 
IL12RB1 
rs393548 (-111) SNP Promoter SNPlex 
rs2305743 SNP Intron 2, HapMap SNPlex 
rs11086087 (5970) SNP Exon 4, non-synonymous SNPlex 
rs429774 SNP Intron 6, HapMap SNPlex 
rs375947 (365/1094/1158) SNP Exon 10, non-synonymous SNPlex 
IL12RB2    
rs11576006 (-1033) SNP Promoter SNPlex 
rs3762317 (-465) SNP Promoter ARMS-PCR 
a
 short tandem repeat (STR) 
 
We investigated polymorphisms from these genes (Table 40) to determine their 
involvement in TB susceptibility in the South African Coloured population.  Promoter 
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polymorphisms in IL12RB2 (Table 40) were also investigated, since this gene was 
previously associated with leprosy [458], an infectious disease caused by 
Mycobacterium leprae.  Coding SNPs in this gene were previously shown to have no 
influence on mycobacterial infection [252,455], but the degree of expression of this 
gene, possibly regulated by promoter polymorphisms, could determine the intensity of 
the cell-mediated immune response to mycobacteria [458].  For this reason we included 
rs3762317, which disrupts a GATA transcription factor binding site [296], and 
rs11576006, which participates in the creation of another GATA site [296], in the 
genotyping experiments.   
 
4.5.1. Results 
4.5.1.1. Single-point statistical analysis 
All polymorphisms were in HWE in controls.  Bonferroni corrections were applied 
using the methodology of Nicodemus et al [76]. 
 
a) IL12B 
Seven SNPs in IL12B were studied as susceptibility markers for TB in the South 
African Coloured population.  After Bonferroni correction [76] the level of significance 
required was set at 0.025.  Under this criterion, none of the analysed SNPs (Tables 41 
and 42) reached statistical significance, even though rs2853696 had a nominally 
significant p value (p = 0.04).  The 3’UTR SNP (rs3212227) [459,460], may influence 
gene expression levels and has previously been associated with TB in certain 
populations [247,456,461], but not in others [444].    This polymorphism was not 
associated with TB in this study either (pCase-control = 0.27, pTDT = 1).  None of the 
remaining SNPs, which included 3 promoter variants, 1 nonsynonymous SNP and 2 
intronic SNPs, were associated with TB in the case-control or TDT analyses.  The 
rs3213096 and rs2853696 SNPs had extremely low minor allele frequencies in the 
South African Coloured population.   
 
TABLE 41.  Single-point statistical analysis in the IL12B case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs730691 T C 0.24 0.49 0.27 0.26 0.50 0.24 0.51 
rs3212217 C G 0.09 0.36 0.55 0.06 0.38 0.56 0.18 
rs3212220 T G 0.10 0.40 0.50 0.06 0.44 0.49 0.11 
rs3213096 A G 0 0.003 0.997 0 0.004 0.996 0.82 
rs2288831 C T 0.10 0.40 0.50 0.06 0.45 0.49 0.12 
rs2853696 A G 0.003 0.114 0.883 0.01 0.16 0.83 0.04 
rs3212227  C A 0.09 0.40 0.51 0.06 0.44 0.50 0.23 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
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TABLE 42. Single-point statistical analysis in the IL12B TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs730691 C 52 : 41 1.30 0.25 
rs3212217 G 36 : 32 0.24 0.63 
rs3212220 T 43 : 40 0.11 0.74 
rs3213096 -
a
 - - - 
rs2288831 C 43 : 40 0.11 0.74 
rs2853696 G 19 :10 2.79 0.09 
rs3212227  - 40 : 40 0 1 
a
 this SNP was not present in the family-based samples. 
 
b) IL12RB1 
The association of IL12RB1 polymorphisms with TB susceptibility in the South African 
Coloured population were tested by genotyping 5 polymorphisms from the gene.  The 
threshold for significance was set at p = 0.013 after Bonferroni correction, since 3 of the 
5 genotyped SNPs were independent of the others.  None of the SNPs were associated 
with TB in the case-control analysis (Table 43).  The rs393548 SNP was significantly 
associated with TB in the TDT analysis (Table 44, p = 0.013).  This polymorphism was 
previously associated with TB [454] in 101 Moroccan families, but was not associated 
with TB in the case-control study of the South African Coloured population.  No other 
SNP attained significance in the TDT analysis.   
 
TABLE 43.  Single-point statistical analysis in the IL12RB1 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs393548  C G 0.04 0.32 0.64 0.03 0.32 0.65 0.52 
rs2305743 A G 0.03 0.33 0.65 0.04 0.29 0.66 0.32 
rs11086087 C G 0.02 0.19 0.78 0.01 0.22 0.77 0.50 
rs429774 C T 0.12 0.44 0.44 0.12 0.44 0.44 0.95 
rs375947 G A 0.15 0.44 0.42 0.16 0.43 0.42 0.89 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test. 
 
TABLE 44. Single-point statistical analysis in the IL12RB1 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs393548  G 39 : 20 6.12 0.013 
rs2305743 G 25 : 20 0.56 0.46 
rs11086087 G 23 : 22 0.02 0.88 
rs429774 C 51 : 48 0.09 0.76 
rs375947 A 49 : 44 0.27 0.60 
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c) IL12RB2 
Two promoter polymorphisms from IL12RB2 were genotyped in this study, one with an 
ARMS-PCR genotyping method (Figure 26, section 3.6.1).  There was no association 
between either of these SNPs and TB in the case-control (Table 45) or TDT (Table 46) 
analysis, since the threshold for significance was set at 0.025 after Bonferroni correction 
using the method of Nicodemus et al [76].  The rs3762317 SNP was previously 
associated with leprosy and determined the clinical type of the disease [458].  The G 
allele of this SNP disrupts a GATA site and leads to a threefold increase in promoter 
activity [296].  The rs11576006 SNP creates a GATA transcription factor binding site 
[296] together with the rs3762315 SNP, which could not be genotyped in this study due 
to technical issues. 
 
TABLE 45.  Single-point statistical analysis in the IL12RB2 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs11576006  C T 0.12 0.50 0.38 0.11 0.44 0.45 0.07 
rs3762317  G A 0.18 0.57 0.24 0.17 0.51 0.31 0.08 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
 
FIGURE 26. A: Sequencing from IL12RB2 revealed the presence of the rs3762317 SNP, 
indicated with an arrow on the chromatogram.  B: A 2% agarose gel with the 
amplification products generated by the ARMS-PCR.  M = 100 bp ladder, GG = 
homozygote G, GA = heterozygote GA, AA = homozygote A, 1 = 695 bp internal 
control product, 2 = 494 bp allele-specific product. 
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TABLE 46. Single-point statistical analysis in the IL12RB2 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs11576006  T 44 : 40 0.19 0.66 
rs3762317  A 22 : 20 0.095 0.76 
 
 
4.5.1.2. IL12B microsatellite analysis 
The D5S291 microsatellite, an (ATT)n repeat, was previously associated with TB in the 
Hong Kong Chinese population [456].  In that study, and several other studies, only 
(ATT)8 and (ATT)9 alleles were observed.  However, in the South African Coloured 
population we also detected (ATT)7 and (ATT)10 alleles (Figure 27) with the 
Genemapper version 3.7 software program (Applied Biosystems).  The presence of an 
(ATT)7 allele in two Swedish families was mentioned in only one other study [290], 
while the (ATT)10 allele was novel.  We verified the presence of these alleles by 
sequencing the microsatellite (Figure 28, section 3.5.2.). 
 
 
 
FIGURE 27. D5S2941 trinucleotide repeat analysis with Genemapper version 3.7. The 
common (ATT)8 and (ATT)9 alleles can be seen in A.  The (ATT)7 allele is visible in B 
and the novel (ATT)10 allele is present  in C. 
 
The number of ATT repeats from the D5S2941 microsatellite marker was determined 
by direct counting (Table 47) and plotted as a distribution graph (Figure 29).  Since this 
graph was bimodal, the alleles were divided into two subclasses, as previously described 
[323-325].  The shorter repeats, with (ATT)7 and (ATT)8, were designated as S alleles 
and the longer repeats, with (ATT)9 and (ATT)10, were designated as L alleles.  The 
genotypic effect of the repeats on susceptibility to TB was evaluated by dividing the 
three genotypes (S/S, S/L and L/L) into two subgroups according to the presence or 
absence of the S allele: genotypes containing the S allele (S/S and S/L) and genotypes 
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without the S allele (L/L).  Possible associations between the disease groups and classes 
of alleles were analysed for significance by the χ
2
 test (Table 48).  We did not find any 
association with the D5S2941 microsatellite and TB susceptibility using a genotype-
based test (p = 0.27) or comparing genotypes with and without the S allele (p = 0.17) in 
the case-control samples.  In the TDT the L allele was transmitted more frequently than 
expected to affected children, but this did not reach statistical significance (Table 49).  
 
 
FIGURE 28. Sequencing of D5S2941 to confirm the presence of the (ATT)7 and (ATT)10 
alleles.  No (ATT)10  homozygote was identified through genotyping, and a heterozygote 
was  sequenced to confirm the existence of this rare allele.  The reverse sequence is 
shown. 
 
TABLE 47. Frequencies of the respective alleles of D5S2941 in the TB cases and 
controls. 
Allele Cases(n) alleles CasesFrequency Controls(n) alleles ControlsFrequency 
(ATT)7 18 0.02 13 0.01 
(ATT)8 581 0.68 633 0.69 
(ATT)9 239 0.28 253 0.28 
(ATT)10 16 0.02 13 0.01 
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FIGURE 29. Distribution graph of (ATT)n repeats of the D5S2941 microsatellite. 
 
TABLE 48.  Microsatellite analysis of D5S2941 in the case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls 
1
b
 2 11 12 22 11 12 22 p value 
D5S2941 
L S 0.09 0.41 0.50 0.08 0.45 0.47 0.27
c 
; 0.17
d
 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from genotype-based χ² test. 
d
 p value of comparison of genotypes with and without S allele.
 
 
TABLE 49. D5S2941 S and L allele TDT analysis. 
Overtransmitted Transmitted:Untransmitted χ² p value 
D5S2941 
L 43 : 35 0.082 0.37 
 
 
4.5.1.3. Haplotype analysis 
Haplotypes in the respective genes were analysed with Haploview v3.3. 
 
a) IL12B 
D’ values between markers in the IL12B gene were usually greater than 50%, indicating 
strong LD in this region (Figure 30).  One haplotype block, which excluded rs3213096 
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due to its low allele frequency, was identified in IL12B (Figure 30).  The rs730691 
5’UTR SNP was also not part of this block in the South African Coloured population.  
Four haplotypes were estimated in the haplotype block.  Haplotype 3 (Tables 50 and 51) 
was nominally associated with TB in both the case-control (p = 0.02) and TDT (p = 
0.02) analyses.  After 10 000 permutations, these associations became less significant (p 
= 0.06 and p = 0.03 respectively).  According to the calculation of the program, 570 out 
of these 10 000 permutations exceeded the best observed χ² (haplotype 3, χ² = 5.76, p = 
0.02) in the case-control analysis.  This means that there is a 6% chance that the 
significant nominal p value of haplotype 3 was observed due to chance alone.  In 
permutation calculations using the family-based TDT data, 334 out of these 10 000 
permutations exceeded the best observed χ² (haplotype 3, χ² = 5.76, p = 0.02), which 
means that there is a 3% chance that this association is due to chance alone in the TDT 
analysis.  Haplotype 3 was tagged by the A allele of rs2853696, a SNP with a low allele 
frequency (0.09) in the South African Coloured population.   
 
TABLE 50. IL12B case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 A-G-T-S-G-G 0.63 0.62 0.49 0.49 0.89 
2 C-G-C-L-T-C 0.25 0.24 0.21 0.64 0.99 
3 A-A-T-S-G-G 0.06 0.09 5.29 0.02 0.06 
4 C-G-C-L-T-G 0.03 0.04 1.12 0.29 0.73 
a
 The order of the SNPs in each block corresponds to Figure 30, with D5S2941 included 
and rs3213096 excluded. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.02 were observed on 570 out of 10 000 occasions (6%).  
 
 
FIGURE 30. Plot of LD between IL12B markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  Squares are coded in the same 
manner as in Figure 21.  
 95 
TABLE 51. IL12B TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p pPermutation
b, c
 
1 A-G-T-S-G-G 33 : 25 1.11 0.29 0.51 
2 C-G-C-L-T-C 24 : 25 0.02 0.90 1 
3 A-A-T-S-G-G 5 : 16 5.76 0.02 0.03 
4 C-G-C-L-T-G 5 : 3 0.43 0.51 1 
a
 The order of the SNPs in each block corresponds to Figure 30. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.02 were observed on 334 out of 10 000 occasions (3%)  
 
b) IL12RB1 
The confidence interval definition of haplotype blocks according to Gabriel et al [89] 
indicated only one haplotype block consisting of two polymorphisms (rs429774 and 
rs11086087) of the five IL12RB1 SNPs genotyped in this study (Figure 31).  This is due 
to the varying degrees of LD between the SNPs of IL12RB2 (Figure 31).  Three 
haplotypes were estimated in this single block in both the case-control (Table 52) and 
TDT (Table 53) analyses.  Haplotype 1 (Table 52) was the most frequent haplotype, 
while haplotype 3 had the lowest frequency in both cases and controls.  Haplotype 1 
was transmitted more frequently than the others in the TDT study (Table 53), but none 
of the haplotypes were associated with TB susceptibility in the South African Coloured 
population. 
 
 
 
FIGURE 31. Plot of LD between IL12RB1 markers analysed in control individuals of 
South African Coloured descent generated by Haploview v3.3.  Squares are coded in 
the same manner as in Figure 21.  
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TABLE 52. IL12RB1 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 T-G 0.66 0.66 0.07 0.79 0.99 
2 C-G 0.24 0.22 1.10 0.29 0.59 
3 C-C 0.11 0.12 0.87 0.35 0.69 
a
 The order of the SNPs in each block corresponds to Figure 31. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.29 were observed on 5910 out of 10 000 occasions (59%). 
 
TABLE 53. IL12RB1 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p pPermutation
b, c
 
1 T-G 39 : 31 0.92 0.34 1 
2 C-G 19 : 26 1.25 0.26 0.42 
3 C-C 18 : 18 0.01 0.94 1 
a
 The order of the SNPs in each block corresponds to Figure 31. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.26 were observed on 4230 out of 10 000 occasions (42%) . 
 
c) IL12RB2 
The 2 promoter polymorphisms genotyped in IL12RB2 were in weak LD with each 
other, and this is why Haploview did not create a haplotype block for them (Figure 32).  
However, we did evaluate the combined effect of these SNPs in a haplotype in both the 
case-control (Table 54) and TDT (Table 55) analyses.  Haplotype 2 (Table 54) in the 
case-control haplotype analysis did show a nominal association with TB (p = 0.05), but 
after permutation testing this association was no longer significant (p = 0.08).  
Haplotype 2 was most frequently transmitted to affected offspring in the TDT (Table 
55), while haplotype 1 had the highest frequency in cases and controls (Table 54).  We 
did not find any association between TB susceptibility and the remaining haplotypes in 
the case-control or family samples. 
 
TABLE 54. IL12RB2 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 T-G 0.33 0.34 0.11 0.75 0.97 
2 T-A 0.29 0.33 3.88 0.05 0.08 
3 C-A 0.25 0.22 1.27 0.26 0.49 
4 C-G 0.13 0.11 3.35 0.07 0.11 
a
 The order of the SNPs in each block corresponds to Figure 32. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.05 were observed on 764 out of 10 000 occasions (8%).  
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FIGURE 32. Plot of LD between IL12RB2 markers analysed in control individuals of 
South African Coloured descent generated by Haploview v3.3.  Squares are coded in 
the same manner as in Figure 21.  
 
TABLE 55. IL12RB2 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p pPermutation
b, c
 
1 T-G 29 : 25 0.36 0.56 0.85 
2 T-A 40 : 31 1.28 0.26 0.41 
3 C-A 21 : 31 2.27 0.13 0.18 
4 C-G 10 : 13 0.40 0.53 0.82 
a
 The order of the SNPs corresponds to Figure 32. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.13 were observed on 1811 out of 10 000 occasions (18%).  
 
4.5.1.4. Comparison of allele frequencies between different populations 
We compared allele frequencies of IL12B (Table 56), IL12RB1 (Table 57) and IL12RB2 
(Table 58) polymorphisms between different populations using previously published 
data [191,252,296,444,454-456,458-465].   
 
The 3’UTR rs3212227 polymorphism from IL12B (Table 56) has been genotyped in 
diverse populations.  The C allele was the minor allele in practically all populations, 
although it had a 50% allele frequency in Japanese, which was similar to the Hong 
Kong Chinese frequency.  The populations from African descent (South African 
Coloured, Cameroon, African American) also had higher frequencies of the A allele in 
comparison with populations from European descent.  The European populations, e.g. 
the British, German, Greek and Spanish populations, had similar frequencies as well.  
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The South African Coloured and Moroccan studies showed similar frequencies for the 
rs393548 promoter SNP and for rs11086087 in IL12RB1.  The frequency of the non-
synonymous rs375947 polymorphism did not differ widely between populations, with 
the G allele being the minor allele in all population listed (Table 57). 
 
The rs11576006 and rs3762317 SNPs (Table 58) of IL12RB2 had lower allele 
frequencies in the European population than in the South African Coloured population.  
The frequency of rs3762317 was also slightly lower in the Japanese population (0.39 vs 
0.43). 
 
TABLE 56.  Comparison of allele frequencies of IL12B SNPs between populations. 
rs3212227 
Population Ref 
C A 
South African Coloured 0.28 0.72 
African American [444] 0.33 0.67 
British [462] 0.21 0.79 
Cameroon [459] 0.38 0.62 
European [460] 0.18 0.82 
German [463] 0.21 0.79 
Greek [459] 0.21 0.79 
Hong Kong Chinese [456] 0.45 0.55 
Indian [461] 0.42 0.58 
Japanese [464] 0.50 0.50 
Spanish [465] 0.21 0.79 
White American [444] 0.15 0.85 
 
 
TABLE 57.  Comparison of allele frequencies of IL12RB1 SNPs between populations. 
rs393548 rs2305743 rs11086087 rs429774 rs375947 
Population                  Ref 
C G A G C G C T G A 
South African Coloured 0.19 0.81 0.19 0.81 0.12 0.88 0.34 0.66 0.37 0.63 
Japanese [191] - - - - - - - - 0.39 0.61 
Japanese [455] - - - - - - - - 0.36 0.64 
Korean [252] - - - - - - - - 0.34 0.66 
Moroccan [454] 0.17 0.83 - - 0.13 0.87 - - 0.26 0.74 
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TABLE 58.  Comparison of allele frequencies of IL12RB2 SNPs between populations. 
rs11576006 rs3762317 
Population Ref 
C T G A 
South African Coloured 0.33 0.67 0.43 0.57 
European [296] 0.21 0.79 0.21 0.79 
Japanese [458] - - 0.39 0.61 
 
 
4.5.2. Discussion 
Members of the interleukin-12 cytokine family are known to affect IFN-γ production 
and are, together with their related receptors, necessary for the regulation of T cell 
responses.  We tested the association of common polymorphisms in genes of this 
cytokine family and their receptors with TB, and evaluated the known allele frequencies 
of SNPs in these genes between populations. 
 
4.5.2.1. IL12B 
IL12B encodes the p40 subunit, a chain which is shared by all members of the IL-12 
cytokine family.  These p40-dependent molecules regulate Th1 responses [429] and are 
either involved in the host control of M.tuberculosis infection [466] (IL-12 and IL-23) 
or may contribute to the disease by acting as an antagonist (IL-12(p40)2) [443].  Several 
variant sites in IL12B, including an insertion/deletion polymorphism [467], an intronic 
microsatellite (D5S2941) [468] and a 3’UTR SNP (rs3212227) [459,460], may 
influence gene expression levels.  These polymorphisms have previously been 
associated with susceptibility to a variety of diseases [461], such as diabetes 
[290,462,468], malaria [469], TB [456,461], psoriasis [470] and hepatitis C virus 
infection [471].   
 
We found a nominally significant association between a haplotype in IL12B and 
resistance to TB in the South African Coloured population.  The haplotype occurred 
more in controls than in cases (p = 0.02, OR = 1.53, 95%CI [1.07-2.02]) and was 
significantly untransmitted to affected offspring in the family-based study (p = 0.02).  
Permutation testing decreased the significance of these associations (p = 0.06 and p = 
0.03 respectively), but revealed that there were very slim chances of these associations 
existing due to chance alone.  The haplotype was tagged by the A allele of the 
rs2853696 SNP, which was not associated with TB on its own.  This suggests that this 
SNP is in LD with the true susceptibility variant.   
 
The 3’UTR SNP rs3212227 was not associated with TB in the South African Coloured 
population.  It was previously associated with TB in Japanese [247], Hong Kong 
Chinese [456] and Indian [461] populations, but not in white Americans or African 
Americans [444].  Kusuhara et al [191] considered 1 intronic SNP (rs2288831) and two 
SNPs downstream of IL12B (rs11135058 and rs6870828) in Japanese, but did not detect 
any association between them and TB.  The non-synonymous rs3213096 was found at 
an extremely low frequency of 0.002 in the South African Coloured population.  This 
variant, which changes a serine to asparagine at position 226 of the IL-12 protein, was 
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first identified in a Japanese population [464], but in that study it was not associated 
with asthma and allergic rhinitis.  In the Japanese study an allele frequency of 0.04 was 
detected.  Since our study had the power to detect an odds ratio of 2.15 with 95% 
confidence given an allele frequency of 0.05 based on the sample size available, we can 
only exclude the possibility that the nonsynonymous rs3213096 polymorphism plays a 
substantial role in TB susceptibility. 
 
We identified the novel (ATT)10 allele (which was confirmed by sequencing) as well as 
the (ATT)7, (ATT)8 and (ATT)9 alleles of the D5S2941 microsatellite.  However, none 
of these were associated with TB in the South African Coloured population.  This 
microsatellite, in intron 2 of IL12B, was previously investigated in TB [456] and 
diabetes [468].  In these studies, which were done in Caucasian-Americans and Hong 
Kong Chinese, only the (ATT)8 and (ATT)9 alleles of this STR were ever observed, 
although the presence of the (ATT)7 allele in two Swedish families was mentioned in 
another diabetes study [290].  There are no reports in the literature which studied this 
marker in African populations.  Since the (ATT)7, (ATT)8 and (ATT)9 alleles were 
identified in individuals from European and Asian descent, we speculate that the 
(ATT)10 allele is a genetic contribution from the African parental population of the 
South African Coloureds. 
 
When comparing the association results found between TB and IL12B polymorphisms, 
conflicting results are apparent.  This could be explained by population differences, 
where IL12B may contribute to TB susceptibility to a larger extent in Asian populations, 
than in European or African populations.    
 
4.5.2.2. IL12RB1 
Mutations in IL12RB1 are the most common genetic cause of MSMD with more than 61 
MSMD patients from 18 different countries presenting with defects in this gene [454].  
IL-12Rβ1, encoded by IL12RB1, is the binding chain in the IL-12R and expression of 
this protein is necessary for interaction of IL-12 with IL-12R [443].   
 
We tested the association of five SNPs in IL12RB1 with TB in the South African 
Coloured population using both case-control and family-based association studies.  The 
G allele of the rs393548 SNP was preferentially transferred to affected children in the 
single-point TDT analysis, although no haplotype was associated with TB in the TDT.  
This polymorphism was previously associated with TB in 101 Moroccan families [454].  
In our case-control study, none of the SNPs evaluated or haplotypes estimated in this 
gene was associated with TB disease.  The apparently contradictory results obtained 
from the case-control and TDT analysis in the South African Coloureds could be 
explained by the smaller sample size of the family-based samples.  This would mean 
that the case-control association study had a higher power to detect potential 
associations than the TDT analysis and that the TDT result is likely to be a false 
positive. 
 
Akahoshi et al [455] reported the first case-control association study assessing IL12RB1 
in TB susceptibility in the general population.  This was done in a Japanese population 
with 98 TB cases and 197 healthy controls.  Two common haplotypes (consisting of 4 
SNPs, of which rs375947 was genotyped in our study) were identified, and 
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homozygosity for the allele 2 haplotype was significantly associated with TB (OR 2.4, 
95% CI 1.20-4.99, p = 0.013).  Healthy subjects with this haplotype had lower levels of 
IL-12-induced signalling.  Remus et al [454] investigated IL12RB1 in 101 Moroccan 
families where two promoter polymorphisms in strong LD with each other (rs436857 
and rs393548) were associated with disease.  However, no association was detected in 
their study with the haplotype reported by Akahoshi et al [455] in the Japanese 
population.  Lee et al [252] did a case-control study (115 TB patients, 151 controls) in 
Koreans and investigated 5 SNPs, but no significant differences were observed between 
cases and controls in terms of the genotypes or haplotypes.  A study to investigate the 
effect of IL12RB1 polymorphisms on susceptibility to and severity of TB was done in 
87 Japanese TB patients and 265 controls [191].  Two intronic SNPs were associated 
with disease, and a haplotype consisting of a different combination of SNPs to the one 
identified by Akahoshi et al [455], was associated with resistance to TB.  This study did 
not replicate the association found with the promoter polymorphisms in the Moroccan 
families [191].  The most recent study to consider polymorphisms and haplotypes in 
IL12RB1 was done in an Indonesian population with 314 TB patients and 316 controls 
[457], but no association was observed for the SNPs or haplotypes tested with TB 
susceptibility. 
 
This study in the case-control samples of the South African Coloured population, as 
well as the Korean [252] and Indonesian [457] studies which did not detect any 
association with IL12RB1, considered larger sample sizes than the two positive reports 
from Japanese studies [191,455].  The association found in the Japanese could be 
population-specific, but it could also be indicative of a false positive result.  For this 
reason, replication of those results should be attempted in an independent, larger 
Japanese population [457]. 
 
4.5.2.3. IL12RB2 
IL12RB2 encodes the signalling chain of the IL-12R and is essential for IL-12 
responsiveness [435,472].  Ohyama et al [458] determined that SNPs in the 5’flanking 
region of IL12RB2 partially determined the clinical types of leprosy and that haplotypes 
in this region which carried more than one SNP showed a lower transcriptional activity 
than the wild type.  We tested two promoter polymorphisms to determine their possible 
involvement with TB susceptibility in the South African Coloured population, since the 
promoter region of IL12RB2 has previously been shown to affect the transcriptional 
activity of the gene [296,458]. 
 
We did not detect a significant association between TB and the rs11576006 or 
rs3762317 SNPs.  These specific promoter polymorphisms have not previously been 
studied in any TB association study, but were associated with leprosy.  No haplotypes 
were associated with disease after correcting for multiple tests.  Akahoshi et al [247] 
genotyped a single SNP (rs12142823) in IL12RB2 in Japanese TB cases and controls, 
but did not find any association between it and TB.  Kusuhara et al [191] considered 5 
intronic SNPs of IL12RB2 in a Japanese population, but did not detect any association 
of this region with TB either.   
 
In conclusion, from our results it is apparent that promoter polymorphisms from 
IL12RB2 are not susceptibility factors for TB in the South African Coloured population. 
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4.6. INTERLEUKIN-18 
Interleukin-18 (IL-18) is a proinflammatory cytokine and, together with IL-12, one of 
the primary inducers of IFN-γ production by T cells [473,474].  The cytokine plays a 
critical role in the cell-mediated immunity against several pathogens, including 
intracellular organisms such as Leishmania, Salmonella and M.tuberculosis [475].  In 
mice IL-18 may influence the course of mycobacterial infection and other cytokines, 
such as IL-12, can not atone for a deficiency of this cytokine [476].  IL-18 can, in turn, 
not act independently of the IL-12 system [477], even though they have their own 
receptors and stimulate different signalling pathways [478].  Peripheral blood 
mononuclear cells from human TB patients produce less IL-18 than those from healthy 
individuals and alveolar macrophages secrete IL-18 when exposed to M.tuberculosis 
[473,479-481].  However, the production of IL-18 needs to be tightly regulated, since an 
excess of this cytokine may lead to topical or systemic injuries in the host [473,480-
482].  IL-18 is also involved in the production of interleukin-32 in response to 
M.tuberculosis [483]. 
 
Despite intensive resequencing of IL18, the gene encoding IL-18, to date no non-
synonymous SNPs have been identified.  Initially a synonymous SNP in exon 4 of the 
gene (rs549908) was the main focus of investigation in association studies [484] and 
studies using monocytes from healthy individuals showed that this SNP may influence 
IL18 transcription in vitro [485].  However, several polymorphisms in the promoter 
region of the gene have also been implicated in various diseases, such as sarcoidosis 
[486], allergic rhinitis [487], arthritis [488] and HIV [489].  The rs1946518 promoter 
SNP was previously associated with sarcoidosis in Japanese patients [486], but this 
finding was not verified in a Dutch [490] or independent Japanese population [491].  
Other IL18 polymorphisms (rs187238 and rs189667) were also investigated in Dutch 
sarcoidosis samples, but no association was observed with disease.  Zhou et al showed 
that the promoter activity of a common haplotype was significantly higher than that of 
other haplotypes in sarcoidosis patients [491].  In fact, the functionality of the promoter 
polymorphisms has been proven previously in a multiple sclerosis study [492].  
However, the variants studied were not associated with multiple sclerosis [492]. 
 
TABLE 59. Polymorphisms genotyped in IL18 in this study. 
Polymorphism Class Location Genotyping method 
rs1946519 SNP Promoter SNPlex 
rs1946518 (-607) SNP Promoter SNPlex 
rs187238 (-137) SNP Promoter SNPlex 
rs5744229 SNP Exon/intron boundary 1 SNPlex 
rs189667 (1248) SNP Intron 1 SNPlex 
rs549908 (105) SNP Exon 4, synonymous SNPlex 
 
 
To date only one other association study between polymorphisms in IL18 and 
susceptibility to TB has been published, namely a recent study by Kusuhara et al which 
considered 21 candidate genes including IL18 [191].  Amongst others, they genotyped 6 
SNPs spread throughout IL18, but did not consider the functional promoter or 
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synonymous polymorphisms, and found no association between this gene and TB 
susceptibility.   
 
We selected functional promoter polymorphisms, the synonymous SNP and other 
variants (Table 59) from the gene to genotype in TB patients and controls from the 
South African Coloured population. 
 
4.6.1. Results 
4.6.1.1. Single-point statistical analysis 
All the SNPs were in HWE for the controls.  The threshold for significance was set at 
0.05, since only one LD block was determined in Haploview (Figure 33).  However, 
none of the analysed SNPs were significantly associated with TB in either the case-
control (Table 60) or TDT (Table 61) study. 
  
The rs1946518 and rs187238 SNPs were not associated with TB in the South African 
Coloured population.  The synonymous rs549908 was also not associated with TB in 
our study, even though this SNP may influence IL18 transcription in vitro [485]. 
 
TABLE 60.  Single-point statistical analysis in the IL18 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs1946519 A C 0.11 .50 0.39 0.14 0.48 0.38 0.46 
rs1946518 T G 0.11 0.49 0.39 0.14 0.48 0.38 0.43 
rs187238  C G 0.02 0.23 0.75 0.01 0.24 0.75 0.71 
rs5744229 A G 0.01 0.06 0.93 0.01 0.07 0.93 0.85 
rs189667  G A 0.02 0.23 0.75 0.01 0.24 0.75 0.48 
rs549908  G T 0.02 0.22 0.76 0.01 0.23 0.76 0.88 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
TABLE 61. Single-point statistical analysis in the IL18 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs1946519 T 45 : 44 0.01 0.92 
rs1946518 T 49 : 45 0.17 0.68 
rs187238  C 28 : 21 1.00 0.32 
rs5744229 G 5 : 1 2.67 0.10 
rs189667  G 25 : 16 1.98 0.16 
rs549908  G 27 :20 1.04 0.31 
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4.6.1.2. Haplotype analysis 
Only one haplotype block was identified for the polymorphisms genotyped in IL18 
(Figure 33).  The rs5744229 SNP was excluded, since its allele frequency was less than 
0.05.  There was no association between any of the polymorphisms studied and 
susceptibility to TB in the case-control (Table 62) or TDT studies (Table 63).  
Haplotype 1 was the most frequent haplotype in cases, controls and samples from the 
families. 
 
 
FIGURE 33. Plot of LD between IL18 markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  Squares are coded in the same 
manner as in Figure 21.  The rs574229 SNP was excluded from the haplotype block, 
since its allele frequency was less than 0.05. 
 
TABLE 62. IL18 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 T-A-G-G-T 0.63 0.61 0.72 0.39 0.74 
2 T-A-G-T-A 0.23 0.25 1.15 0.28 0.58 
3 G-G-C-T-A 0.12 0.12 0.006 0.94 1 
a
 The order of the SNPs in each block corresponds to Figure 33. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.28 were observed on 5823 out of 10 000 occasions (58%).  
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TABLE 63. IL18 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p pPermutation
b, c
 
1 T-A-G-G-T 37 : 27 1.54 0.21 0.28 
2 T-A-G-T-A 21 : 33 3.12 0.08 0.07 
3 G-G-C-T-A 19 : 14 0.76 0.38 1 
a
 The order of the SNPs in each block corresponds to Figure 33. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.08 were observed on 726 out of 10 000 occasions (7%)  
 
4.6.1.3. Comparison of allele frequencies between populations 
Two promoter SNPs (rs1946518 and rs187238) and a synonymous SNP (rs5549908) 
have often been studied in various populations.  We compared the allele frequencies for 
these SNPs in the South African Coloured population with that of other populations 
(Table 64). 
 
Allele frequencies for the promoter SNP rs1946518 were available for six populations.  
The South African Coloured population had the same allele frequency for rs1946518 as 
the Czechoslovakian population (T allele = 0.38), which was similar to the allele 
frequency of white Americans (T allele = 0.34).  The G allele was the major allele of 
rs1946518 in almost all populations, but not in the Koreans.  African Americans had the 
lowest allele frequency (T allele = 0.28) for this SNP. 
 
The rs187238 allele frequency of the South African Coloured population was compared 
to that of seven other populations.  In this instance, a similar allele frequency was 
detected in the Korean population (0.13), while the rest of the populations had higher 
frequencies for this SNP.  The synonymous rs5549908 SNP used to be the main focus 
of investigation in association studies [484].  In the South African Coloured population 
this SNP was in complete LD with rs187238.  Allele frequencies of rs5549908 were 
similar to those of Japanese and Korean populations, but lower than those of Chinese. 
 
TABLE 64.  Comparison of allele frequencies of IL18 between populations. 
rs1946518 rs187238 rs5549908 
Population                            Ref 
T G C G G T 
South African Coloured 0.38 0.62 0.13 0.87 0.13 0.87 
African Americans  [493] 0.28 0.72 0.23 0.77 - - 
Chinese [488] - - - - 0.23 0.77 
Czechoslovakians [487] 0.38 0.62 0.28 0.72 - - 
Japanese [494] 0.43 0.57 0.19 0.81 0.12 0.88 
Koreans [495] 0.54 0.46 0.13 0.87 0.15 0.85 
Swiss [496] - - 0.27 0.73 - - 
White Americans  [493] 0.34 0.66 0.27 0.73 - - 
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4.6.2. Discussion 
IL-18 can induce production of  IFN-γ by T cells [473,474] and plays an important role 
in the cell-mediated immunity against several pathogens such as M.tuberculosis [475].  
Expression of the IL18 gene, which encodes this cytokine, may be regulated by 
promoter polymorphisms.  Since no other study that examined these specific 
polymorphisms of IL18 in TB has been published to date, we genotyped the SNPs of 
interest in cases, controls and family samples from the South African Coloured 
population. 
 
We did not detect any associations between six single SNPs, or 3 haplotypes consisting 
of these SNPs, in the case-control or TDT analyses.  The rs1946518 and rs187238 
polymorphisms were previously associated with sarcoidosis [486], asthma [495-497], 
coronary artery disease [498] and type 1 diabetes [499], while the rs549908 SNP may 
influence IL18 transcription [485].  Only one recent TB genetic association study has 
considered IL18 polymorphisms [191], but did not detect any association with disease 
either.  These polymorphisms differed from those genotyped in our study. 
 
Allele frequencies of commonly genotyped polymorphisms were compared between 
different populations.  The South African Coloured population shared similar allele 
frequencies for rs1946518 with Czechoslovakians, and resembled Asian populations for 
rs187238 and rs549908. 
 
In conclusion, IL18 polymorphisms are not susceptibility factors in the South African 
Coloured population. 
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4.7. SH2 DOMAIN PROTEIN 1A 
More male than female TB patients are observed worldwide [117] and even though 
other factors (societal, environmental or hormonal [66]) may account for this 
observation, the presence of a TB susceptibility gene on chromosome X cannot be 
discounted.  A previous linkage study [66] using samples from the South African 
Coloured population indicated that chromosome Xq26 may contain a susceptibility gene 
for TB.  Campbell et al [265] tested the association of variants in the CD40 ligand gene 
located on chromosome Xq26 with TB, but found no association with the disease.   
 
MSMD (as discussed in section 4.1.) is a rare syndrome and affected individuals are 
typically predisposed to clinical disease which is caused by normally nonpathogenic 
mycobacteria.  Five disease-causing autosomal genes have been found to contain 
mutations in these individuals.  However, these genes could not explain the X-linked 
recessive inheritance pattern seen in some families [500].  Recently it was shown that 
X-linked recessive MSMD is caused by mutations in the NFkB essential modulator 
gene (NEMO) located on chromosome Xq28 [352].  Another study by Bustamante et al 
[501] examining patients from a large family with X-linked recessive MSMD did not 
find any mutations in NEMO.  This family was used in a linkage study which indicated 
that the Xq25-26.3 and the Xp11.2-p21.2 could contain the causative mutation.  Since 
MSMD is caused by mutations in X-linked genes in some patients, it is possible that 
common polymorphisms in these genes could contribute to TB susceptibility in the 
general population.  This hypothesis has already been proven true for common variants 
in certain MSMD-causing genes [454-456,502]. 
 
Pasquinelli et al [503] recently found that expression of the signaling lymphocytic 
activation molecule-associated protein (SAP) abolished the production of IFN-γ in T 
cells from TB patients and that disease severity correlated with SAP expression.  SAP is 
encoded by the gene known as SH2 domain protein 1A, Duncan's disease 
(lymphoproliferative syndrome) (SH2D1A) and is predominantly expressed by T, NK 
and some B cells [504].  SH2D1A, which is mutated or absent in patients with X-linked 
lymphoproliferative disease (XLP), is present on chromosome Xq25-q26.  This region 
(Xq26) showed evidence of containing TB susceptibility genes during a genome-wide 
scan in South African Coloureds and Gambians [66], as mentioned above.   
 
SH2D1A is known to be regulated at both the transcriptional and the post-transcriptional 
stage and has a functionally confirmed Ets binding site present near the transcription 
start site of the gene [505].  The human basal promoter (from position -167 to -134) of 
SH2D1A has been identified [505], but it is very likely that other factors are also 
involved in promoter activity of the gene.  Such factors could include differential 
methylation (which is present in the SH2D1A promoter [506]), that may promote or 
prevent the binding of transcription factors, or SNPs that create or destroy transcription 
factor binding sites.   
 
This part of the study further investigates the linkage found with chromosome Xq26 in a 
previous genome-wide scan [66] by selecting a candidate gene from the region 
identified. We hypothesise that high levels of SAP may interfere with Th1 cytokine 
responses, and therefore IFN-γ levels, and could cause an increased susceptibility to TB.  
To test this, we sequenced the region upstream of SH2D1A to identify polymorphisms 
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that could influence transcription of the gene and genotyped a SNP that creates putative 
transcription factor binding sites.   
 
4.7.1. Results 
4.7.1.1. Sequencing and in silico promoter analysis 
Sequencing (Figure 34A) of the putative promoter of SH2D1A in 10 individuals did not 
reveal any novel SNPs, but 3 known variants were present in this region, namely G-
631A (rs990545), G-494A (rs7357894) and C-347T (rs12164382).  The polymorphisms 
were in complete linkage disequilibrium (D’ = 1 and r
2
 = 1, data not shown).  We then 
used the SNPInspector program [314] to determine the potential effects of the SNPs on 
the SH2D1A sequence.  Only rs990545 created 2 putative transcription factor binding 
sites (for CCAAT enhancer binding protein, beta (C/EBP-β) and pregnane X receptor 
(PXR), respectively) and we therefore selected this polymorphism to genotype in all the 
samples from the female and male DNA collections.  A tetraprimer ARMS-PCR 
method (Figure 34B, section 3.6.2.) was used for genotyping. 
 
 
 
FIGURE 34. A: Sequencing from SH2D1A revealed the presence of the rs990545 
polymorphism, indicated with an arrow on the chromatogram.  B: A 2% agarose gel 
with the amplification products generated by the tetraprimer ARMS-PCR.  M = marker, 
GA = heterozygote GA, GG = homozygote G, AA = homozygote A, 1 = 695 bp internal 
control product, 2 = 450 bp G allele product, 3 = 296 bp A allele product. 
 
4.7.1.2. Single-point statistical analysis 
The female dataset was in HWE for both cases and controls, indicating the probability 
of correct genotyping.  Since males have one X chromosome only, they were all 
hemizygous for rs990545 and not tested for HWE. 
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Genotype and allele frequencies for female subjects and allele data for male individuals 
are listed in Tables 65 and 66.  The G allele of the rs990545 SNP was associated with 
susceptibility to TB in the female dataset (pgenotypes = 0.016; palleles = 0.021, OR = 1.3 
[1.04-1.65]) which was analysed initially as it provided both hetero- and homozygotes.  
To replicate this finding, we analysed the allelic distribution of this polymorphism in 
males unrelated to the females and again found a significant association (p = 0.014, OR 
= 1.6 95% CI [1.11-2.33]).  Since X-inactivation takes place in females, we compared 
  
TABLE 65. Genotype frequencies and association result of the SH2D1A variant 
investigated in the South African Coloured female population using a case-control 
study.  
rs990545 GG GA AA p value 
TB (n
a
=269) 137 (0.51)
b
 101 (0.38) 31 (0.11) 
Controls (n=449) 180 (0.40) 212 (0.47) 57 (0.13) 
0.016 
a 
number of samples
 
b
The frequency of each genotype is indicated in brackets.  
 
females homozygous for either of the alleles of the SNP separately [507].  We observed 
a non-significant trend (p = 0.058) for this analysis, with the GG genotype occuring 
more frequently in cases than controls.  An analysis of the combined female and male 
allelic data, revealed a strong association (p = 0.0009, OR = 1.39 [1.14-1.68]) between 
TB and the G allele of rs990545. 
 
TABLE 66. Allele frequencies and association results of the SH2D1A variant 
investigated in the South African Coloured population using a case-control study.  
rs990545 G A p value OR
a
 [95% CI
b
] 
Female heterozygotes and homozygotes 
TB (n
c
=269) 375 (0.70)
d
 163 (0.30) 
Controls (n=449) 572 (0.64) 326 (0.36) 
0.021 1.31 [1.04-1.65] 
Male hemizygotes 
TB (n=270) 194 (0.72) 76 (0.28) 
Controls (n=238) 146 (0.61) 92 (0.39) 
0.014 1.61 [1.11-2.33] 
Female and male subjects 
TB (n=539) 569 (0.70) 239 (0.30) 
Controls (n=687) 718 (0.63) 418 (0.37) 
0.0009 1.39 [1.14-1.68] 
a
 odds ratio 
b 
confidence interval 
c
 number of samples 
d
 The frequency of each genotype is indicated in brackets. 
 
4.7.1.3. Cloning of the SH2D1A gene promoter 
Cloning of the SH2D1A promoter region into the pGEM
®
-T Easy vector system resulted 
in two constructs, namely pGEM(SAP G) and pGEM(SAP A).  Each contained one 
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allele (G or A) of the rs990545 SNP.  Sequencing of the pGEM constructs confirmed 
that they contained the correct SH2D1A insert (Figure 35A).  The insert was subcloned 
from the pGEM constructs into a pGL4 luciferase reporter vector, namely 
pGL4.10[luc2].  The luciferase constructs were named pGL4(SAP G) and pGL4(SAP 
A) and the nucleotide sequences of the inserts were verified by sequencing (Figure 
35B).  
 
 
FIGURE 35. Sequencing of the pGEM-T and pGL4 constructs were aligned with the 
expected SH2D1A insert.  The alleles of the rs990545 SNP are marked in black.  A) The 
pGEM(SAP A) and pGEM(SAP G) constructs.  B) The pGL4(SAP A) and pGL4(SAP G) 
constructs.  
 
4.7.2. Discussion 
Chromosome Xq26 was indicated as a region possibly containing a TB susceptibility 
gene during the first genome-wide scan [66], but no X-linked gene has been associated 
with TB to date [265].  Globally, fewer female than male TB patients are detected [117] 
and even though other factors may contribute to this discrepancy, it is possible that a TB 
susceptibility gene on the X chromosome may be the underlying cause.   
 
Here we report the association of a polymorphism (rs990545) in the promoter of the X-
linked SH2D1A gene with susceptibility to TB in a South African population.  
Expression of SAP, encoded by SH2D1A, has previously been shown to be the greatest 
in TB patients with low immune responses, suggesting that the SAP protein may be 
involved in the outcome of TB infection [503].  In addition, reduction of SAP 
expression caused M.tuberculosis antigen-stimulated T cells to produce high levels of 
IFN-γ [503].     
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We found an association between the G allele of the rs990545 SH2D1A SNP and 
susceptibility to TB in female and male case-control sample sets from the South African 
Coloured population (Tables 65 and 66).  Since SH2D1A is X-linked, the data was 
separated by gender [508].  This association was significant for the female sample set 
on both the genotypic and allelic level and the finding was replicated in the allelic 
frequency in the male sample.  A combined analysis of the female and male data also 
showed a highly significant association.  
 
The A allele of rs990545 in SH2D1A creates two putative transcription factor binding 
sites, namely for C/EBP-β and PXR, and this polymorphism could therefore contribute 
to the regulation of the transcriptional activity of SH2D1A.  C/EBP-β is stimulated by 
IFN-γ [509] and has three different isoforms, of which two are activators and one is a 
repressor [510].  This transcription factor can act as a mycobacterial or bacterial 
response element [511] and regulates the acute phase-responsive genes under the 
control of interleukin-6 [509].  PXR is a nuclear receptor and an activator of several 
cytochrome P450 genes [512].  Interestingly, PXR is activated by rifampicin [513], a 
drug used extensively to treat TB.  Both C/EBP-β and PXR could be involved in 
regulating SH2D1A transcription, since transcription factors can bind to overlapping 
binding sites without competition [514].  To test this hypothesis in the future two 
luciferase expression vectors controlled by the SH2D1A promoter fragment, containing 
either the A or G allele of rs990545, were constructed in this study. 
Since the A allele of rs990545 is more frequent in controls than TB cases, it is feasible 
that the creation of the C/EBP-β and PXR transcription factor binding sites could lead to 
the binding of their respective transcription factors and inhibition of SH2D1A 
transcription.  This would cause lower levels of SAP and could lead to a stronger Th1 
response, which would be advantageous during infection with M.tuberculosis.   
 
The association observed with the rs990545 polymorphism could be true, but could also 
be due to LD with another polymorphism in the same or another gene on the X 
chromosome.  Recently, X-linked recessive MSMD has been found to be caused by 
mutations in NEMO [352], located in the chromosome Xq28 region. Therefore future 
studies of the importance of the X-linked SH2D1A gene in TB should evaluate the 
functionality of the rs990545 promoter polymorphism in TB to confirm the hypothesis 
of this study. 
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4.8. TOLL-LIKE RECEPTORS  
The family of mammalian Toll-like receptors (TLRs) consists of at least 12 proteins, 
each with a distinct function, which initiate the innate immune response, an essential 
component in the host defence against infection with micro-organisms.  This initiation 
is done through either interferon-regulatory factor-dependent or nuclear factor-κβ-
dependent signalling pathways [515].  This chain of events is set off by the recognition 
of pathogen-associated molecular patterns (PAMPs), which are microbial components 
that are crucial for the survival of the micro-organism and therefore difficult for it to 
change [516].  The TLR-induced mechanism eventually allows the modulation of the 
adaptive immune system in response to infections.  TLRs are type I transmembrane 
receptors and are characterised by an intracellular Toll/interleukin-1 receptor (TIR) 
domain and an ectodomain of leucine-rich repeats (LRR) [517-519] (Figure 36).   
 
 
FIGURE 36. Illustration of the role of TLRs in initiating the immune system.  The 
extracellular leucine rich repeat (LRR) and intracellular Toll/interleukin-1 receptor 
(TIR) domains are indicated. 
 
TLRs are central components of the innate immune response to mycobacterial infection 
[520,521] and act as part of the pattern recognition system to signal the presence of 
M.tuberculosis in the host [522].  TLR2 and TLR4 were found to be nonredundant 
recognition systems of the bacterium [522]. The importance of TLR pathways in the 
sensing of mycobacteria was further shown in a mouse model deficient for myeloid 
differentiation factor 88 (MyD88), an adaptor molecule utilized by nearly all receptors 
of the TLR family [523].  These mice were extremely susceptible to infection with 
M.tuberculosis [523].  TLRs are also expressed on T cells and may modulate T cell 
activation by TLR ligands [524].   
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TLR2 has a vital role in the responsiveness to several bacterial products [525-529], such 
as leptospiral LPS [528] and mycobacterial lipoproteins [527].  In Th1 cells from mice, 
TLR2 stimulation induced IFN-γ production, cell proliferation and cell survival [524].  
IL-12 and IL-2 enhanced these effects, indicating that TLR2 is a specific activator of 
Th1 responses, while other TLRs investigated in the study did not alter Th2 responses 
[524].  Two recent studies showed that M.tuberculosis may inhibit macrophage 
responses to IFN-γ by a TLR2-dependent pathway [530,531], one of several 
mechanisms used by the bacterium to inhibit the host immune system.  Another popular 
hypothesis argues that TLR2 favours Th2 responses during M.tuberculosis infection and 
contributes to the disease in this manner [532]. 
 
TLR2 knockout mice are highly susceptible to M.tuberculosis infection [533,534] and 
have a short survival time.  These mice also have a higher burden of mycobacteria when 
compared to mice with the functional gene [535].  For this reason, polymorphisms in 
TLR2 have been investigated with regards to TB in a variety of populations.  An 
association between TB and TLR2, with a SNP named Arg677Trp [536] which appeared 
to be functional in mycobacterial disease [537], proved to be false, after it was 
established that Arg677Trp was an artifact due to the presence of a pseudogene region 
[538].  The rs5743708 SNP (Arg753Gln) was investigated in TB cases and controls 
from Turkey and it was suggested that this SNP may contribute to the risk of developing 
TB [229].  There was a slight deviation from Hardy-Weinberg in the control population 
and the authors speculated that this could be due to the high incidence of cosanguinity 
in the Turkish population [229].  This possibility necessitates the replication of the 
association of rs5743708 with TB in another population.  Yim et al [302] studied the 
5’UTR region of the TLR2 gene and identified a microsatellite polymorphism in intron 
2 of the gene.  The frequency of this GT repeat polymorphism varied significantly 
between populations, and modified promoter activity.  This microsatellite was 
subsequently associated with rheumatoid arthritis [323], colorectal cancer [539] and TB 
[291].  Shorter GT repeats were present more often among TB patients and in validation 
samples from Korea, were associated with weaker promoter activity and reduced 
expression of TLR2 on CD14+ peripheral blood monocytes [291].  Variants in TLR2 
have also been associated with other diseases, such as asthma where a promoter 
polymorphism, rs4696480, was associated with disease [540] and staphylococcal 
infection [536]. 
 
TLR4 was the first mammalian toll receptor to be characterised [518] and was identified 
as the mediator of LPS inflammatory responses [264,541-543].  This receptor can also 
respond to heat-labile soluble mycobacterial components as well as viable 
M.tuberculosis and TLR4 will initiate the innate immune system when exposed to these 
[544,545].  In addition, mice deficient in TLR4 developed chronic lung infection when 
exposed to M.tuberculosis and produced less IL-12p40 and MCP-1 [546].  Two 
missense mutations in TLR4, namely rs4986790 (Asp299Gly) and rs4986791 
(Thr399Ile), affect the extracellular domain of the TLR4 protein and were associated 
with hyporesponsiveness to LPS [547], an increased incidence of septic shock [548] and 
with Gram-negative and haematogenous osteomyelitis [549].  The rs4986790 
polymorphism was previously investigated in Gambian TB patients, but no influence in 
LPS responsiveness or susceptibility with the disease was determined [264].  The 
rs4986791 SNP was not tested, since it was not present in Gambians [550]. 
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The results of current studies indicate that the activation of several TLRs contribute to 
an efficient innate response against mycobacteria and support the idea that both the 
TLR2 and TLR4 proteins play a role in sensing mycobacteria and initiating an 
antimycobacterial immune response [551].  Due to the importance of the pattern-
recognition receptors in recognising invading microorganisms, we chose TLR2 and 
TLR4 (encoding the receptors TLR2 and TLR4 respectively), as candidate genes.  We 
selected polymorphisms (Table 67) in the TLR2 and TLR4 genes to genotype in the 
South African Coloured population, based on their possible function in host defence 
against TB. 
 
TABLE 67. Polymorphisms genotyped in the TLR2 and TLR4 genes. 
Polymorphism Class Location Genotyping method 
TLR2 
rs4696480 SNP Promoter SNPlex 
TLR2_GT STR Intron 2 Capillary electrophoresis 
rs3804099 SNP Exon 3, synonymous SNPlex 
rs3804100 SNP Exon 3, synonymous SNPlex 
rs5743704 SNP Exon 3, non-synonymous SNPlex 
rs5743708 (Arg753Gln) SNP Exon 3, non-synonymous SNPlex 
TLR4 
rs1927914 SNP Promoter SNPlex 
rs10759932 SNP Promoter SNPlex 
rs2770148 SNP Exon 3/intron 2 boundary SNPlex 
rs4986790 (Asp299Gly) SNP Exon 3, non-synonymous SNPlex 
rs4986791 (Thr399Ile) SNP Exon 3, non-synonymous TaqMan 
rs11536889 SNP 3' UTR SNPlex 
rs11536891 SNP 3' UTR SNPlex 
 
 
4.8.1. Results 
4.8.1.1. Single-point statistical analysis 
Single-point statistical evaluations of TLR2 and TLR4 polymorphisms were done with 
case-control and TDT analyses.  All SNPs were in HWE in the control samples.  
Correction for multiple testing was done using the definition in Haploview based on the 
study of Nicodemus et al [76]. 
 
a) TLR2 
Five SNPs were studied as TB susceptibility factors in the South African Coloured 
population using case-control (Table 68) and TDT analyses (Table 69).  After correcting 
for multiple tests, the cut-off for significance was set at 0.01.  According to this criterion 
only the synonymous rs3804100 SNP was significantly associated with TB (p = 0.01, 
OR = 1.67 95%CI [1.1-2.5]).  However, this association was only detected in the case-
control samples (Table 68).  The non-synonymous rs5743708 SNP was previously 
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associated with TB in a Turkish population [229], but this finding was not replicated in 
our study, which had a larger sample size and therefore more power.  None of the three 
remaining SNPs were associated with TB.   
  
TABLE 68.  Single-point statistical analysis in the TLR2 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs4696480 A T 0.14 0.43 0.43 0.12 0.47 0.41 0.51 
rs3804099 T C 0.17 0.48 0.35 0.20 0.49 0.31 0.29 
rs3804100 C T 0 0.08 0.92 0 0.14 0.86 0.01 
rs5743704 A C 0 0.01 0.99 0 0.01 0.99 0.88 
rs5743708 A G 0 0.03 0.97 0 0.01 0.99 0.38 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
TABLE 69. Single-point statistical analysis in the TLR2 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs4696480 T 50 : 46 0.17 0.68 
rs3804099 T 61 : 48 1.55 0.21 
rs3804100 C 15 : 8 2.13 0.14 
rs5743704 C 4 : 2 0.67 0.41 
rs5743708 G 1 : 0 1 0.32 
 
 
b) TLR4 
Seven TLR4 SNPs were genotyped to test their possible association with TB in the case-
control (Table 70) and family-based (Table 71) studies.  The level for significance was 
set at 0.01 after correcting for multiple tests.  With this stringent requirement for 
significance, none of the SNPs were associated with TB in the case-control (Table 70) 
or TDT (Table 71) analyses. 
 
The nonsynonymous rs4986790 and rs4986791 SNPs were previously associated with 
hyporesponsiveness to LPS [547] and affect the extracellular domain of the TLR4 
protein.  The rs4986790 SNP was previously investigated in a Gambian TB association 
study who found no association between this SNP and disease [264] and rs4986791 was 
not present in samples from the Gambians.  For this reason we included these two 
polymorphisms in our study.  However, we did not detect any association between these 
coding SNPs and TB (Tables 70 and 71). 
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TABLE 70.  Single-point statistical analysis in the TLR4 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs1927914 T C 0.10 0.44 0.46 0.14 0.45 0.41 0.09 
rs10759932 C T 0.01 0.22 0.77 0.01 0.27 0.72 0.20 
rs2770148 T C 0.04 0.34 0.63 0.03 0.26 0.71 0.04 
rs4986790  G A 0 0.12 0.88 0 0.09 0.91 0.22 
rs4986791  T C 0 0.05 0.95 0 0.04 0.96 0.63 
rs11536889 C G 0.01 0.12 0.87 0.01 0.17 0.82 0.09 
rs11536891 C T 0.06 0.39 0.55 0.08 0.34 0.58 0.31 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
TABLE 71. Single-point statistical analysis in the TLR4 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs1927914 C 43 : 29 2.72 0.10 
rs10759932 T 28 : 24 0.31 0.58 
rs2770148 C 33 : 23 1.79 0.18 
rs4986790  - 9 : 9 0 1 
rs4986791  C 11 : 8 0.47 0.49 
rs11536889 G 12 : 8 0.80 0.37 
rs11536891 C 31 :28 0.15 0.70 
 
 
4.8.1.2. TLR2 microsatellite analysis 
The TLR2 microsatellite (TLR2_GT), present in intron 2 of the gene and associated with 
weaker promoter activity [291], was genotyped in the South African Coloured 
population to determine its association with TB.  This marker was previously associated 
with TB in Koreans [291].  In that study a number of repeat alleles, ranging from (GT)12 
to (GT)28, were observed. 
 
To genotype this microsatellite, we used capillary electrophoresis of fluorescently 
labelled PCR products (Section 3.7).  The Genemapper version 3.7 program was used in 
the analysis of the results and represented the repeats visually on electropherograms 
(Figure 37).  The repeat alleles were confirmed by sequencing (Section 3.5.6.).  We 
detected alleles ranging from (GT)12 to (GT)27 (Table 72).  We did not detect any (GT)14 
or (GT)28 alleles in the South African Coloured population, which differs from the 
findings in the Korean study [291]. 
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FIGURE 37. (GT)n dinucleotide repeat analysis with Genemapper version 3.7.  The 
(GT)12 and (GT)17 alleles are visible on this electropherogram. 
 
TABLE 72. Frequencies of the respective alleles of TLR2_GT in the TB cases and 
controls. 
Allele Cases(n) alleles CasesFrequency Controls(n) alleles ControlsFrequency 
(GT)12 39 0.05 36 0.04 
(GT)13 34 0.04 55 0.06 
(GT)14 0 0.00 0 0.00 
(GT)15 31 0.04 24 0.03 
(GT)16 17 0.02 27 0.03 
(GT)17 52 0.06 59 0.07 
(GT)18 181 0.21 163 0.19 
(GT)19 118 0.14 119 0.14 
(GT)20 104 0.12 106 0.12 
(GT)21 47 0.06 34 0.04 
(GT)22 58 0.07 67 0.08 
(GT)23 101 0.12 110 0.13 
(GT)24 14 0.02 23 0.03 
(GT)25 38 0.05 42 0.05 
(GT)26 7 0.01 6 0.01 
(GT)27 1 0.00
a
 1 0.00
*
 
a
 This allele occurred in less than 1% of the samples 
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The numbers of GT repeats from the TLR2 microsatellite marker were determined by 
direct counting and plotted as a distribution graph (Figure 38).  Since this graph was 
trimodal, the alleles were divided into three subclasses, as described by studies in the 
analysis of microsatellite polymorphisms [291,323-325].  Alleles with 16 or less GT 
repeats were designated as S alleles, those with (GT)17 to (GT)22 as M alleles and those 
with 23 or more GT repeats as L alleles.  To evaluate the genotypic effect on the 
development of TB, the six genotypes (S/S, S/M, S/L, M/M, M/L, L/L) resulting from 
this classification were divided into two subgroups depending on the presence of the S 
allele [291].  Genotypes including the S allele were S/S, M/S and L/S, while genotypes 
without the S allele were M/M, M/L and L/L.  Association between the TLR2 
microsatellite and TB was tested using a two-tailed chi-square test.  For the TDT, the M 
and L alleles were combined in a single group. 
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FIGURE 38.  Distribution graph of (GT)n repeats of the TLR2_GT microsatellite. 
 
TABLE 73.  Microsatellite analysis of TLR_GT in the case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls 
1
b
 2 11 12 22 11 12 22 p value 
 
 
 
TLR2_GT S M/L 0.02 0.24 0.73 0.03 0.62 0.71 0.49
c 
; 0.36
d
 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from genotype-based χ² test. 
d
 p value of comparison of genotypes with and without S allele.
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We did not find any association with the TLR2_GT microsatellite and TB susceptibility 
(Table 73) using a genotype-based test (p = 0.49) or comparing genotypes with and 
without the S allele (p = 0.36).  A TDT in the family-based samples established that the 
S allele was transmitted to affected children more often than expected, but this was not 
significantly so (Table 74). 
 
TABLE 74. TLR2_GT TDT analysis. 
Overtransmitted Transmitted:Untransmitted χ² p value  
TLR2_GT S 25 : 15 2.5 0.11 
 
 
4.8.1.3. Haplotype analysis 
Haplotype and LD analysis for the TLR2 and TLR4 genes were done with the 
Haploview program.   
 
a) TLR2 
LD across the TLR2 gene region was not strong (Figure 39).  However, the rs3804099 
and rs3804100 SNPs were in complete LD.  These two SNPs were also part of a single 
haplotype block identified in this region, which did not include rs4696480, TLR2_GT, 
rs5743704 and rs5743708.  Three haplotypes were identified in the haplotype block 
(Tables 75 and 76). 
 
Haplotype 1 was only associated with disease in the case-control analysis (p = 0.02) and 
remained significant after permutation testing (p = 0.04).  Haplotype 2 (Tables 75 and 
76) was nominally associated with TB in both the case-control and TDT studies.  This 
association was still significant in the case-control group after permutation testing, but 
became less significant in the TDT analysis.  According to calculation of the Haploview 
program 2% of permutations exceeded the best p value, meaning that there is a 2% 
chance that the nominally significant p value was a random statistical fluctuation.  
However, in the TDT haplotype analysis (Table 76) there was a 9% chance of this result 
not being significant. 
 
TABLE 75. TLR2 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 C-C 0.04 0.07 5.86 0.02 0.04 
2 C-T 0.55 0.49 7.20 0.01 0.02 
3 T-T 0.41 0.45 2.50 0.11 0.25 
a
 The order of the SNPs in the block corresponds to Figure 39. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.01 were observed on 186 out of 10 000 occasions (2%). 
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FIGURE 39.  Plot of LD between TLR2 markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  Squares are coded in the same 
manner as in Figure 21. 
 
TABLE 76. TLR2 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p value p valuePermutation
b, c
 
1 C-C 10 : 6 0.89 0.35 0.67 
2 C-T 33 : 51 4.21 0.04 0.09 
3 T-T 50 : 35 2.64 0.10 0.22 
a
 The order of the SNPs in each block corresponds to Figure 39. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.04 were observed on 859 out of 10 000 occasions (9%). 
 
b) TLR4 
LD across the TLR4 gene region varied (Figure 40).  The rs1927914, rs10759932 and 
rs2770148 SNPs were in complete LD.  These three SNPs were also part of a single 
haplotype block, which did not include the SNPs in the 3’ region of TLR4, identified in 
this region.  Four haplotypes were identified in the haplotype block (Tables 77 and 78).  
Haplotype 2 (Tables 77 and 78) was nominally associated with TB in the case-control (p 
= 0.03, OR = 1.31, 95% CI [1.03-1.66]) and TDT (p = 0.01) studies.  This association 
was still significant in the TDT group after permutation testing, but became less 
significant in the case-control analysis.  According to the calculations of the Haploview 
program, 3% of permutations exceeded the best p value, meaning that there is a 3% 
chance that the nominally significant p value was a random statistical fluctuation.  
However, in the case-control haplotype analysis (Table 77), there was a 9% chance of 
this result not being significant. 
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TABLE 77. TLR4 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b, c
 
1 C-C-T 0.12 0.15 2.96 0.09 0.27 
2 C-T-C 0.20 0.16 4.97 0.03 0.09 
3 C-T-T 0.36 0.33 2.25 0.13 0.39 
4 T-T-T 0.32 0.37 4.33 0.04 0.13 
a
 The order of the SNPs in each block corresponds to Figure 40. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.03 were observed on 913 out of 10 000 occasions (9%). 
 
 
 
FIGURE 40.  Plot of LD between TLR4 markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  Squares are coded in the same 
manner as in Figure 21. 
 
TABLE 78. TLR4 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p value p valuePermutation
b
 
1 C-C-T 16 : 23 1.37 0.24 0.60 
2 C-T-C 25 : 10 6.44 0.01 0.03 
3 C-T-T 36 : 31 0.42 0.52 0.89 
4 T-T-T 22 : 34 2.60 0.11 0.29 
a
 The order of the SNPs in each block corresponds to Figure 40. 
b 
Permutation test p values were calculated from 100 000 permutations in Haploview. 
c
 p values less than 0.01 were observed on 2685 out of 100 000 occasions (3%).  
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4.8.1.4. Comparison of allele frequencies between populations 
We compared previously published allele frequencies of TLR2 (Table 79) and TLR4 
(Table 80) from different populations with that from the South African Coloured 
controls of this study. 
 
TABLE 79.  Comparison of allele frequencies of rs4696480 and rs5743708 between 
populations. 
rs4696480 rs5743708 
Population 
A T A G 
South African Coloured 0.36 0.64 0.01 0.99 
African American [58] 0.40 0.60 Absent 
Austrians and Germans [540] 0.51 0.49 - - 
European, Utah [59,62] - - 0.05 0.95 
French [536] - - 0.03 0.97 
Spanish [549] - - 0.01 0.99 
Turkish [229] - - 0.05 0.95 
 
 
TABLE 80.  Comparison of allele frequencies of rs4986790 and rs4986791 between 
populations. 
rs4986790 rs4986791 
Population 
G A T C 
South African Coloured 0.04 0.96 0.03 0.97 
European, Utah [59,62] 0.03 0.97 0.03 0.97 
Europeans [540] 0.08 0.92 - - 
Gambians [264] 0.11 0.89 Absent 
Han Chinese, Beijing [59,62] Absent Absent 
Japanese, Tokyo [59,62] Absent Absent 
Spanish  [549] 0.07 0.93 0.08 0.92 
Yoruba, Ibadan, Nigeria [59,62] 0.03 0.97 Absent 
 
 
The rs4696480 and rs5743708 SNPs from TLR2 have been genotyped in several 
European populations and also in African Americans (Table 79).  The A allele of the 
rs5743708 SNP was present at low frequencies in all populations genotyped and was 
absent in African Americans.  The T allele of rs4696480 was the major allele in the 
South African Coloured and African American populations, while the A allele of this 
SNP was the major allele in Europeans. 
 
The allele frequencies of the rs4986790 and rs4986791 SNPs (Table 80) from TLR4 of 
the South African Coloured population were compared to Europeans, Gambians and the 
four HapMap populations [59,62] (Section 4.9.1.)  The A allele of the rs4986790 
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polymorphism was frequently present in the Gambian population, but absent in Asians.  
The South African Coloured population and the HapMap individuals from European 
descent had the same allele frequencies for rs4986791 (T = 0.03 and C = 0.97).  This 
polymorphism was more polymorphic in the Spanish population (minor T allele 
frequency = 0.08), but not present in the three remaining populations. 
 
4.8.2. Discussion 
Several TLRs contribute to an efficient innate immune response against mycobacteria. 
TLR2 and TLR4 are nonredundant recognition systems for M.tuberculosis [522], which 
may initiate an antimycobacterial immune response [551].  Since these pattern-
recognition receptors are important in recognising invading micro-organisms, we chose 
two of these genes, namely TLR2 and TLR4, as candidate genes.  TLR2 encodes the 
TLR2 protein which plays an essential role in the responsiveness to several bacterial 
products, including that of M.tuberculosis.  TLR4 encodes TLR4 which responds to 
heat-labile soluble mycobacterial components as well as viable M.tuberculosis and will 
activate innate immunity when exposed to these [544,545].  We investigated 
polymorphisms from the two genes in the South African Coloured population to 
determine if they are susceptibility factors for TB. 
 
We detected a significant association between the synonymous rs3804100 SNP of TLR2 
and TB (p = 0.013, OR = 1.67 95%CI [1.1-2.5]) in the case-control analysis, but not in 
the TDT analysis.  The T allele occurred more frequently in cases than in controls.  This 
SNP was not highly polymorphic, with a minor allele frequency of 0.07 in the controls.  
Since this SNP does not affect the protein structure of TLR2, we cannot speculate on the 
function of it, if any, in TB.  A haplotype (haplotype 2, Tables 75 and 76) containing the 
T allele of this SNP was also associated with TB susceptibility in both the case-control 
and TDT studies.  However, the TDT showed an opposite association, with haplotype 2 
being undertransmitted to TB offspring.  This contradictory result could therefore 
suggest that this association is an artefact, but could also be explained by the smaller 
sample size of the TDT-group when compared to the case-control group.  We did not 
find a statistically significant association between the rs5743709 TLR2 SNP and TB.  
This SNP was previously associated with TB in a Turkish population [229].  That study 
showed a slight deviation from HWE in the control population and the authors 
speculated that this could be due to the high incidence of consanguinity in the Turkish 
population [229].  However, this deviation from HWE could also contribute to a false 
positive association.  Since this polymorphism was in HWE in both the cases and 
controls from the South African Coloured population, our finding of no association is 
probably correct.  We investigated more samples, and therefore have more power to 
detect smaller effect sizes than the Turkish study. 
 
The TLR2_GT microsatellite was previously associated with TB in a study by Yim et al 
[291].  Shorter GT repeats were more often present among TB patients from Korea and 
were associated with weaker promoter activity and reduced expression of TLR2 on 
CD14+ peripheral blood monocytes [291].  However, we did not find any association 
between alleles of this microsatellite and TB (Tables 73 and 74).   
 
We did not find any association between the seven TLR4 SNPs genotyped and TB 
susceptibility in the South African Coloured population.  These seven SNPs included 
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the non-synonymous rs4986790 and rs4986791 polymorphisms, which affect the 
extracellular structure of the TLR4 protein.  The rs4986790 SNP was not a 
susceptibility factor in a Gambian TB association study either [264].   
 
We also considered a haplotype block consisting of three SNPs (rs1927914, rs10759932 
and rs2770148) and found that a haplotype (haplotype 2, Tables 77 and 78) was 
associated with TB susceptibility.  The haplotype occurred more often in cases than in 
controls (p = 0.03, OR = 1.31, 95% CI [1.03-1.66]).  It was also transmitted to affected 
offspring more often than expected (p = 0.01).  During permutation testing for the TDT 
and case-control haplotype analyses, which was done to correct for multiple testing, 
these significant p values occurred randomly in 3% and 9% of the 10 000 runs, 
respectively.  This suggests that this is a true significant association.  These 3 SNPs 
were not individually associated with TB, but were part of a haplotype block associated 
with disease.  Therefore it is possible that the true, unidentified susceptibility variant is 
in LD with this block, or further upstream of the promoter region of TLR4. 
 
In summary, we found an association between a 5’ haplotype of TLR4 and TB 
susceptibility in both the case-control and TDT analyses.  We also found an association 
between a synonymous SNP, of unknown function, in the TLR2 case-control study, 
which was not detected in the TDT study. 
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4.9. THE WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5A AND 
FRIZZLED HOMOLOG 5 (DROSOPHILA) 
Both the innate and acquired immune systems are necessary to eradicate mycobacteria 
from the host [552].  Recently, a microarray-based gene-expression screening of  
mycobacteria-infected macrophages was done to search for novel regulatory pathways 
in innate responses to infection [553].  This study suggested that the Wingless /Frizzled 
(WNT/FZD) signalling system connects the innate and adaptive immunity during 
infections (Figure 41) and implicated the wingless-type MMTV integration site family, 
member 5A (WNT5A) protein in human defence against infection with M.tuberculosis 
[553].   
 
 
FIGURE 41. Possible model of WNT5A and FZD5 as modulators of the relationship 
between antigen-presenting cells and T lymphocytes.  WNT5A gene transcription is 
initiated by TLR-mediated activation of antigen-presenting cells.  The WNT5A protein 
interacts with its receptor FZD5 and regulates the IL-12 response in an autocrine 
manner.  This induces IFN-γ production by T lymphocytes.  Since these lymphocytes 
also express FZD5, WNT5A may directly cause IFN-γ release.  Adapted from [553].   
 
Blumenthal et al [553] demonstrated that WNT5A is expressed by antigen-presenting 
cells when they are stimulated by mycobacteria or other bacterial structures.  In 
addition, both WNT5A and its receptor, frizzled homolog 5 (FZD5), regulate IL-12 and 
IFN-γ production in antigen-presenting cells when exposed to mycobacteria.  The 
expression of WNT5A depended on TLR signalling and the activation of the NF-κB 
pathway.  WNT5A and FZD5 were also present on human mononuclear cells and in 
granulomatous lesions of the lungs of TB patients [553].  The WNT gene family 
consists of several structurally related genes which encode secreted signalling proteins.  
Their receptors are members of the FZD gene family which encodes 7-transmembrane 
domain proteins [554].  The WNT proteins, which include WNT5A, have been 
implicated in cell proliferation [555], differentiation [556], developmental processes 
[557] and oncogenesis [558].   
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The HapMap project (Section 1.2.2.) attempts to determine the common arrangement of 
DNA variation in the human genome [59].  The first phase of the study genotyped one 
common SNP (with an allele frequency greater than 5%) every 5 kilobases in 269 DNA 
samples from 4 populations, namely 90 Yoruba individuals from Ibadan in Nigeria, 90 
individuals of European descent from Utah, 45 Han Chinese individuals from Beijing 
and 45 Japanese from Tokyo [62].  The project proved the redundancy among SNPs 
located closely together and this enabled researchers to select haplotype tagging SNPs.  
These SNPs represent the common variation in a genomic region and selecting them for 
genotyping in association studies may optimise these studies. The HapMap also made it 
possible to extract genomic variation information without resequencing.   
 
We selected haplotype tagging SNPs (Table 81) from all four populations of the 
HapMap to test for a possible gene-based association between WNT5A and FZD5 and 
TB susceptibility.  All four HapMap populations were considered, because similar 
populations might have contributed to the genetic composition of the admixed South 
African Coloured population.  TagSNPs were selected with the Tagger program in 
Haploview, using the default criteria of r
2
 = 0.8 and LOD = 3.   
 
TABLE 81.  Tagging SNPs genotyped in WNT5A and FZD5 in this study. 
Polymorphism  Location Genotyping method 
WNT5A 
rs3796232  5' upstream SNPlex 
rs1795651  5' upstream SNPlex 
rs7624718  5' upstream SNPlex 
rs557077  Promoter TaqMan 
rs566926  Intron 1 SNPlex 
rs648872  Intron 1 SNPlex 
rs815541  Intron 1 SNPlex 
rs9311564  Intron 2 SNPlex 
rs472631  Intron 3 SNPlex 
rs556874  Intron 4 SNPlex 
rs11918967  Intron 4 SNPlex 
rs7622120  Intron 4 SNPlex 
rs590386  3' UTR SNPlex 
FZD5 
rs10188753  5' upstream SNPlex 
rs718290  5' upstream SNPlex 
rs7582078  5' upstream SNPlex 
rs2010400  Promoter SNPlex 
rs6708488  Promoter SNPlex 
rs3731568  3' UTR SNPlex 
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4.9.1. Results 
4.9.1.1. Single-point statistical analysis 
All polymorphisms were in HWE in the control samples.  Bonferroni corrections were 
applied using the methodology of Nicodemus et al [76]. 
 
a) WNT5A 
We tested 13 haplotype-tagging SNPs in the WNT5A gene region from the HapMap to 
genotype all samples from the South African Coloured population.  The threshold for 
significance was set at 0.008, since 3 independent LD blocks and 3 independent SNPs 
were determined for this region (Figure 42).  Under this criterion, none of the SNPs 
reached statistical significance in either the case-control (Table 82) or TDT analyses 
(Table 83).  However, some nominal significant p values were observed in the case-
control (rs566926, rs7622120) and TDT (rs590386) analyses.  None of these weak 
associations were found in both the case-control and TDT and are therefore probably 
false positives. 
 
TABLE 82.  Single-point statistical analysis in the WNT5A case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs3796232 G C 0.27 0.50 0.23 0.22 0.48 0.30 0.06 
rs1795651 A G 0.10 0.41 0.49 0.11 0.43 0.46 0.76 
rs7624718 G A 0.02 0.15 0.83 0 0.18 0.82 0.07 
rs557077 C T 0.22 0.46 0.32 0.21 0.48 0.31 0.85 
rs566926 A C 0.04 0.21 0.75 0.04 0.29 0.67 0.03 
rs648872 T C 0.02 0.27 0.71 0.03 0.27 0.70 0.85 
rs815541 G C 0 0.12 0.88 0.01 0.15 0.84 0.28 
rs9311564 G A 0.01 0.08 0.91 0 0.07 0.93 0.70 
rs472631 C T 0.14 0.42 0.44 0.16 0.46 0.38 0.22 
rs556874 A G 0.09 0.39 0.52 0.10 0.46 0.44 0.06 
rs11918967 G C 0.19 0.46 0.35 0.23 0.48 0.29 0.09 
rs7622120 A G 0.10 0.38 0.52 0.09 0.47 0.44 0.02 
rs590386 A G 0.03 0.22 0.75 0.02 0.21 0.77 0.45 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
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TABLE 83. Single-point statistical analysis in the WNT5A TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs3796232 G 57 : 54 0.08 0.78 
rs1795651 G 48 : 39 0.93 0.33 
rs7624718 A 18 : 15 0.27 0.60 
rs557077 T 55 : 40 2.37 0.12 
rs566926 C 30 : 22 1.23 0.27 
rs648872 C 32 : 27 0.42 0.52 
rs815541 C 19 : 13 1.13 0.29 
rs9311564 A 9 : 5 1.14 0.29 
rs472631 - 47 : 47 0 1 
rs556874 A 41 : 35 0.47 0.49 
rs11918967 C 60 :49 1.11 0.29 
rs7622120 A 46 : 40 0.42 0.52 
rs590386 A 27 : 14 4.12 0.04 
 
 
b) FZD5 
We tested 6 haplotype-tagging SNPs in the FZD5 gene region from the HapMap to 
genotype in the case-control and family-based samples from the South African 
Coloured population.  The threshold for significance was set at 0.017, since three SNPs 
(rs6708488, rs7582078 and rs10188753) were not independent of other SNPs (Figure 
43).  Under this criterion, none of the SNPs reached statistical significance in either the 
case-control (Table 84) or TDT analyses (Table 85).  No nominally significant p values 
were observed either.   
 
The rs2010400 and rs718290 SNPs were not highly polymorphic in the South African 
Coloured samples.  In fact, no homozygous T (the minor allele) individuals were 
detected for the rs2010400 SNP, while only 1% of all the individuals genotyped for 
rs718290 were homozygous for the minor C allele. 
 
TABLE 84.  Single-point statistical analysis in the FZD5 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs10188753 G A 0.10 0.40 0.50 0.09 0.41 0.50 0.91 
rs718290 C T 0.01 0.18 0.81 0.01 0.15 0.84 0.41 
rs7582078 A C 0.19 0.46 0.35 0.17 0.47 0.36 0.54 
rs2010400 T G 0 0.01 0.99 0 0.01 0.99 0.85 
rs6708488 G A 0.06 0.28 0.66 0.03 0.32 0.65 0.11 
rs3731568 C A 0.05 0.33 0.62 0.05 0.34 0.61 0.97 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
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TABLE 85. Single-point statistical analysis in the FZD5 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs10188753 G 49 : 33 3.12 0.08 
rs718290 T 17 : 11 1.29 0.26 
rs7582078 A 42 : 29 2.38 0.12 
rs2010400 T 4 : 3 0.14 0.71 
rs6708488 A 37 : 27 1.56 0.21 
rs3731568 A 37 : 27 1.56 0.21 
 
 
4.9.1.2. Haplotype analysis 
Haplotypes and LD in the respective genes were analysed with Haploview using the 
95% confidence interval definition from Gabriel et al [89].  This definition excludes all 
SNPs with allele frequencies lower than 0.05 from the analysis.  Permutation testing 
was done for all haplotypes to help ensure that no false positives would be accepted as 
true indicators of association. 
 
a) WNT5A 
Three haplotype blocks were identified for the WNT5A gene and four SNPs with 
frequencies lower than 0.05 (rs590386, rs9311564, rs566926 and rs557077) were 
 
 
FIGURE 42. Plot of LD between WNT5A markers analysed in control individuals of 
South African Coloured descent generated by Haploview v3.3.  Squares are coded in 
the same manner as in Figure 21.  
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excluded from this analysis by Haploview (Figure 42).  The strength of LD across the 
region was varied.  Eleven haplotypes were identified in three blocks in both the case-
control (Table 86) and TDT (Table 87) analyses.  Haplotype 1 had the highest 
frequency.  Several of the haplotypes in the respective blocks had nominally significant 
p values in the case-control samples.  Haplotypes 1, 2, 8 and 10 (Table 86) in the case-
control analysis had p values less than 0.05, but this was not the case in the TDT 
analysis (Table 87). 
 
TABLE 86. WNT5A case-control haplotype analysis by Haploview [313]. 
Block
 a
 Haplotype FreqCases FreqControls χ² p value p valuePermutation
b
 
1 1 G-C-G 0.58 0.53 4.85 0.03 0.21 
 2 A-G-A 0.28 0.33 5.11 0.02 0.19 
 3 G-G-G 0.13 0.14 0.82 0.36 0.97 
2 4 T-C-C 0.49 0.45 2.49 0.11 0.67 
 5 C-C-C 0.35 0.38 2.58 0.11 0.64 
 6 T-C-T 0.10 0.08 1.61 0.20 0.87 
 7 T-G-T 0.06 0.08 2.08 0.15 0.80 
3 8 A-G-G 0.42 0.37 5.38 0.02
c
 0.16 
 9 A-A-C 0.31 0.32 0.55 0.46 0.99 
 10 A-G-C 0.18 0.22 4.41 0.04 0.27 
 11 G-G-G 0.10 0.09 0.03 0.86 1.00 
a
 The order of the SNPs in each block corresponds to Figure 42. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.02 were observed on 1627 out of 10 000 occasions (16%).  
 
TABLE 87. WNT5A TDT haplotype analysis by Haploview [313]. 
Block
 a
 Haplotype Transmitted : untransmitted χ² p  pPermutation
b, c
 
1 1 G-C-G 42 : 32 1.35 0.25 0.88 
 2 A-G-A 28 : 29 0.02 0.90 1 
 3 G-G-G 19 : 27 1.39 0.24 0.59 
2 4 T-C-C 34 : 35 0.02 0.90 1 
 5 C-C-C 35 : 31 0.25 0.61 1 
 6 T-C-T 14 : 12 0.07 0.79 1 
 7 T-G-T 10 : 13 0.49 0.48 1 
3 8 A-G-G 30 : 36 0.70 0.40 1 
 9 A-A-C 36 : 32 0.25 0.61 1 
 10 A-G-C 27 : 24 0.09 0.76 1 
 11 G-G-G 15 : 12 0.23 0.63 1 
a
 The order of the SNPs in each block corresponds to Figure 42. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.24 were observed on 5877 out of 10 000 occasions (59%)  
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b) FZD5 
No haplotype blocks were identified for the FZD5 gene region (Figure 43) and LD 
across the section was mostly weak.  Since no haplotypes were observed using the 
definition from Gabriel et al, we evaluated all the SNPs together in a single haplotype 
(Tables 88 and 89).   
 
Fourteen haplotypes were identified in the case-control analysis (Table 88) and 16 in the 
TDT (Table 89) analysis.  Haplotype 1 (Table 88) had the highest frequency in the case-
controls, while haplotype 2 (Table 89) had the most transmissions to affected offspring.  
Haplotype 9 had a nominally significant p value (p = 0.03) in the case-control analysis 
(Table 88), while haplotypes 11 and 14 in the TDT had nominally significant p values 
(Table 89).  None of the haplotypes were associated with TB after permutation testing in 
either the case-control or TDT analyses. 
 
 
 
 
FIGURE 43. Plot of LD between FZD5 markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  Squares are coded in the same 
manner as in Figure 21.  No haplotype block could be calculated.  
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TABLE 88. FZD5 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b
 
1 A-A-G-C-T-A 0.26 0.28 0.69 0.41 0.99 
2 A-A-G-A-T-G 0.14 0.15 0.36 0.55 1 
3 C-A-G-C-T-A 0.13 0.13 0.11 0.74 1 
4 A-A-G-A-T-A 0.10 0.10 0 0.98 1 
5 A-C-G-C-T-A 0.07 0.08 0.17 0.68 1 
6 C-A-G-A-T-G 0.05 0.05 0.04 0.84 1 
7 A-C-G-A-T-G 0.04 0.04 0.09 0.77 1 
8 A-A-G-C-C-A 0.04 0.04 0.001 0.98 1 
9 A-A-G-A-C-A 0.04 0.03 4.49 0.03
c
 0.11 
10 A-C-G-A-T-A 0.04 0.03 1.02 0.31 0.95 
11 A-A-G-C-T-G 0.03 0.02 0.46 0.50 1 
12 A-C-G-C-T-G 0.02 0.02 0.02 0.88 1 
13 C-A-G-C-T-G 0.01 0.01 0.002 0.97 1 
14 C-A-G-A-T-A 0.01 0.01 0.02 0.90 1 
a
 The order of the SNPs in each block corresponds to Figure 43. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.03 were observed on 1102 out of 10 000 occasions (11%).  
 
TABLE 89. FZD5 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p pPermutation
b, c
 
1 A-A-G-C-T-A 19 : 20 0.05 0.83 1 
2 A-A-G-A-T-G 29 : 18 2.68 0.10 0.63 
3 C-A-G-C-T-A 14 : 17 0.44 0.51 1 
4 A-A-G-A-T-A 11 : 12 0.02 0.88 1 
5 A-C-G-C-T-A 9 : 11 0.28 0.60 1 
6 A-C-G-A-T-G 9 : 3 2.45 0.12 0.70 
7 C-A-G-A-T-G 9 : 7 0.24 0.62 1 
8 A-A-G-A-C-A 4 : 5 0.07 0.79 1 
9 A-A-G-C-T-G 5 : 3 0.49 0.48 1 
10 A-C-G-A-T-A 4 : 4 0.11 0.74 1 
11 A-A-G-C-C-A 0 : 4 4.31 0.04 0.15 
12 C-A-G-C-T-G 3 : 3 0.08 0.77 1 
13 A-C-G-C-T-G 2 : 2 0.03 0.87 1 
14 A-C-G-C-C-A 0 : 4 4.08 0.04 0.18 
15 C-A-G-A-T-A 2 : 3 0.03 0.86 1 
16 C-C-G-A-T-G 0 : 2 1.78 0.18 0.82 
a
 The order of the SNPs in each block corresponds to Figure 43. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.04 were observed on 1455 out of 10 000 occasions (15%)  
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4.9.1.3. Comparison of WNT5A and FZD5 with HapMap populations 
We compared allele frequencies of WNT5A (Table 90) and FZD5 (Table 91) 
polymorphisms between the South African Coloured control population and the four 
HapMap populations, namely 90 Yoruba individuals from Ibadan in Nigeria, 90 
individuals of European descent from Utah, 45 Han Chinese individuals from Beijing 
and 45 Japanese from Tokyo [59,62].   
 
The thirteen polymorphisms genotyped in WNT5A were compared between all 
populations available (Table 90).  The rs9311564 SNP was dimorphic in the South 
  
TABLE 90. Comparison of WNT5A allele frequencies between the South African 
Coloured population and the four HapMap populations [59,62]. 
SNP Allele 
South 
African  
Coloured 
Yoruba, 
Ibadan, 
Nigeria 
European, 
Utah 
Han 
Chinese,  
Beijing 
Japanese,  
Tokyo 
G 0.46 0.35 0.48 0.23 0.17 
rs3796232 
C 0.54 0.65 0.53 0.77 0.83 
A 0.32 0.41 0.33 0.13 0.03 
rs1795651 
G 0.68 0.59 0.67 0.87 0.97 
G 0.09 0.09 0.14 0.06 0.13 
rs7624718 
A 0.91 0.91 0.86 0.94 0.87 
C 0.45 0.21 0.85 0.87 0.83 
rs557077 
T 0.55 0.79 0.15 0.13 0.17 
A 0.18 0.02 0.21 0.60 0.75 
rs566926 
C 0.82 0.98 0.79 0.40 0.25 
T 0.16 0.33 0.16 0.07 0.17 
rs648872 
C 0.84 0.68 0.84 0.93 0.83 
G 0.08 0.01 0.16 0.07 0.14 
rs815541 
C 0.92 0.99 0.84 0.93 0.86 
G 0.04 0.11 0 0 0 
rs9311564 
A 0.96 0.89 1 1 1 
C 0.39 0.38 0.48 0.61 0.75 
rs472631 
T 0.61 0.62 0.53 0.39 0.25 
A 0.33 0.22 0.44 0.61 0.75 
rs556874 
G 0.67 0.78 0.56 0.39 0.25 
G 0.47 -
a
 0.44 0.68 0.89 
rs11918967 
C 0.53 - 0.56 0.32 0.11 
A 0.33 -
a
 0.49 0.59 0.77 
rs7622120 
G 0.67 - 0.51 0.41 0.23 
A 0.12 0.23 0.05 0.08 0.15 
rs590386 
G 0.88 0.78 0.95 0.92 0.85 
a
 These SNPs were not genotyped in this population. 
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African Coloured and Yoruba Nigerian populations and monomorphic in the remaining 
populations.  This polymorphism is therefore probably of African origin.  The major 
allele of six SNPs (rs557077, rs566926, rs472631, rs556874, rs11918967 and 
rs7622120) differed between the populations.  For five of these six SNPs, the alternate 
allele was more frequent in the two Asian populations than in the other populations.  
However, in the South African Coloureds and Yoruba Nigerians, the rs557077 SNP 
major allele was different to that from the populations of European and Asian descent. 
 
Six polymorphisms from FZD5 (Table 91) were available for comparison between the 
five different populations.  Two of these (rs718290 and rs2010400) were present in the 
South African Coloured and Yoruba Nigerian populations, but monomorphic in the 
other populations.  These polymorphisms are therefore probably unique to populations 
of African descent.  For the remaining polymorphisms of FZD5, all populations shared 
the same major allele for all SNPs. 
 
TABLE 91. Comparison of FZD5 allele frequencies between the South African Coloured 
population and the four HapMap populations [59,62]. 
SNP Allele 
South 
African  
Coloured 
Yoruba, 
Ibadan, 
Nigeria 
European, 
Utah 
Han 
Chinese,  
Beijing 
Japanese,  
Tokyo 
G 0.29 0.33 0.47 0.27 0.32 
rs10188753 
A 0.71 0.67 0.53 0.73 0.68 
C 0.08 0.23 0 0 0 
rs718290 
T 0.92 0.77 1 1 1 
A 0.40 0.31 0.48 0.26 0.31 
rs7582078 
C 0.60 0.69 0.52 0.74 0.69 
T 0.01 0.05 0 0 0 
rs2010400 
G 0.99 0.95 1 1 1 
G 0.19 0.33 0.12 0.41 0.29 
rs6708488 
A 0.81 0.67 0.88 0.59 0.71 
C 0.22 0.11 0.42 0.19 0.27 
rs3731568 
A 0.78 0.89 0.58 0.81 0.73 
 
 
4.9.2. Discussion 
The WNT5A protein was recently implicated in human host defence against infection 
with M.tuberculosis [553].  Both WNT5A and its receptor FZD5 may regulate IL-12 
and IFN-γ production in antigen-presenting cells when exposed to mycobacteria.  We 
used a gene-based approach and typed haplotype-tagging SNPs, selected from the 
HapMap, in the case-control and family-based sample collections of the South African 
Coloured population to test for possible associations of these novel candidate genes with 
TB.  None of the WNT5A or FZD5 SNPs genotyped was associated with disease in the 
case-control or TDT analyses.  In addition, no haplotypes from these genes were 
associated with TB either.   
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We also compared the allele frequencies of the genotyped SNPs with those of the 
HapMap populations.  The HapMap project genotyped one common SNP (with an allele 
frequency greater than 5%) every 5 kilobases in 269 DNA samples from 4 populations, 
namely Yoruba from Africa, European in Utah, and Chinese/Japanese [62].  We 
observed that certain SNPs were specific to the populations with an African ancestry.  
None of the other SNPs were specific to a certain population.  A different major allele 
was noted for certain SNPs, especially in the Asian populations. 
 
In conclusion, this is the first study to consider WNT5A and FZD5 polymorphisms as 
susceptibility factors for TB.  Since we did not detect any association with haplotype-
tagging SNPs in these samples, it is possible that these genes are not involved in TB 
susceptibility, at least in the South African Coloured population.  
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CHAPTER 5 
CANDIDATE GENES FROM OTHER 
GRANULOMATOUS DISEASES 
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5.1. INTRODUCTION   
Granulomas are present in a number of diseases.  A granuloma typically consists of a 
centre of epithelioid macrophages surrounded by lymphocytes, and formation of this 
structure is thought to be a protective response against injury, inflammation or infection.  
The development of a granuloma is an intricate process involving the recruitment and 
organization of various cell types [559].  Granulomas can develop due to infectious 
diseases, such as tuberculosis (TB), or because of idiopathic disorders such as 
sarcoidosis and Crohn’s disease (CD) (Table 92).  Given this similarity, susceptibility 
genes in other granulomatous diseases provide worthwhile candidate genes for testing in 
TB. 
 
TABLE 92. Comparison of TB, sarcoidosis and Crohn’s disease. 
  TB Sarcoidosis Crohn’s disease 
Incidence 
• Higher in  
developing countries [4]. 
• Similar in developing 
and developed  
countries [560]. 
• Higher in  
developed countries [561]. 
Granu- 
loma 
• Caseating [19]. 
• Mostly present  
in lungs [19]. 
• Non-caseating [560]. 
• In two or more 
organs [560]. 
• Non-caseating [562]. 
• Mostly in the  
gastro-intestinal  
tract [562]. 
Aetiology • Infectious pathogen. • Unknown. • Unknown. 
Suscep- 
tibility 
factors 
• Genetic. 
• Environmental. 
• Bacterial. 
• Genetic. 
• Environmental. 
• Genetic. 
• Environmental. 
 
 
Sarcoidosis is a multiorgan disorder that affects mostly the lungs and lymphatic system.   
The disease is of unknown aetiology, but some evidence supports the hypothesis that it 
is caused by an infectious agent in genetically susceptible hosts [560].  Sarcoidosis has 
been considered to be a different form of TB [563], because of some similarities 
between the diseases, such as the presence of granulomas and coughing [564].  This is 
still a popular hypothesis and recently the Mycobacterium tuberculosis (M.tuberculosis) 
heat shock protein 70 was suggested to have an influence in the pathogenesis of 
sarcoidosis [565].  Susceptibility genes in sarcoidosis can therefore also be considered 
as candidate genes for TB and vice versa.  Associations have been detected in both 
diseases with the same candidate genes, such as natural resistance associated 
macrophage protein 1(NRAMP1) [210,260] and human leukocyte antigen (HLA) 
[277,566].   
 
While TB granulomas occur mostly in the lungs, CD granulomas are found in the 
intestine but can also appear in the lungs.  Since TB and CD share this pathophysiologic 
characteristic, susceptibility genes for CD are plausible candidate genes for 
investigation in TB.  Moreover, although the cause of CD is unknown, evidence is 
mounting that barrier function is compromised by genetic variants that can hinder 
interaction with bacterial antigens [567].  While it appears that the normal flora plays a 
pivotal role in the pathophysiology of the disease [568], a controversial theory 
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[569,570] suggests that Mycobacterium avium subspecies paratuberculosis is one of the 
causative agents in CD [571].  If true, this would increase the disease similarities and 
the chance of overlapping genetic susceptibilities. 
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5.2. BUTYROPHILIN-LIKE 2 GENE 
The butyrophilin-like 2 gene (BTNL2, BTL-II) was first identified by comparing the 
human and mouse genomic sequences at the HLA class II and class III regions [572].  It 
is one of the B7 receptor family genes and was hypothesised to have a possible function 
as a T cell co-stimulatory molecule [289], because of amino acid homology to B7-1 
(CD80) and B7-2 (CD86).  These co-stimulatory molecules were found to be important 
for an effective T cell response against mycobacteria in a mouse model of TB [573].  A 
recent study determined that BTNL2 inhibits T cell activation in mice [574].  Recently, 
a truncating splice site variation in BTNL2 was associated with sarcoidosis in a German 
population [289].  This association was subsequently confirmed by others in an 
additional population, namely white Americans [575].  Interestingly, this single 
nucleotide polymorphism (SNP) alone (rs2076530) was associated with sarcoidosis 
only in white populations but not in African American patients.  However a three-locus 
haplotype including this SNP was associated with the disease in African Americans 
[575].  The rs2076530 SNP alters the splicing pattern of the gene and a premature stop 
codon is formed.  The protein product of this splice form is truncated and could limit the 
T cell downregulatory function of BTNL2 [289].   
 
It has been shown that M.tuberculosis and lipopolysaccharides can induce BTNL2 in 
monocyte-derived macrophages [289].  Variations in BTNL2 could therefore have a 
possible function in genetic susceptibility or resistance to TB.  In this study, we 
sequenced BTNL2 and investigated the influence of the gene in TB, applying 
population-based and family-based association study designs in South African Coloured 
population.  
 
5.2.1. Results 
5.2.1.1. Mutation detection  
The putative promoter region, 8 exons and flanking regions of the gene were amplified 
(Section 3.5.1.) and the products were visualised in 2% agarose gels (Figure 44).  
Chromatograms were produced during sequencing of the PCR products and were used 
to determine the quality of the sequencing.  Clear peaks with low background signal 
were an indication of good quality.   
 
The alignment of sequence data with the expected product was performed with 
Sequencher version 4.2 (Figure 45).   
 
SGCaller [288] was used to automatically genotype the observed variations in all the 
sequenced samples (Figure 46).  The calls from the program were verified by 
concurrently viewing the chromatogram.  Sequencing of BTNL2 in the South African 
Coloured population led to the identification of 76 SNPs: 5 upstream of the gene, 29 
exonic, 31 intronic and 11 downstream of the gene.  Of the SNPs detected, 15 were 
novel, but were either in introns or had a very low allele frequency.  The allele 
frequencies, chromosome position and rs-numbers are listed in Addendum A6. 
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FIGURE 44. Amplification of the BTNL2 products for sequencing in a 2% agarose gel.  
A 100 bp molecular weight marker was used.  The gel photographs are numbered 
according to section 3.5.1 (1-8) and the size of each fragment is indicated. 
 
 
FIGURE 45. Alignment of sequence data with the expected product using the Sequencher 
program. 
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FIGURE 46. SGCaller was used to call genotypes in the sequenced samples. 
 
TABLE 93.  Single-point statistical analysis in the BTNL2 case-control study design.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls SNP 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs3817974 G A 0.01 0.25 0.74 0.02 0.22 0.76 0.32 
rs17208699 C A 0.01 0.19 0.80 0.01 0.17 0.82 0.44 
rs3817973 A G 0.11 0.38 0.51 0.08 0.36 0.56 0.21 
rs3817972 A G 0.01 0.20 0.79 0.02 0.17 0.81 0.28 
ss65713168 T C 0.01 0.23 0.76 0.01 0.21 0.78 0.39 
ss65713167 C A 0.01 0.23 0.76 0.02 0.21 0.77 0.36 
ss65713164 A G 0.01 0.23 0.76 0.02 0.21 0.77 0.36 
ss65713163 T C 0.01 0.23 0.76 0.02 0.21 0.77 0.37 
rs2076530 G A 0.11 0.40 0.49 0.07 0.38 0.55 0.065 
rs9268480 A G 0.05 0.25 0.70 0.02 0.22 0.76 0.023 
rs2076529 G A 0.11 0.39 0.50 0.07 0.38 0.55 0.083 
ss65713152 A T 0.01 0.25 0.74 0.02 0.24 0.74 0.74 
ss65713150 T C 0.01 0.25 0.74 0.02 0.24 0.74 0.73 
rs3763317 G A 0.18 0.48 0.34 0.18 0.47 0.35 0.94 
rs9268501 A C 0.15 0.45 0.40 0.15 0.45 0.40 0.99 
rs9268502 G A 0.15 0.45 0.40 0.15 0.45 0.40 0.98 
rs9268503 G A 0.14 0.46 0.40 0.15 0.45 0.40 0.96 
rs9268504 C G 0.15 0.45 0.40 0.15 0.45 0.40 0.98 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
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5.2.1.2. Single-point SNP analyses in BTNL2  
According to the set inclusion criteria (Section 3.5.), 18 SNPs were genotyped in the 
entire DNA collection (Table 93).  The influence of these SNPs in TB was investigated 
with a case-control study design and a transmission disequilibrium test (TDT).  All 
genotyped SNPs were in Hardy-Weinberg equilibrium (HWE) in the control group.  
The level of significance was 0.017 after Bonferroni correction. Under this criterion, 
none of the analysed SNPs reached statistical significance.  The SNP rs2076530 was not 
significantly associated with TB in our case-control study (p = 0.065, Table 93) or TDT 
(p = 0.44, Table 94).  Comparisons of the genotype frequencies of the remaining 17 
SNPs analysed showed a significant p value of 0.023 for the rs9268480 SNP (Table 93) 
in the case-control group.  Given the adjusted significance level in our study, this p 
value is not considered to reflect an association.  None of the other SNPs examined 
were found to be associated with the disease.  Altogether, single marker analysis 
detected no association between TB and any of the SNPs investigated in the BTNL2 
gene.  
 
TABLE 94. Single-point statistical analysis in the BTNL2 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs3817974 G 30-26 0.286 0.59 
rs17208699 G 22-20 0.095 0.76 
rs3817973 C 42-35 0.636 0.43 
rs3817972 G 22-21 0.023 0.88 
ss65713168 T 30-24 0.667 0.41 
ss65713167 C 29-23 0.692 0.41 
ss65713164 A 28-21 1 0.32 
ss65713163 T 29-25 0.296 0.59 
rs2076530 A 44-37 0.605 0.44 
rs9268480 C 30-18 3 0.083 
rs2076529 A 46-38 0.762 0.38 
ss65713152 T 22-15 1.324 0.25 
ss65713150 C 22-15 1.324 0.25 
rs3763317 C 60-44 2.462 0.12 
rs9268501 T 63-43 3.774 0.052 
rs9268502 C 63-43 3.774 0.052 
rs9268503 C 63-43 3.774 0.052 
rs9268504 C 63-43 3.774 0.052 
 
 
5.2.1.3.Haplotype analyses 
The Haploview program [313] identified three haplotype blocks (Figure 47) for the 
markers genotyped in BTNL2 in the case-control samples studied.  Strong linkage 
disequilibrium (LD) exists across the BTNL2 gene region in the South African Coloured 
population (Figure 47).  Haplotype 6 (Table 95) was tagged by the minor A allele of 
rs9268480 and although it was nominally significant, evaluation of global significance 
between cases and controls with the haplotyping program Cocaphase [101] yielded a 
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non-significant global p-value (p > 0.05) for each of the three haplotype blocks after 10 
000 permutations (Table 95).  
 
TABLE 95.  BTNL2 case-control haplotype analysis by Cocaphase. 
 
Global test Individual tests 
Block
a
 
p value
b
 Haplotype (case/control frequency) 
p value 
1 0.17 1 A-A-G-G-C-A-G-C-A-G-A (0.694/0.733) 0.067 
    2 A-A-G-G-C-A-G-C-G-G-A (0.00490/0.00633) 0.39 
    3 A-A-G-G-C-A-G-T-A-G-A (0/0.00106) 0.27 
    4 A-A-G-G-T-C-G-C-A-G-A (0.00123/0) 0.21 
    5 A-A-A-G-C-A-G-C-A-G-A (0.00123/0.00527) 0.13 
    6 A-A-A-G-C-A-G-C-G-A-G (0.173/0.132) 0.017 
    7 G-C-A-A-T-C-A-T-G-G-G (0.0993/0.0949) 0.76 
    8 G-A-A-A-C-A-G-C-G-G-G (0.00735/0.00422) 0.38 
    9 G-A-A-A-T-C-A-T-G-G-G (0.00123/0.00317) 0.38 
    10 G-A-A-G-T-C-A-T-G-G-G (0.0184/0.0200) 0.80 
2 0.91 11 A-T (0.139/0.141) 0.91 
    12 T-C (0.861/0.859) 0.91 
3 0.83 13 G-C-A-A-G (0.0454/0.0367) 0.36 
    14 G-A-G-G-C (0.375/0.375) 0.98 
    15 G-A-G-A-C (0.00119/0.00105) 0.93 
    16 A-C-A-A-G (0.579/0.798) 0.72 
a 
The order of the SNPs in each block corresponds to Figure 47. 
b
Permutation test p values were calculated from 10 000 permutations in Cocaphase 
[101], to correct for multiple testing while taking account of correlation between 
markers and haplotypes.
 
 
Haploview also identified the same three haplotype blocks for the markers genotyped in 
BTNL2 in the samples from the TB families.  None of the estimated haplotypes were 
nominally significant and therefore evaluation of global significance for the TDT with 
the TDTphase program [101] also gave a non-significant global p-value (p > 0.05) for 
each of the three haplotype blocks after 10 000 permutations (Table 96).   
 
The TDTphase and Cocaphase programs infer haplotype phase. Only 12 haplotypes 
were estimated in the families in comparison with 16 estimated in the case-control 
haplotype analysis.  Four haplotypes (haplotypes 3, 4, 9 and 15 in Table 95) were not 
present in the family samples (Table 96) and had extremely low frequencies in the case-
control group.  The absence of these haplotypes in the families can therefore be due to 
their low frequencies in the general population and do not represent a real difference 
between the sample groups. 
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TABLE 96.  BTNL2 TDT haplotype analysis by TDTphase.
 
Global test Individual tests 
Block
a
 
p value
b
 Haplotype (transmitted/untransmitted) 
p value 
1 0.41 1 A-A-G-G-C-A-G-C-A-G-A (159/151) 0.32 
   2 A-A-G-G-C-A-G-C-G-G-A (0/1) 0.24 
   3 A-A-A-G-C-A-G-C-A-G-A  (1/0) 0.24 
   4 A-A-A-G-C-A-G-C-G-A-G (17/24) 0.25 
   5 G-C-A-A-T-C-A-T-G-G-G  (13/16) 0.56 
    6 G-A-A-A-C-A-G-C-G-G-G (1/2) 0.56 
  7 G-A-A-G-T-C-A-T-G-G-G  (5/2) 0.25 
2 0.62 8 A-T (19/22) 0.62 
    9 T-C (206/203) 0.62 
3 0.23 10 G-C-A-A-G (3/6) 0.31 
   11 G-A-G-G-C (40/25) 0.12 
    12 A-C-A-A-G (26/38) 0.20 
a 
The order of the SNPs in each block corresponds to Figure 47. 
b
Permutation test p 
values were calculated from 10 000 permutations in TDTphase [101], to correct for 
multiple testing while taking account of correlation between markers and haplotypes. 
 
 
FIGURE 47. Plot of LD between all markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  The 5’- and 3’- ends of the 
gene are indicated.  D’-values (%) are indicated on the squares.  The colours of the 
squares represent LD strength, with red being strong, and blue weak, LD.  Haplotype 
blocks are outlined in black. 
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5.2.1.4. Comparison of BTNL2 data between South Africans and Americans 
The South African control data was compared to previously published genotyping data 
from African-American and white American individuals [575]. Rybicki et al. [575] 
detected 10 SNPs in the exon 5 / intron 5 region of BTNL2.  For the analysis, data on 
three overlapping SNPs, namely rs2076529, rs9268480 and rs2076530, were available 
from both studies.  Comparison of the 3 SNPs in common revealed that the South 
African allele frequencies were in general more similar to those of the African-
Americans than to the white Americans.  In addition, 2 of the 5 other SNPs (ss38346932 
and ss38346939) found by Rybicki et al. [575] were identified by sequencing 24 control 
individuals from the South African samples (Table 97).  The frequencies of these 2 
SNPs were also more similar to the African-American population than the white 
Americans. 
 
5.2.1.5. Comparison of BTNL2 data between South African Coloureds and Germans 
Comparative analyses were done of 482 South African Coloured controls from this 
study and 533 German controls from another study [289] using 6 SNPs that were 
genotyped in both populations (Table 97).  The allele frequencies were very similar for 
4 of the SNPs, but in 2 instances differed significantly (rs2076530 p = 0.03 and 
rs2076529 p = 0.04).  The allele frequencies for these SNPs in Germans were similar to 
those found in white Americans [575].  With the block definition used in Haploview, 
two haplotype blocks were identified in the South African population and three in the 
German population.  The reason for this difference is the slightly stronger LD observed 
in South African Coloureds across this region (Figure 48). 
 
 
FIGURE 48. Comparison of LD between the South African Coloured and German 
populations for 6 common SNPs.  Squares are coded in the same manner as in Figure 
47.  Two haplotype blocks were identified for the South Africans and three for the 
Germans. 
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5.2.2. Discussion 
TB and sarcoidosis are both granulomatous diseases, occur mainly in the lungs and can 
cause coughing and weight loss [564].  Because of these similarities in presentation of 
the diseases, we investigated the involvement of BTNL2, a susceptibility gene for 
sarcoidosis, in tuberculosis, using samples of South African Coloured descent.  This 
gene was first identified as a sarcoidosis susceptibility factor by Valentonyte et al. 
[289], and Rybicki et al. confirmed the association between sarcoidosis and rs2076530 
in white Americans, but not in African-Americans [575].  We did not observe a 
significant association of the truncating splice site SNP (rs2076530) with TB at the 
genotype level.  Interestingly, the truncating allele A was more frequent in controls.  
Since BTNL2 has a T cell downregulatory effect in mice [574], individuals with the 
truncated product could have a stronger T cell response, depending on which T cell 
subset was affected most.  This could be an advantage in TB, since resistance to TB is 
dependant on the T helper 1 cell response of the infected individual.  The rs9268480 
SNP adjacent to rs2076530 showed a nominally significant association, but this 
disappeared on stringent correction.  BTNL2 is on chromosome 6, which also carries the 
HLA genes.  Rybicki et al. [575] reported a high level of LD between rs9268480 and 
HLA-DRB1 for both white Americans and African-Americans.  Two recent studies 
reported that the association observed between BTNL2, multiple sclerosis [576] and 
Graves’ disease [577] was secondary to HLA-DRB1.  It is therefore possible that in the 
South African samples rs9268480 is also in LD with this region, which has been 
implicated as a susceptibility factor in TB [152,165,277].  None of the 16 other SNPs 
analysed in BTNL2 were associated with disease (Tables 93 and 94) and no association 
was found between any of the estimated haplotypes and TB (Tables 95 and 96). 
 
Comparisons between the South African Coloured and German populations revealed 
slightly stronger LD for the South African population in the BTNL2 region.  For this 
reason, two haplotype blocks were identified in the South African Coloured population 
and three in the Germans.  Stronger LD is expected in admixed populations [578] such 
as the South African Coloured population. 
 
The South African Coloured population has several different parental populations, 
including European whites and sub-Saharan African populations.  The German 
population is outbred and genetically relatively homogeneous and could (together with 
the white Americans) be considered as an approximation for the white parental 
population, while the African-Americans could be evaluated as another admixed 
population [578].  The comparison of the allele frequencies for polymorphisms in exon 
5 / intron 5 (Table 97) between the populations revealed that, for this restricted region of 
the genome, the South African Coloured population is more similar to African-
Americans than to whites.  Therefore, the lack of association with the functional BTNL2 
SNP and TB in the South African Coloured population could reflect the African 
admixture and would not preclude a role of rs2076530 in a white TB population, in a 
similar manner as seen with sarcoidosis [575].  Future work should evaluate BTNL2 in a 
TB sample set with no African genetic contribution, to determine if the association of 
this gene with disease could be population-specific.  Due to the high incidence of latent 
TB infection in the control community (unpublished results), we have tested the role of 
BTNL2 in disease progression only and it is still possible that this gene may play a role 
in primary infection. 
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5.3. CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 15 GENE 
The caspase recruitment domain-containing protein 15 gene (CARD15) encodes the 
nucleotide-binding oligomerization domain 2 protein (NOD2) [569] and was identified 
as a susceptibility gene for CD [308,579,580].  The R702W (rs2066844), G908R 
(rs2066845) and 1007fs (rs2066847) polymorphisms in CARD15 were independently 
associated with this form of inflammatory bowel disease [579] in European, white 
American and French Canadian populations.  The R702W variant, caused by a C to T 
transition, results in an arginine to tryptophan change in NOD2, while G908R is formed 
by a G to C transversion and changes a glycine to arginine. The 1007fs polymorphism is 
formed by a cytosine insertion at the second nucleotide in codon 1007 [580].  This 
results in a frameshift and substitutes leucine for proline, which leads to the truncation 
of NOD2 in the leucine-rich repeat region of the protein [579].  The truncated NOD2 
protein formed as a consequence of the 1007fs insertion in CARD15 leads to a decrease 
in the responsiveness of NF-ĸB to the bacterial ligand muramyl dipeptide [580]. 
Muropeptides are breakdown products of peptidoglycans from Gram-negative and 
Gram-positive bacteria, which are also present in the cell walls of M. tuberculosis [581]. 
Mycobacterial infection induces activation of the transcription factor NF-ĸB [582].  
R702W and G908R, like 1007fs, also occur in the vicinity of the leucine-rich repeat 
region of the protein and compromise the recognition of muramyl dipeptides [583].  
 
It was recently demonstrated that NOD2 is an essential recognition system of M. 
tuberculosis [522] and CARD15 could consequently be considered as a candidate gene 
in TB.  In a case-control study with Gambian TB patients [240] no associations were 
found with promoter polymorphisms of CARD15, and the three CD variants R702W, 
G908R and 1007fs were absent in the Gambian population.  We therefore aimed to 
genotype these CD-associated polymorphisms in TB patients and controls from the 
admixed South African Coloured population and conducted a case-control association 
study to determine if the variants predispose to TB. 
 
5.3.1. Results 
The three CD polymorphisms in CARD15 were genotyped in TB and control samples 
from the study population.  Genotyping for the three variants was done on an automated 
platform with the TaqMan
®
 system (Applied Biosystems, Foster City, USA) and assays 
were designed as published previously [308,309].  All variants were in HWE. 
 
The genotype (Table 98) and allele (Table 99) frequencies for the polymorphisms were 
very low and the minor alleles were found only in the heterozygous state.  Comparison 
of the genotype frequencies for the three polymorphisms revealed no association 
between any of the variants and TB (Table 98).  Since all three CARD15 variants are 
relatively rare and have been shown to occur on separate haplotypes [579], we 
compared the frequencies of carriers (i.e. heterozygote and double heterozygote carriers 
of any of the three SNPs) between the cases and the controls.  The carrier frequencies 
were not significantly different in the two groups (0.03 vs. 0.05; p = 0.22).  
 
The TDT showed similar results (Table 100) to the case-control study, with extremely 
low frequencies of the minor alleles.  The R702W and G908R polymorphisms were 
 148 
found in 5 and 4 families respectively, while the 1007fs variant was not present in any 
of the 185 families genotyped.   
 
TABLE 98. Genotype frequencies of the CARD15 variants investigated in the South 
African Coloured population using a case-control study design.  
  R702W G908R 1007fs 
CC 0.986 (421)
 a
 GG 0.995 (426) wt/wt 0.991 (423) 
CT 0.014 (6) GC 0.005 (2) wt/insC
b
 0.009 (4) TB 
TT 0 CC 0 insC/insC 0 
CC 0.977 (468) GG 0.992 (476) wt/wt 0.983 (423) 
CT 0.023 (11) GC 0.008 (4) wt/insC 0.017 (8) Controls 
TT 0 CC 0 insC/insC 0 
p-value 0.46 0.69 0.39 
a
 The number of individuals with each genotype is indicated in brackets.   
b
 insC, cytosine insertion 
  
TABLE 99. Allele frequencies of the CARD15 variants investigated in the South African 
Coloured population is a case-control study design.   
  R702W G908R 1007fs 
C 0.993 (848)
a
 G 0.998 (854) C 0.995 (850) 
TB 
T 0.007 (6) C 0.002 (2) insC
b
 0.005 (4) 
C 0.989 (947) G 0.996 (956) C 0.992 (950) 
Controls 
T 0.011 (11) C 0.004 (4) insC 0.008 (8) 
p-value 0.47 0.69 0.40 
a
 The number of alleles is indicated in brackets.   
b
 insC, cytosine insertion 
 
TABLE 100. TDT results for CARD15.   
SNP Minor allele Families
a
 Frequency
b
 Transmitted:Untransmitted 
R702W T  5 0.01 4 : 1 
G908R C  4 0.006 2 : 2 
1007fs insC 0 0 0 
a
The number of families where at least one individual has the minor allele is indicated. 
b
Frequency of the minor allele. 
 
5.3.2. Discussion 
The pathophysiology of both TB and CD is characterised by the presence of 
granulomas.  We investigated the role of the CD susceptibility gene CARD15 in TB in 
the South African Coloured population, because NOD2, the protein encoded by 
CARD15, was found to be an essential recognition mechanism for M. tuberculosis 
[522].  To this end, three variants that affect the leucine-rich-repeat recognition domains 
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of NOD2 and that represent the main genetic risk associated with this gene in CD were 
genotyped. 
 
This is the first report of allele frequencies for the R702W, G908R and 1007fs 
polymorphisms in TB samples from the South African Coloured population.  The 
variant alleles of these polymorphisms are found at frequencies of about 2%, 3% and 
3% respectively in the European populations [561], but were present at frequencies 
below 1.1% in this study collection in both the family and case-control groups (Tables 
98 and 100).  The frequencies of two (R702W, G908R) of the three variants genotyped 
in this control group were not significantly different (p > 0.05) from those observed in 
controls in a CD study of another South African Coloured sample set, which detected 
minor allele frequencies of 0.03 for R702W, 0.005 for G908R and 0.04 for 1007fs 
[584].  A genetic input from European ancestors is the most likely explanation for the 
presence of the CD variants in this admixed South African population, since these 
polymorphisms were not found at all in Gambians [240] or various Asian populations 
[561,585].  However, at least for the CARD15 locus, it seems that the genetic 
contribution from Europeans was relatively small.  
 
TB is present in epidemic proportions in the South African Coloured population from 
the Western Cape province, while the occurrence of CD in this population is relatively 
rare [586].  In other African populations with a low incidence of CD, the 
polymorphisms associated with CD were absent [240].  The rarity of the CD-associated 
CARD15 polymorphisms in the South African Coloured population could in part 
explain the lower incidence of CD observed in this group [586], but other factors – such 
as the availability of health care and the higher frequency of infectious diarrhoea - could 
hinder the diagnosis of CD in this population [587].  Low frequencies for these 
mutations have also been observed in African-American CD patients [587].  The 
variants were previously investigated in CD [584] in an independent sample set of 
South African Coloureds (ncases = 76, ncontrols = 100), but no association was detected 
with the disease.  
 
We did not find any statistically significant association between the polymorphisms 
studied and TB due to their low allele frequencies in both the South African Coloured 
case and control samples and family samples.  This study therefore did not have enough 
power to detect small effect sizes.  The common disease-common variant hypothesis 
states that the risk of contracting a common disease is determined by the presence of 
common variants in the population [588].  It can also be assumed that the detection of 
disease genes is facilitated in a population in which high exposure and high prevalence 
brings most of the genetic susceptibility alleles to manifestation.  Since TB is a common 
disease in the South African Coloured population, the low allele frequencies of the 
CARD15 mutations in this population indicate that the gene with its rare variants does 
not play a major role in predisposing to the disease.  These variants could however still 
be predisposing factors in other populations where they are more frequently present.  An 
investigation of TB cases and controls from another population with a higher frequency 
of CARD15 polymorphisms is therefore desirable.  
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In summary, we determined that CARD15 is not a major susceptibility factor in South 
African Coloured TB patients.  The low frequency of these variants in the population 
studied makes it unlikely that they play any role in disease aetiology. 
  
CHAPTER 6 
CANDIDATE GENES WHICH ARE 
DIFFERENTIALLY EXPRESSED 
BETWEEN TUBERCULOSIS CASES AND 
CONTROLS 
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6.1. INTRODUCTION  
At any given time, four groups of individuals who respond differently to infection with 
Mycobacterium tuberculosis (M.tuberculosis) can be identified in a community affected 
by tuberculosis (TB) [271].  These are 1) patients with active TB, named the “active” 
group, 2) individuals who have had several episodes of TB, even though they responded 
to and were cured after six months of TB treatment, designated as the “recurrent” group, 
3) individuals who had TB only once and who were cured after chemotherapy, 
classified as the “cured” group, and 4) M.tuberculosis-infected individuals with a 
positive Mantoux test, who have never presented with the active disease, designated the 
“latent” group.  A recent paper [271], in which DNA-array analysis experiments were 
done in the South African Coloured population, identified 337 genes which were 
differentially expressed in the blood of the four groups.  Of these differentially 
expressed biomarkers, nine (Table 101) could be used to discriminate between the 
outcomes after infection and disease as described above.   
 
TABLE 101. Genes differentially expressed between the four TB groups.  From [271]. 
Symbol Gene name Function 
RIN3 Ras and Rab interactor 3 
Intracellular trafficking, 
endosome 
LY6G6D Lymphocyte antigen 6 complex, locus G6D Immunological, receptor 
TEX264 Testis expressed 264 Unknown 
C14orf2 Chromosome 14 open reading frame 2  Unknown 
SOCS3 Suppressor of cytokine signalling 3 
Immunological, 
apoptosis 
KIAA2013 Hypothetical protein KIAA2013  
Unknown, in silico 
predicted motif/domain 
ASNA1 
ArsA arsenite transporter, ATP-binding, 
homolog 1 (bacterial) 
Solute transporter, anion 
transporting ATPase 
ATP5G1 
ATP synthase, H+ transporting, mitochondrial 
F0 complex, subunit c (subunit 9) 
Solute transporter, energy 
NOLA3 Nucleolar protein family A, member 3  Nuclear, RNA processing 
 
 
The genes encoding these biomarkers are therefore novel candidate genes for 
susceptibility to TB.  In addition to these 9 biomarkers, we considered the list of 337 
differentially expressed genes and sorted them according to their ability to distinguish 
between the latent and recurrent groups.  These two groups were selected since we 
considered them to represent the extremes of the four phenotypes of TB i.e. latently 
infected individuals were considered to be more resistant, while patients with recurrent 
episodes were considered to be more susceptible to TB.  We excluded all genes with p ≥ 
0.05.  This resulted in a second list of 24 genes (Table 102) which were investigated 
using the published literature to determine their possible function in TB.   
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TABLE 102. Genes differentially expressed between the latent and recurrent groups.  
From [271]. 
Differentially 
expressed 
Accession 
number  
Differentially 
expressed 
Accession 
number 
FLJ22875 NM_032231 TCF19 NM_007109 
FANCE NM_021922 OSBPL5 NM_020896 
PTMA NM_002823 SCARB2 NM_005506 
TEX264 NM_015926 TBXA2R NM_001060 
GCN5L1 NM_001487 OSBPL10 NM_017784 
FLJ21709 NM_032206 IGSF6 NM_005849 
B2M NM_004048 ITGAE NM_002208 
KIAA0750 NM_014632 AV696234 AV696234 
CCDC55 NM_032141 RGC32 NM_014059 
SFRS4 NM_005626 CD6 NM_006725 
CCL3 NM_002983 CHODL NM_024944 
TIMP1 NM_003254 LOC51231 NM_016440 
 
 
From the genes listed in Tables 101 and 102, we selected two novel candidate genes, 
namely testis expressed 264 (TEX264) and suppressor of cytokine signalling 3 (SOCS3), 
to investigate their role in TB susceptibility in the South African Coloured population, 
based on their ability to distinguish between the phenotypes of TB.   
 
6.1.1 Testis expressed 264 
Testis expressed 264 (TEX264), located on chromosome 3p21.31, was selected as a 
candidate gene because of differential gene expression patterns in blood from patients 
with active, cured, latent or recurrent TB [271] and is a candidate gene by experiment.  
In the DNA-array expression analysis (Figure 49), this gene could distinguish between 
the latent and recurrent groups.  This observation was confirmed with quantitative 
reverse-transcriptase PCR (qRT-PCR) [271].   
 
 
FIGURE 49.  Expression profile of TEX264.  Measurements were done by DNA array 
analysis and qRT-PCR.  This gene could distinguish between patients with recurrent 
episodes of TB and latently infected individuals.  From [271]. A = active, R = 
recurrent, C = cured, L = latent. 
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Thus far, TEX264 is a gene of unknown function, but the TEX264 protein is most 
abundantly expressed in the larynx and lymph (EST Profile Viewer, Unigene, NCBI), 
indicating some possible role in the immune system.  TEX264 is found mainly 
extracellularly [589,590] and was first identified as a novel secreted protein during a 
bioinformatics assessment [591].  We sequenced the coding regions of the gene to 
identify known and novel single nucleotide polymorphisms (SNPs) in the gene and 
genotyped selected polymorphisms in the samples from the South African Coloured 
population to investigate their possible association with TB susceptibility. 
 
6.1.2. Suppressor of cytokine signalling 3 
Members of the suppressor of cytokine signalling (SOCS) protein family act as negative 
feedback inhibitors [592] of cytokines which signal through the Janus kinase/signal 
transducer and activators of transcription (JAK/STAT) pathway.  Eight SOCS family 
members have been identified to date [593] and transcription of their respective 
encoding genes is induced by cytokines, hormones and growth factors [594].  SOCS-1, 
SOCS-3 and the cytokine-inducible SH2-containing protein (CIS) are the best 
understood members of the protein family [594] and can all be induced in cells from the 
innate immune system, such as macrophages and dendritic cells [595].  SOCS-1 and 
SOCS-3 are part of a related pair, with their amino acid sequences being more similar to 
each other than to other proteins of the SOCS family [596].  These two related 
regulators were both induced in murine macrophages infected with M.bovis bacillus 
Calmette-Guérin (BCG) and it was suggested that these molecules are part of a 
mechanism responsible for a poor response to interferon gamma (IFN-γ) during 
mycobacterial infection [597].  SOCS-1 and SOCS-3 were also directly induced by 
lipopolysaccharides (LPS) [598] and CpG-DNA [599].  This induction was independent 
of protein synthesis and the JAK/STAT pathway, proving that SOCS expression can be 
activated by toll-like receptor (TLR) signalling pathways.   
 
SOCS-3 is an intracellular protein, the expression of which is rapidly upregulated by 
IFN-γ [600].  A STAT-binding site, present in the proximal region of the SOCS3 
promoter, is needed for this response to IFN-γ [600].  In mice deficient for SOCS3, 
immune responses to infection were impaired.  This was a result of the production of an 
excess of transforming growth factor β and interleukin-10 (IL-10) [601].  Three 
intracellular pathogens, namely Leishmania donovani [602], Listeria monocytogenes 
[603] and Salmonella enterica [604], can induce the expression of SOCS-3 in 
macrophages and thereby inhibit cytokine signalling.  This response could be part of the 
normal immune system, where continued macrophage activation may be detrimental to 
the host [603], but pathogens could also exploit this inhibitory mechanism to suppress 
macrophage activation [602].  Since SOCS-3 is highly expressed [271] in patients with 
active TB (Figure 50), it is possible that M.tuberculosis could be upregulating 
transcription of SOCS3 to avoid destruction within macrophages.  The high expression 
levels of  SOCS-3 could also be an indicator of an ongoing immune response [271], 
since patients with recurrent episodes of disease expressed extremely low levels (Figure 
50) of this protein, indicating an impaired immune response [271].  However, low levels 
of SOCS-3 [271] were also observed in cured and latently infected individuals (Figure 
50), supporting the hypothesis that M.tuberculosis infection actively stimulates the 
expression of SOCS-3.  Since this has been observed in macrophages infected with 
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M.bovis BCG [597], the involvement of SOCS-3 in the M.tuberculosis-induced 
inhibition of macrophage activity is quite possible. 
 
SOCS3 was selected as a candidate gene for TB based on results from the gene 
expression study of Mistry et al [271] and is a candidate gene by experiment.  We 
selected three SOCS3 polymorphisms (Table 103) from dbSNP [58] and the literature 
[605,606] to genotype in the samples from the South African Coloured population. 
 
 
FIGURE 50.  Expression profile of SOCS3.  Measurements were done by DNA array 
analysis and qRT-PCR.  This gene was highly expressed in patients with active disease, 
but not in patients with recurrent episodes of TB.  From [271]. A, R, C and L are 
defined in Figure 49. 
 
TABLE 103. Polymorphisms genotyped in SOCS3. 
Polymorphism Class Location Genotyping method 
rs4969168 SNP 3'UTR
a
 SNPlex 
rs4969169 SNP 3'UTR  SNPlex 
rs7207782 SNP Promoter   SNPlex 
a
 untranslated region (UTR) 
 
6.2. RESULTS 
6.2.1. TEX264 
The coding regions of the TEX264 were amplified (Section 3.5.5.) and the products 
were visualised on 2% agarose gels (Figure 51).  Sequencing of the coding regions of 
TEX264 identified two novel polymorphisms (Figure 52) in the South African Coloured 
population.  These novel polymorphisms were submitted to the dbSNP database [58] 
and received unique rs-numbers.  Base 28551 A to G (Figure 52A, rs28730659, in 
intron 3) is a non-coding polymorphism and has an allele frequency of 0.1.  The 
genotyping data from this SNP did not pass quality checking as described in section 
3.11.1 and was therefore excluded from further analysis.  Base 33205 (Figure 52B, 
rs28994878, in exon 5) is a synonymous polymorphism and has an allele frequency of 
0.07.  This novel SNP, together with 2 polymorphisms in the 5’ region of the gene 
(Table 104), was genotyped in all samples. 
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FIGURE 51.  Amplification of TEX264 products for sequencing.  The five coding exons 
of this gene were amplified in seven separate PCR reactions.  The gel photographs are 
numbered according to section 3.5.5 (1.1 – 5.2) and the size of each fragment is 
indicated. N = negative control. 
 
 
FIGURE 52.  Sequencing of the coding regions of TEX264 and the detection of novel 
polymorphisms, highlighted in grey.  A) The rs28730659 A/G SNP is present in intron 3.  
B) The synonymous rs28994878 C/T SNP is in exon 5. 
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TABLE 104. Polymorphisms genotyped in the TEX264 gene. 
Polymorphism Class Location Genotyping method 
rs6775666 SNP Promoter SNPlex 
rs4355273 SNP 5’UTR SNPlex 
rs28994878 SNP Exon 5, synonymous SNPlex 
 
 
6.2.1.1. Single-point statistical analysis 
The three TEX264 polymorphisms were successfully genotyped in samples from the 
case-control and family-based studies.  All SNPs were in Hardy-Weinberg equilibrium 
(HWE) for the control group.  The threshold for significance was set at p = 0.025 after 
Bonferroni correction, since rs6775666 and rs4355273 were part of a single haplotype 
block and therefore not independent of each other.   
 
The novel synonymous rs28994878 SNP was not associated with TB susceptibility in 
the South African Coloured population in our case-control study (p = 0.90, Table 105) 
or transmission disequilibrium test (TDT, p = 0.40, Table 106).  The two 
polymorphisms rs6775666 and rs4355273 in the 5’UTR region of the gene, which could 
potentially modify expression of TEX264, were also not associated with disease 
susceptibility (Tables 105 and 106). 
 
TABLE 105.  Single-point statistical analysis in the TEX264 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs6775666 A G 0.002 0.088 0.91 0.002 0.108 0.89 0.62 
rs4355273 C G 0.01 0.08 0.91 0.002 0.114 0.884 0.15 
rs28994878 T C 0 0.07 0.93 0 0.06 0.94 0.90 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
TABLE 106. Single-point statistical analysis in the TEX264 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs6775666 G 13 : 11 0.17 0.68 
rs4355273 G 13 : 8 1.19 0.28 
rs28994878 T 4 : 2 0.67 0.41 
 
 
6.2.1.2. Haplotype analysis 
The Haploview program [313] identified a single haplotype block (Figure 53) consisting 
of the two polymorphisms in the 5’ region of TEX264.  The rs28994878 SNP was 
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excluded from this haplotype since the block definition from Gabriel et al [89] labelled 
its linkage with the other variants as uncertain. 
 
Two haplotypes were determined for the case-control (Table 107) and TDT (Table 108) 
samples in the haplotype block.  Haplotype 1 was the most frequent haplotype in both 
groups.  None of the haplotypes were associated with TB susceptibility in either the 
case-control or TDT haplotype analyses (Tables 107 and 108). 
 
 
FIGURE 53.  Plot of linkage disequilibrium (LD) between TEX264 markers analysed in 
control individuals of South African Coloured descent generated by Haploview v3.3.  
D’-values (%) are indicated on the squares.  The colours of the squares represent LD 
strength, with red being strong, and blue weak.  Haplotype blocks are outlined in black. 
 
TABLE 107. TEX264 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b
 
1 G-G 0.95 0.94 1.10 0.29 0.64 
2 A-C 0.05 0.06 0.87 0.35 0.67 
a
 The order of the SNPs in each block corresponds to Figure 53. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.29 were observed on 6420 out of 10 000 occasions (64%). 
 
TABLE 108. TEX264 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p value p valuePermutation
b
 
1 G-G 11 : 9 0.20 0.65 1 
2 A-C 9 : 10 0.05 0.82 1 
a
 The order of the SNPs in each block corresponds to Figure 53. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.65 were observed on 10 000 out of 10 000 occasions (100%). 
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6.2.2. SOCS3 
6.2.2.1. Single-point statistical analysis 
The three SNPs in SOCS3 were genotyped in the case-control and TDT samples sets.  
All SNPs were in HWE in the control population.  After Bonferroni correction using the 
methodology of Nicodemus et al [76], the level of significance required was set at  
p = 0.017.  According to this criterion none of the polymorphisms analysed were 
associated with TB susceptibility in either the case-control study (Table 109) or TDT 
(Table 110). 
 
TABLE 109.  Single-point statistical analysis in the SOCS3 case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs4969168 G A 0.17 0.49 0.34 0.22 0.50 0.28 0.07 
rs4969169 T C 0 0.11 0.89 0 0.13 0.87 0.66 
rs7207782 A G 0.04 0.34 0.62 0.06 0.35 0.59 0.34 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
TABLE 110. Single-point statistical analysis in the SOCS3 TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs4969168 A 58 : 41 2.92 0.09 
rs4969169 C 15 : 7 2.91 0.09 
rs7207782 G 30 : 27 0.16 0.69 
 
 
6.2.2.2. Haplotype analysis 
Haploview [313] did not calculate any haplotype blocks (Figure 54) for the three SNPs 
genotyped in SOCS3 when considering the haplotype block definition of Gabriel et al 
[89].  However, when a definition of a single spine of LD was used, the three variants 
were part of a haplotype block.  Six haplotypes were calculated in the haplotype block 
in both the case-control (Table 111) and TDT (Table 112) haplotype analyses.   
 
Haplotype 2 was the most frequently observed haplotype in the case-control and family-
based samples.  This haplotype showed a nominally significant association with TB 
susceptibility in the case-control analysis (p = 0.03, Table 111).   
 
To correct for multiple testing, we did 10 000 permutations using Haploview [313].  
According to this program, 835 out of the 10 000 permutations exceeded the best 
observed p value of haplotype 2.  This means that there is an 8% chance that the 
significant nominal p value of haplotype 2 was observed due to chance alone.  This 
haplotype was not associated with disease in the TDT analysis (Table 112).  However, 
haplotype 6 was nominally associated with TB susceptibility (p = 0.05, Table 112).  
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There was a 16% chance that this association was due to chance alone and not 
surprisingly, it was not detected in the case-control analysis. 
 
 
FIGURE 54.  Plot of LD between SOCS3 markers analysed in control individuals of 
South African Coloured descent generated by Haploview v3.3.  Squares are coded in 
the same manner as in Figure 53.  No haplotype blocks were identified by Haploview 
using the haplotype block definition from Gabriel et al[89]. 
                                                      
TABLE 111. SOCS3 case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b
 
1 A-C-A 0.01 0.01 0.01 0.93 1 
2 A-C-G 0.54 0.48 4.88 0.03 0.08 
3 A-T-G 0.03 0.04 0.16 0.69 1 
4 G-C-A 0.20 0.22 1.78 0.18 0.56 
5 G-C-G 0.20 0.22 0.83 0.36 0.86 
6 G-T-G 0.03 0.03 0.59 0.44 0.93 
a
 The order of the SNPs in each block corresponds to Figure 54. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.03 were observed on 835 out of 10 000 occasions (8%). 
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TABLE 112. SOCS3 TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p value p valuePermutation
b
 
1 A-C-A 2 : 1 0.31 0.58 0.99 
2 A-C-G 44 : 34 1.33 0.25 0.71 
3 A-T-G 4 : 3 0.07 0.79 1 
4 G-C-A 24 : 20 0.32 0.57 0.98 
5 G-C-G 25 : 35 1.48 0.22 0.62 
6 G-T-G 2 : 8 3.82 0.05 0.16 
a
 The order of the SNPs in each block corresponds to Figure 54. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.05 were observed on 1630 out of 10 000 occasions (16%). 
 
6.3. DISCUSSION 
Gene expression studies can suggest novel candidate genes to investigate in diseases 
and such a study has been done in TB using individuals from the South African 
Coloured population [271].  The TEX264 and SOCS3 genes were investigated as factors 
contributing to TB susceptibility in the South African Coloured population.  Expression 
of these genes, together with that of 7 other genes, made it possible to discriminate 
between the four phenotypes of TB, as defined before, namely active, recurrent, latent 
and cured [271].  TEX264 could discriminate between individuals in the latent group, 
where it was expressed at the highest level, and those with recurrent disease, while 
SOCS3 was expressed at a higher level in patients with active TB than in the other 
groups.  We hypothesised that polymorphisms in these genes could play a role in TB 
susceptibility. 
 
The SNPs investigated in TEX264 included a novel polymorphism identified in the 
South African Coloured population (rs28994878).  However, none of the SNPs or 
haplotypes were associated with TB.  This was also the case for the polymorphisms and 
haplotypes investigated in SOCS3.  The SOCS3 gene was previously associated with 
Type 1 diabetes [607] and atopic dermatitis [605]. 
 
Although we found no association between polymorphisms in these novel candidate 
genes and TB susceptibility, it is still possible that they contribute to the disease by a 
mechanism not determined by genetic variation.  This includes regulation of gene 
expression by M.tuberculosis, which has previously been shown to modulate the 
immune response of the host [608].  Different strains of M.tuberculosis can elicit 
different immune responses in different individuals [609-611].  Other candidates 
identified in the gene expression study from Mistry et al [271] could be investigated to 
determine if they play a role in genetic susceptibility to TB. 
  
 
CHAPTER 7 
A CANDIDATE GENE FROM A GENOME-
WIDE LINKAGE SCREEN 
 161 
7.1. INTRODUCTION  
Linkage studies are used to outline chromosomal regions containing putative 
susceptibility genes, either by a genome-wide scan, which ensures that all major 
genomic regions involved in disease susceptibility are identified, or by concentrating on 
a candidate region.  This methodology creates the possibility of identifying novel genes 
and pathways which were not formerly considered to be disease-contributing factors.   
The approach has been successfully used in the analysis of monogenic diseases, but 
varying results have been found in research considering complex diseases, such as 
tuberculosis (TB), where more than one gene can influence disease susceptibility, and 
individual genes are generally of small effect.  An example of a linkage study which 
focused on a candidate region, namely chromosome 17q11-q21 region, is that of 
Jamieson et al [65].  A region on mouse chromosome 11 was previously shown to 
contain susceptibility genes to another intracellular pathogen [64].  Evaluation of the 
syntenic chromosome 17q11-q21 region in humans suggested that four genes 
contributed separately to TB susceptibility [65].   
 
The use of genome-wide scans in TB genetics has suggested several susceptibility loci 
(Section 1.2.2.1.).  These include regions on chromosome 15q and Xq, implicated in TB 
susceptibility of the South African population [66], as well as chromosome 2q35 in 
aboriginal Canadians [68].  A study in Brazilians, which examined TB and leprosy 
families, suggested three regions (10q26.13, 11q12.3 and 20p12.1) [69].  A recent 
genome scan in Moroccan families suggested that chromosome 8q12-q13 may contain a 
major dominant-acting TB susceptibility gene [70].  Little overlap between 
susceptibility regions has been found when comparing the different TB linkage studies.  
This is understandable, because the strongest linkage observed may be exclusive to a 
specific family or population and thus impossible to identify in other studies [71].  The 
phenotyping used to identify affected individuals is also crucial.  A new genome-wide 
scan, as yet unpublished (Cooke et al), which also investigated the South African 
Coloured population, has led to the identification of a novel susceptibility gene in the 
chromosome 20q13.31-33 region.  In that study, 40 single nucleotide polymorphisms 
(SNPs) in the chromosomal region identified were screened.  In the initial analysis, 
polymorphisms from two genes showed evidence of disease association in Gambian TB 
samples.  Additional SNPs from these genes were then genotyped in populations from 
Guinea-Bissau and The Republic of Conakry.  The most convincing candidate gene in 
this region was cathepsin Z (CTSZ), while the neighbouring TH1-like (Drosophila) 
(TH1) and tubulin, beta 1 (TUBB1) genes were also potential candidates.  A significant 
association (p = 0.005) was seen with a 3’ untranslated region (UTR) SNP (rs10369) of 
CTSZ, but not with the only non-synonymous polymorphism of this gene (rs9760).  
TUBB1 also showed a weakly significant association (p = 0.04), but the association was 
not consistent across the study populations.   
 
Genome-wide linkage studies in TB genetics have not conclusively established major 
loci for the disease.  However, Cooke et al suggested that this study approach may serve 
as a strategy to investigate genomic regions more likely to contain susceptibility genes, 
an advantage to researchers in countries where SNP genotyping is still expensive.  
Therefore, we selected a candidate gene in the chromosomal region identified by Cooke 
et al to investigate its possible role in TB susceptibility in the South African Coloured 
population. 
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7.2. CATHEPSIN Z 
Cathepsin Z (CTSZ [612], also known as cathepsin P [613], X [614] or Y [615]) is one 
of the 11 cysteine proteases of the papain family [616].  Proteins of this family are 
mostly localised in lysosomes, where they form a vital component of the lysosomal 
proteolytic system.  They may also be found in the cytosol or extracellularly, usually as 
precursors of their active forms [613].  They are essential in biological processes such 
as bone resorption, apoptosis [615] and extracellular matrix remodelling (ECM).  In the 
immune system, cathepsins are involved in antigen processing and maturation of the 
major histocompatibility complex (MHC) class II molecules [616].  CTSZ is mostly 
expressed in immune cells, such as macrophages and monocytes [617,618], and a role 
for the protein in the immune response has been hypothesised [619].  However, no 
specific immune function has been identified for this protein as far as could be 
ascertained.  The protein has a considerable similarity to cathepsins B, C and L [620].  
The enzyme has both carboxymonopeptidase and carboxydipeptidase activities, but 
shows little endopeptidase activity [615].  Recently it has been suggested that CTSZ 
may be used as a diagnostic marker in inflammatory diseases [621].   
 
Several members of the cathepsins have been implicated in TB.  It has been found that 
cathepsin L maturation and activity can be impaired by Mycobacterium tuberculosis 
(M.tuberculosis) and M.avium [622].  This diminished the ability of macrophages to 
present antigens.  However, infection of macrophages with the mycobacteria had no 
effect on the maturation of cathepsins B or D.  Cathepsins are differentially expressed 
during M.tuberculosis infection and this expression is specifically associated with 
macrophages present in the granuloma [623].  Another cysteine cathepsin, namely 
cathepsin W, was identified as a risk factor for the extrapulmonary dissemination of 
human TB [624].  The involvement of cathepsins in a caspase-independent pathway 
which modulates apoptosis by macrophages infected with M.tuberculosis was recently 
suggested [625] and confirmed in a second study [626].   As yet, there is no direct 
evidence of a function for CTSZ in TB.  However, since this enzyme is expressed 
mostly in macrophages, and because of its homology to other cathepsins involved in 
TB, the gene encoding this protein is a candidate gene for TB susceptibility.  
Furthermore, CTSZ is a candidate gene due to its location in the chromosome 20q13.31-
33 region (Section 7.1) and its possible role in the immune response.  We selected 7 
polymorphisms (Table 113) from this gene to genotype in the case-control and family-
based samples from the South African Coloured population. 
 
TABLE 113. Polymorphisms genotyped in CTSZ in this study. 
Polymorphism Class Location Genotyping method 
rs448943 SNP 3'UTR
a
 SNPlex 
rs10369 SNP 3'UTR SNPlex 
rs13720 SNP 3'UTR SNPlex 
rs6064734 SNP Exon 6, synonymous SNPlex 
rs3787492 SNP Exon 6/intron 5 boundary SNPlex 
rs163785 SNP Exon 4, synonymous SNPlex 
rs11540881 SNP Exon 4, synonymous SNPlex 
a
 untranslated region 
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7.2.1. Results 
7.2.1.1. Single-point statistical analysis 
Seven SNPs were successfully genotyped in all the TB cases, controls and family-based 
samples from the South African Coloured population (Tables 114 and 115).  Of the 
seven polymorphisms genotyped, three (rs6064734, rs163785 and rs11540881) were 
found to be monomorphic in all samples and were excluded from further analyses.  The 
remaining four SNPs were analysed in the case-control and family-based samples and 
were all in Hardy-Weinberg equilibrium (HWE) for the control population.   
 
A p value of 0.025 would be necessary to achieve statistical significance, as rs3787492 
was in linkage equilibrium with the three other SNPs and considered to be an 
independent test.  The three 3’UTR polymorhisms rs448943, rs10369 and rs13720 were 
in linkage disequilibrium (LD). 
 
TABLE 114.  Single-point statistical analysis in the CTSZ case-control study design.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs448943 G C 0.26 0.46 0.28 0.22 0.49 0.29 0.36 
rs10369 T C 0.06 0.35 0.60 0.04 0.34 0.62 0.54 
rs13720 G A 0.04 0.27 0.69 0.04 0.30 0.66 0.58 
rs6064734 Monomorphic 
rs3787492 T C 0.05 0.38 0.57 0.06 0.41 0.53 0.33 
rs163785 Monomorphic 
rs11540881 Monomorphic 
a 
number of investigated individuals.  
b 
Allele 1 is the minor allele.  
c
 p value from a genotype-based χ² test
 
 
The 3’UTR polymorphism rs10369 was not significantly associated with TB in our 
case-control study (p = 0.54, Table 114) or TDT (p = 0.08, Table 115).  This SNP was 
previously associated (Cooke et al, unpublished data) with TB in samples from The 
Gambia, Guinea-Bissau and The Republic of Conakry.  None of the other 3’UTR SNPs 
were associated with disease (Tables 114 and 115).   
 
We also investigated the rs3787492 SNP located in an exon/intron boundary of CTSZ, 
because it could be involved in alternative splicing of the gene. Two transcript variants 
of this gene have been found previously (CTSZ Entrez Gene Summary, NCBI).  This 
SNP was not associated with TB in our study.  Altogether, single marker analysis 
detected no association between TB and any of the SNPs investigated in the CTSZ gene. 
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TABLE 115. Single-point statistical analysis in the CTSZ TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs448943 G 50 :47 0.09 0.76 
rs10369 T 39 : 25 3.06 0.08 
rs13720 - 28 : 28 0 1 
rs6064734 Monomorphic 
rs3787492 C 32 : 30 0.07 0.80 
rs163785 Monomorphic 
rs11540881 Monomorphic 
 
 
7.2.1.2. Haplotype analysis 
The Haploview program [313] identified a single haplotype block (Figure 53) for three 
of the markers genotyped in CTSZ in the control samples.  The LD between the 
rs448943, rs10369 and rs13720 3’UTR markers in this block was strong.  The 
exon/intron boundary SNP (rs3787492) was not part of this block.  Since no additional 
information on the haplotype block containing this SNP was available, it was not 
considered in the statistical analysis of CTSZ haplotypes with TB in this study. 
 
 
 
FIGURE 55.  Plot of LD between CTSZ markers analysed in control individuals of South 
African Coloured descent generated by Haploview v3.3.  D’-values (%) are indicated 
on the squares.  The colours of the squares represent LD strength, with red being 
strong, and blue weak.  Haplotype blocks are outlined in black.  The rs6064734, 
rs163785 and rs11540881 SNPs were monomorphic in this study. 
 
Four haplotypes were determined in both the case-control (Table 116) and TDT (Table 
117) haplotype analyses.  Haplotype 1 was the most frequently observed haplotype in 
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both analyses.  Haplotypes 2 (p = 0.01) and 3 (p = 0.02) were transmitted to TB 
offspring more frequently than expected in the TDT analysis (Table 117).  The most 
significant association was observed on 645 out of 10 000 occasions (6%) during 
permutation testing.  Since the level of significance was set at 5%, these results are not 
reflections of true associations.  None of the remaining haplotypes in the case-control or 
TDT analyses were associated with TB. 
 
TABLE 116. CTSZ case-control haplotype analysis by Haploview [313]. 
Block 1
a
 FreqCases FreqControls χ² p value p valuePermutation
b
 
1 C-C-A 0.33 0.34 0.18 0.67 0.97 
2 G-C-A 0.26 0.26 0.06 0.81 1 
3 G-T-A 0.23 0.21 0.97 0.33
c
 0.72 
4 C-C-G 0.18 0.19 0.65 0.42 0.83 
a
 The order of the SNPs in each block corresponds to Figure 53. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.33 were observed on 7243 out of 10 000 occasions (72%). 
 
TABLE 117. CTSZ TDT haplotype analysis by Haploview [313]. 
Block 1
a
 Transmitted:untransmitted χ² p value p valuePermutation
b
 
1 C-C-A 39 : 36 0.09 0.76 0.99 
2 G-C-A 24 : 44 5.98 0.01
c
 0.06 
3 G-T-A 29 : 14 5.12 0.02 0.10 
4 C-C-G 23 : 20 0.34 0.56 0.94 
a
 The order of the SNPs in each block corresponds to Figure 53. 
b 
Permutation test p values were calculated from 10 000 permutations in Haploview. 
c
 p values less than 0.01 were observed on 645 out of 10 000 occasions (6%). 
 
7.2.2. Discussion 
In this chapter, polymorphisms in CTSZ were tested as susceptibility factors in TB.  
This gene was previously associated with the disease in a two-stage genome-wide 
linkage study (Cooke et al, unpublished data).  We attempted to replicate the association 
observed in their study in the case-control and family-based samples from the South 
African Coloured population. 
We did not find any association between the 3’UTR SNP rs10369 and TB 
susceptibility, although the C allele of this SNP was associated with the disease in the 
unpublished study from Cooke et al.  We also found no association between the other 
3’UTR or synonymous SNPs genotyped in our study.  These supposedly synonymous 
SNPs (rs6064734, rs163785 and rs11540881) were reported to be polymorphic in the 
dbSNP database and were therefore included in genotyping.  However, they were 
monomorphic in all the samples from the South African Coloured population genotyped 
in this study. 
 
The genome-wide screen from Cooke et al was done in two steps, which strengthens the 
case for an involvement of CTSZ in TB.  Even so, it is possible that other genes in the 
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chromosome 20q13.31-33 region may be in LD with CTSZ.  Another explanation is that 
CTSZ is not a major contributor to TB and that our study did not have enough power to 
detect such a small effect size.  In fact, the study from Cooke et al did suggest a minor 
genetic effect (OR 0.49) of CTSZ in TB. 
 
In conclusion, polymorphisms and haplotypes in CTSZ are probably not associated with 
TB in the South African Coloured population.  Future studies should consider other TB 
candidate genes in the chromosome 20q13.31-33 region. 
  
CHAPTER 8 
FUNCTIONAL POLYMORPHISMS THAT 
INFLUENCE SUSCEPTIBILITY TO 
IMMUNE-MEDIATED DISEASES OTHER 
THAN TUBERCULOSIS 
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8.1. INTRODUCTION  
Immune-mediated diseases may be affected by several similar genes, which can disrupt 
immune homeostasis and contribute to disease pathology [627]. Inflammation, a 
common manifestation of the innate immune system after injury or infection and also 
observed during tuberculosis (TB) infection [628], can disrupt immune homeostasis.   
 
Acute inflammation, normally seen after injuries, involves the infiltration of tissues by 
leukocytes and plasma, while chronic inflammation (Figure 56), such as observed 
during Mycobacterium tuberculosis (M.tuberculosis) infection, is characterised by 
mononuclear immune cell infiltration of tissues.  It can serve as a protective mechanism 
to remove or destroy the causative agent, limit the spread of infection and prepare the 
damaged region for healing [629].  
 
 
 
 
FIGURE 56. Bladder biopsy showing chronic granulomatous inflammation. From [630]. 
 
However, inflammation is a two-edged sword and could, when misdirected by the 
immune system, also attack the host organism [629].  Diseases where this is the case 
include psoriasis, rheumatoid arthritis and asthma, and several of these diseases share 
common susceptibility genes.  In some cases, functional polymorphisms have been 
identified in these genes and were associated with various immune-mediated diseases as 
well as TB.  However, opposite associations between these functional variants, 
previously associated with immune-mediated diseases, and TB have frequently been 
observed.   
 
An example is the A allele of the -308 single nucleotide polymorphism (SNP) in the 
tumour necrosis factor (TNF superfamily, member 2) (TNF) gene promoter which leads 
to a higher rate of TNF transcription in expression studies [631,632].  This allele was 
associated with immune-mediated diseases such as systemic lupus erythematosus [633], 
rheumatoid arthritis [634] and inflammatory bowel disease (IBD, which includes the 
subphenotypes Crohn’s disease and ulcerative colitis) [635].  High levels of TNF-α in 
these diseases are detrimental to the host and treatment may involve the use the TNF-α 
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inhibitors such as infliximab.  In patients latently infected with M.tuberculosis, 
infliximab treatment led to reactivation of the disease [636], suggesting that TNF-α is 
necessary to control TB infection.  The alternative low TNF-α producing G allele of the 
-308 TNF SNP was subsequently associated with TB susceptibility [171,172], lending 
support to this suggestion.   
 
Correa et al [172] proposed that heterozygotes of the TNF promoter polymorphism have 
a survival advantage, since individuals with homozygous GG genotypes would be 
resistant to TB, but susceptible to autoimmune diseases.  This supported the hypothesis 
that autoimmune diseases are a result of natural selection for an increased resistance to 
TB.  In addition, their results suggested that some susceptibility genes are not specific to 
a certain disease, but that related immunogenetic systems contribute to common 
diseases.   
 
To test this hypothesis, we selected from the literature several functional 
polymorphisms in candidate genes, previously associated with other immune-mediated 
disorders, to genotype in the samples from the South African Coloured population.  This 
was an exploratory study to determine the possible association of these SNPs with TB. 
 
8.2. CANDIDATE GENES FROM IMMUNE-MEDIATED DISEASES OTHER THAN TB 
We selected 27 SNPs from 22 susceptibility genes, previously associated with various 
immune-mediated diseases, to genotype with the SNPlex genotyping method (Section 
3.9) in samples from the South African Coloured population.  These genes, the SNPs 
genotyped in them, the immune-mediated diseases they were previously associated with 
and their functional effects are listed in Table 118. 
 
TABLE 118. Functional polymorphisms previously associated with other immune-
mediated diseases which were genotyped as described in this chapter. 
SNP Selected previous disease associations and functional effect Ref 
ATP-binding cassette, subfamily B (MDR/TAP), member 1 (ABCB1) 
rs3789243 
rs1045642 
rs2032582 
Intestinal bowel disease (IBD) 
Associated with altered protein or gene expression activity. 
[637,638] 
ATG16 autophagy related 16-like 1 (S. cerevisiae) (ATG16L1) 
rs2241880 
Crohn’s disease 
Nonsynonymous SNP, involved in autophagocytosis pathway 
implicated in resistance to intracellular pathogens. 
[92,639] 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) 
rs3087243 
Several autoimmune diseases, such as systemic lupus 
erythematosus and coeliac disease 
Alters the ratio of splice variants. 
[640,641] 
Class II, major histocompatibility complex, transactivator (CIITA) 
rs3087456 
Systemic lupus erythematosus, rheumatoid arthritis 
Associated with regulation of class II MHC expression. 
[642-
644] 
 
 169 
SNP Selected previous disease associations and functional effect Ref 
Fc receptor-like 3 (FCRL3) 
rs7528684 
Rheumatoid arthritis, systemic lupus erythematosus 
C allele was associated with higher transcriptional activity. 
[645,646] 
Interleukin 1 receptor antagonist (IL1RN) 
rs2419598 
Rheumatoid arthritis, ankylosing spondylitis 
Associated with reduced protein production 
[647,648] 
Interleukin 23 receptor (IL23R) 
rs11209026 
Psoriasis, Crohn’s disease 
Nonsynonymous coding polymorphism affects amino acid 
structure of the protein. 
[97,470] 
Interleukin 6 signal transducer (gp130, oncostatin M reporter) (IL6ST) 
rs3730293 
rs3729961 
Periodontitis 
Nonsynonymous polymorphisms which change amino acid 
sequence of the protein. 
[649] 
Insulin induced gene 2 (INSIG2) 
rs7566605 
Obesity 
May result in elevated triglyceride levels. 
[650] 
Membrane-spanning 4 domains, subfamily F, member 2 (MS4A2) 
rs569108 
Asthma 
Increased expression on basophils. 
[651,652] 
Nel-like 1 (NELL1) 
rs1607616 
IBD  
Novel disease gene 
(Franke et al, accepted) 
Peptidyl arginine deiminase, type IV (PADI4) 
rs2240340 
Rheumatoid arthritis 
Affects stability of transcripts as part of a haplotype. 
[653] 
Peroxisome proliferator-activated receptor gamma (PPARG) 
rs2067819 
rs3892175 
Crohn’s disease 
Regulate expression of an underlying genetic susceptibility in 
mice 
[654] 
Prostaglandin E receptor 4 (subtype EP4) (PTGER4) 
rs1992660 
Crohn’s disease 
Modulates expression of PTGER4. 
[655] 
Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) 
rs2476601 
Diabetes, rheumatoid arthritis, TB 
Alters P1 binding site in protein. 
[656-
660] 
Runt-related transcription factor 1 (RUNX1) 
rs2268277 
Rheumatoid arthritis 
Alters binding site in this transcription factor. 
[661] 
Solute carrier family 22,(organic cation transporter),member 4 (SLC22A4) 
rs1050152 
Crohn’s disease  
Alters transcription and transporter function of protein. 
[662,663] 
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SNP Selected previous disease associations and functional effect Ref 
Solute carrier family 22,(organic cation transporter),member 5(SLC22A5) 
rs11739135 
Crohn’s disease  
Alters transcription and transporter function of protein. 
[662,663] 
Tumour necrosis factor (TNF superfamily, member 2) (TNF) 
rs1799964 
rs1800629 
Psoriatic arthritis, Crohn’s disease  
Upregulates transcription of gene. 
[664-
666] 
Tumour necrosis factor superfamily, member 1A (TNFRSF1A) 
rs767455 
Crohn’s disease  
Polymorphism influences disease phenotype. 
[667] 
Tumour necrosis factor superfamily, member 1B (TNFRSF1B) 
rs3397 
Crohn’s disease  
Polymorphism influences disease phenotype. 
[667] 
Tumour necrosis factor (ligand) superfamily, member 15  (TNFSF15) 
rs6478108 
rs7848647 
Crohn’s disease  
May influence expression levels of the protein. 
[668] 
 
 
8.2.1. Results 
8.2.1.1. Single-point statistical analysis 
All SNPs were in Hardy-Weinberg equilibrium (HWE) in the control samples.  Since 
this was an exploratory study, no corrections for multiple testing were done and the 
threshold for significance was set at 0.05.   
 
Four SNPs, from RUNX1, IL1RN, CIITA and TNFRSF1B, were associated with TB in 
the case-control study (Table 119).  One significant association (p = 0.02), with a SNP 
in INSIG2, was detected in the transmission disequilibrium test (TDT, Table 120), but 
this polymorphism was not associated with disease in the case-control study.  Since the 
case-control study has greater power than the TDT to detect associations, it is likely that 
this is not a reflection of a true genetic association. 
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TABLE 119.  Single-point statistical analysis in the case-control study.          
Genotype frequencies 
Allele 
Cases (n
a
=432) Controls (n=482) Cases vs Controls Polymorphism 
1
b
 2 11 12 22 11 12 22 p value
c
 
rs1045642 T C 0.07 0.35 0.58 0.08 0.40 0.52 0.15 
rs1050152 T C 0.01 0.16 0.83 0.01 0.19 0.80 0.35 
rs11209026 A G 0 0.06 0.94 0 0.05 0.95 0.61 
rs11739135 A G 0 0.16 0.84 0.01 0.18 0.80 0.37 
rs1607616 A T 0.15 0.45 0.40 0.13 0.48 0.39 0.61 
rs1799964 C T 0.04 0.38 0.58 0.04 0.35 0.62 0.50 
rs1800629 A G 0.01 0.24 0.75 0.02 0.27 0.71 0.55 
rs1992660 G A 0.22 0.48 0.31 0.20 0.52 0.27 0.34 
rs2032582 T G 0.06 0.31 0.63 0.06 0.35 0.59 0.44 
rs2067819 A G 0.07 0.37 0.56 0.07 0.38 0.55 0.91 
rs2240340 G A 0.16 0.49 0.35 0.21 0.45 0.35 0.17 
rs2241880 C T 0.12 0.39 0.49 0.12 0.45 0.43 0.27 
rs2268277 G C 0.17 0.47 0.36 0.23 0.51 0.26 0.006 
rs2419598 A T 0.13 0.44 0.42 0.18 0.50 0.33 0.01 
rs2476601 A G 0 0.03 0.97 0 0.03 0.97 0.74 
rs3087243 A G 0.08 0.33 0.59 0.08 0.34 0.58 0.95 
rs3087456 A G 0.05 0.37 0.58 0.10 0.44 0.46 0.0004 
rs3397 T C 0.10 0.40 0.50 0.14 0.43 0.43 0.04 
rs3729961 G C 0.10 0.44 0.46 0.09 0.39 0.52 0.16 
rs3730293 C T 0.03 0.33 0.64 0.03 0.30 0.67 0.66 
rs3789243 T C 0.14 0.45 0.41 0.15 0.46 0.39 0.70 
rs3892175 A G 0.01 0.19 0.80 0.01 0.16 0.83 0.58 
rs569108 C T 0.01 0.24 0.75 0.02 0.27 0.71 0.39 
rs6478108 C T 0.04 0.34 0.63 0.05 0.36 0.59 0.41 
rs7528684 A G 0.10 0.41 0.49 0.10 0.48 0.42 0.08 
rs7566605 C G 0.04 0.31 0.65 0.05 0.31 0.64 0.82 
rs767455 C T 0.08 0.37 0.55 0.05 0.40 0.55 0.16 
rs7848647 T C 0.04 0.34 0.62 0.07 0.33 0.60 0.26 
rs8055955 A G 0.04 0.36 0.60 0.04 0.31 0.65 0.30 
a 
number of individuals investigated.  
b 
Allele 1 is the minor allele. 
 
c
 p value from a genotype-based χ² test
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TABLE 120. Single-point statistical analysis in the TDT. 
SNP Overtransmitted Transmitted:Untransmitted χ² p value 
rs1045642 T 48 : 45 0.10 0.76 
rs1050152 T 15 : 13 0.14 0.71 
rs11209026 A 11 : 9 0.20 0.65 
rs11739135 G 14 : 13 0.04 0.85 
rs1607616 A 56 : 46 0.98 0.32 
rs1799964 C 39 : 33 0.50 0.48 
rs1800629 G 26 : 24 0.08 0.78 
rs1992660 G 51 : 49 0.04 0.84 
rs2032582 T 37 : 33 0.23 0.63 
rs2067819 G 33 : 22 2.20 0.14 
rs2240340 A 58 : 49 0.76 0.38 
rs2241880 C 40 : 34 0.49 0.49 
rs2268277 C 48 : 34 2.39 0.12 
rs2419598 T 53 : 48 0.25 0.62 
rs2476601 - - 0 1 
rs3087243 A 28 : 27 0.02 0.89 
rs3087456 A 43 : 32 1.61 0.20 
rs3397 C 46 : 36 1.22 0.27 
rs3729961 G 45 : 32 2.20 0.14 
rs3730293 T 32 : 31 0.02 0.90 
rs3789243 C 46 : 38 0.76 0.38 
rs3892175 G 14 : 9 1.09 0.30 
rs569108 C 26 : 23 0.18 0.67 
rs6478108 T 33 : 28 0.41 0.52 
rs7528684 A 53 : 49 0.16 0.69 
rs7566605 G 44 : 24 5.88 0.02 
rs767455 C 34 : 31 0.14 0.71 
rs7848647 C 27 : 18 1.80 0.18 
rs8055955 A 24 : 22 0.09 0.77 
 
 
8.2.2. Discussion 
In this chapter we have tested the involvement of functional SNPs, previously 
associated with other immune-mediated diseases, in host genetic susceptibility to TB.  
These variants are TB susceptibility candidates, since it is possible that similar 
immunogenetic mechanisms may contribute to susceptibility to common diseases [172].  
This is evident from the treatment of some immune-mediated diseases in patients 
latently infected with M.tuberculosis who then develop active TB [636,669].  
Polymorphisms from four genes were significantly associated with TB in the case-
control study and one SNP was associated with TB in the TDT.   
 
The CIITA rs3087456 SNP was associated with TB (p = 0.0004, OR = 1.53 95% CI 
[1.24-1.88]) in the South African Coloured population.  This promoter polymorphism 
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was previously associated with rheumatoid arthritis and systemic lupus erythematosus 
[642,644] and regulates the expression of the CIITA gene [643].  The protein encoded is 
essential in the expression of MHC class II molecules.  Mice deficient for the CIITA 
gene are extremely susceptible to M.tuberculosis infection [670].  The study also 
showed that CIITA expression in mice with a functional CIITA was elevated after 
infection with the bacterium and that this increased expression decreased the growth 
rate of the mycobacteria three weeks after infection [670].  It is therefore likely that the 
A allele of the rs3087456 SNP may contribute to resistance to TB in humans.  This 
association is the only one that would remain significant after a stringent Bonferroni 
correction (p = 0.01). 
 
The rs2268277 SNP (p = 0.006, OR = 1.36 95% CI [1.12-1.65]) is present in the 
RUNX1 gene and was previously associated with rheumatoid arthritis [661].  This SNP 
alters a binding site in the RUNX1 protein, which is a transcription factor.  The protein 
regulates the expression of many genes involved in the immune system, such as the 
macrophage colony-stimulating factor receptor and T cell receptor β genes [671].  It is 
therefore possible that it may also regulate the expression of genes involved in the host 
defense against M.tuberculosis.   
 
The rs2419598 SNP in IL1RN was associated with TB in the South African Coloured 
population (p = 0.01, OR = 1.33 95% CI [1.10-1.61]).  This SNP was previously 
associated with rheumatoid arthritis and ankylosing spondylitis [647,648] and reduced 
production of the IL1RN protein.  Wilkinson et al determined that a haplotype 
containing a repeat polymorphism of IL1RN was associated with TB [253].  They also 
found that M. tuberculosis-induced IL1RN protein production was increased in healthy 
individuals with this haplotype compared to individuals without it.  Awomoyi et al 
studied the same polymorphism as Wilkinson et al, but found no association with TB 
susceptibility in Gambians [193].   
 
The TNFRSF1B rs3397 SNP was weakly associated with TB in our study (p = 0.04, OR 
= 1.22 95% CI [1.00-1.49]).  The TNF-α receptor encoded by this gene, TNF receptor 2 
(TNFR2), is part of the TNF superfamily and may influence the biological activity of 
TNF-α by acting as both an agonist and an antagonist [672].  Mice without a functional 
copy of the TNFRSF1B gene die when infected with M.bovis BCG, but are more 
resistant to infection than TNFRSF1A knockout mice [673].  Certain mycobacterial 
strains, such as H37RV, induce the release of TNFR2 by infected alveolar macrophages.  
This leads to the inhibition of TNF-α and decreases apoptosis of the infected 
macrophages [674].  In a recent study Stein et al [426] found an association between 
disease and the TNFRSF1A gene, also part of the TNF superfamily, but we did not 
observe any association in our study. 
 
The INSIG2 rs7566605 SNP was associated with TB only in the TDT (p = 0.02), but 
due to the reduced power of the TDT in comparison to the case-control study it is 
probably not a reflection of a true association.  The rs2476601 PTPN22 SNP was 
previously associated with TB in Colombians [659], but was not associated with disease 
in our study of the South African Coloured population.  This gene encodes the Lyp 
protein which binds to C-terminal Src tyrosine kinase to suppress T cell activation.  The 
rs2476601 SNP alters a P1 binding motif in the protein which prevents C-terminal Src 
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tyrosine kinase from binding it.  This inhibits formation of the complex and suppresses 
T cell activation [660]. 
 
The small values of the odds ratios from the associated SNPs indicate that these 
polymorphisms are not major contributors to TB susceptibility.  Since this was an 
exploratory study, no corrections for multiple testing were done.  For this reason, a 
replication study in a different population group is necessary.  Such a project is 
currently being done in TB samples from Ghana.  If associations are found with the 
same markers as in this study, it will verify the involvement of these functional SNPs in 
genetic susceptibility to TB in the global population.  However, these associations could 
also be specific to the South African Coloured population and might therefore not be 
reproducible in other populations. 
 
  
CHAPTER 9 
CONCLUDING REMARKS 
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This study contributes significantly to the TB host genetics field, since several candidate 
genes, never investigated before, were tested as susceptibility factors.  In addition, we 
considered susceptibility genes previously identified in other populations.  This is 
important, because association results should ideally be replicated in more than one 
population.  In total, 136 polymorphisms in 39 genes (Table 121), selected because of 
their potential involvement in host genetic susceptibility to tuberculosis (TB), were 
genotyped in the South African Coloured population during this study.  All 
polymorphisms were analysed using both case-control studies and transmission 
disequilibrium tests (TDTs); and linkage disequilibrium (LD) as well as haplotypes in 
the candidate genes were investigated.  We also determined allele frequencies for 
polymorphisms, which allowed comparisons to other populations. 
 
TABLE 121.  Polymorphisms genotyped and their single-point association results. 
Polymorphism Case-control study TDT Section 
C-C chemokine ligand-2 gene 4.2.1 
rs2857654    
rs1024611    
rs1024610    
rs3760399    
rs3760396    
rs4586    
rs2530797    
Interleukin 4 gene 4.3.1 
rs2243248    
rs2243250    
rs2070874    
rs2243251    
rs2243291    
Interleukin 10 gene 4.4.1 
rs1800890     
rs1800893    
rs1800896    
rs1800871    
rs1800872    
rs3024490    
rs3790622    
rs3024496     
rs3024498    
Interleukin 12, beta gene 4.5.1.a) 
rs730691    
rs3212217    
rs3212220    
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Polymorphism Case-control study TDT Section 
D5S291    
rs3213096    
rs2288831    
rs2853696    
rs3212227     
Interleukin 12 receptor, beta 1 4.5.1.b) 
rs393548     
rs2305743    
rs11086087    
rs429774    
rs375947    
Interleukin 12 receptor, beta 2 gene 4.5.1.c) 
rs11576006     
rs3762317     
Interleukin 18 gene 4.6.1 
rs1946519    
rs1946518    
rs187238     
rs5744229    
rs189667     
rs549908     
SH2 domain protein 1A gene (SH2D1A) 4.7.1 
rs990545  Not done
a
  
Toll-like receptor 2 gene (TLR2) 4.8.1 
rs4696480    
TLR2_GT    
rs3804099    
rs3804100    
rs5743704    
rs5743708    
Toll-like receptor 4 gene 4.8.1 
rs1927914    
rs10759932    
rs2770148    
rs4986790    
rs4986791    
rs11536889    
rs11536891    
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Polymorphism Case-control study TDT Section 
Wingless-type MMTV integration site family, member 5A gene 4.9.1 
rs3796232    
rs1795651    
rs7624718    
rs557077    
rs566926    
rs648872    
rs815541    
rs9311564    
rs472631    
rs556874    
rs11918967    
rs7622120    
rs590386    
Frizzled homolog 5 gene 4.9.1 
rs10188753    
rs718290    
rs7582078    
rs2010400    
rs6708488    
rs3731568    
Butyrophilin-like 2 gene (BTNL2) 5.2.1 
rs3817974    
rs17208699    
rs3817973    
rs3817972    
ss65713168    
ss65713167    
ss65713164    
ss65713163    
rs2076530    
rs9268480    
rs2076529    
ss65713152    
ss65713150    
rs3763317    
rs9268501    
rs9268502    
rs9268503    
rs9268504    
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Polymorphism Case-control study TDT Section 
Caspase recruitment domain-containing protein 15 gene (CARD15) 5.3.1 
rs2066844    
rs2066845    
rs2066847    
Testis expressed 264 gene (TEX264) 6.2.1 
rs6775666    
rs4355273    
rs28994878    
Suppressor of cytokine signalling 3 gene (SOCS3) 6.2.2 
rs4969168    
rs4969169    
rs7207782    
Cathepsin Z (CTSZ) 7.2.1 
rs448943    
rs10369    
rs13720    
rs6064734    
rs3787492    
rs163785    
rs11540881    
ATP-binding cassette, subfamily B (MDR/TAP), member 1 gene 8.2.1 
rs3789243    
rs1045642    
rs2032582    
ATG16 autophagy related 16-like 1 (S. cerevisiae) gene 8.2.1 
rs2241880    
Cytotoxic T-lymphocyte-associated protein 4 gene  8.2.1 
rs3087243    
Class II, major histocompatibility complex, transactivator gene (CIITA) 8.2.1 
rs3087456    
Fc receptor-like 3 gene 8.2.1 
rs7528684    
Interleukin 1 receptor antagonist gene (IL1RN) 8.2.1 
rs2419598    
Interleukin 23 receptor gene 8.2.1 
rs11209026    
Interleukin 6 signal transducer (gp130, oncostatin M reporter) gene 8.2.1 
rs3730293    
rs3729961    
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Polymorphism Case-control study TDT Section 
Insulin induced gene 2 (INSIG2) 8.2.1 
rs7566605    
Membrane-spanning 4 domains, subfamily F, member 2 gene 8.2.1 
rs569108    
Nel-like 1  8.2.1 
rs1607616    
Peptidyl arginine deiminase, type IV gene 8.2.1 
rs2240340    
Peroxisome proliferator-activated receptor gamma gene 8.2.1 
rs2067819    
rs3892175    
Prostaglandin E receptor 4 (subtype EP4) gene 8.2.1 
rs1992660    
Protein tyrosine phosphatase, non-receptor type 22 gene 8.2.1 
rs2476601    
Runt-related transcription factor 1 gene (RUNX1) 8.2.1 
rs2268277    
Solute carrier family 22,(organic cation transporter),member 4 gene 8.2.1 
rs1050152    
Solute carrier family 22,(organic cation transporter),member 5 gene 8.2.1 
rs11739135    
Tumour necrosis factor (TNF superfamily, member 2) gene 8.2.1 
rs1799964    
rs1800629    
Tumour necrosis factor superfamily, member 1A gene 8.2.1 
rs767455    
Tumour necrosis factor superfamily, member 1B gene (TNFRSF1B) 8.2.1 
rs3397    
Tumour necrosis factor (ligand) superfamily, member 15 gene 8.2.1 
rs6478108    
rs7848647    
 Not associated with TB susceptibility. 
 Associated with TB susceptibility. 
a
 No TDT was done for this X-linked polymorphism, since one sample from each family 
was used to increase the sample numbers of the case-control study. 
 
Twelve candidate genes which could regulate interferon gamma (IFN-γ) levels during 
TB were selected from literature searches.  Two polymorphisms, in SH2D1A and TLR2, 
had significant associations with TB in the case-control studies.  In addition, a novel 
allele of a microsatellite was identified in the study population.  Since most of these 
IFN-γ-regulating genes on their own were not identified as genetic susceptibility factors 
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for TB in this study, it is possible that their combined effect on the production of this 
cytokine may contribute to disease in the South African Coloured population.  This is a 
future study direction. 
 
Susceptibility genes from granulomatous diseases other than TB, namely sarcoidosis 
and Crohn’s disease (CD), were investigated.  We did not detect any association of the 
polymorphisms tested in these genes (BTNL2, CARD15) with TB susceptibility in the 
South African Coloured population.  In addition, 15 novel single nucleotide 
polymorphisms (SNPs) in BTNL2 were identified from resequencing samples from the 
South African Coloured population.   
 
We selected two genes (TEX264, SOCS3), derived from an expression-array analysis, to 
investigate as novel candidate genes for TB susceptibility.  During this study, 2 novel 
polymorphisms were identified in the samples from the South African Coloured 
population.  No statistical associations were found between selected polymorphisms in 
the two genes and TB.  A candidate gene (CTSZ) located in a region that was previously 
identified as containing TB susceptibility genes was investigated as a susceptibility 
gene, but we detected no association.   
 
In an exploratory study, we tested the involvement of various known functional 
polymorphisms involved in other immune-mediated diseases, in TB susceptibility.  Four 
SNPs in CIITA, RUNX1, IL1RN and TNFRSF1B were associated with TB susceptibility 
in the case-control analyses, while one SNP in INSIG2 was associated in the TDT.  
 
Even though this work did not replicate several previously described associations, it is 
still of value.  Association results that are not statistically significant or are negative are 
often not published, which makes it difficult to interpret the real importance of a 
reported association.  Some of the previously published associations considered during 
our study had extremely low sample numbers and were therefore underpowered.  The 
lack of reproducibility of certain associations could also be a result of ethnic-specific 
associations.  Alternatively, polymorphisms could have smaller effect sizes in the South 
African Coloured population than we were able to detect with our sample. 
 
The human immune system consists of a complex network of interacting pathways 
which protect against infection.  Some of these pathways are redundant and when a 
defect is present they may compensate for each other.  Within pathways, components 
may also be redundant.  For this reason it is extremely difficult to detect the effect of a 
single gene polymorphism, which could be one explanation for why we did not find 
statistical associations with certain SNPs.  A proposed solution to this is to consider all 
the genes in a pathway known to be involved in TB, which may mean that single SNP 
and candidate gene analysis might become of less importance individually, and require 
consolidation. 
 
The South African Coloured population, a unique admixed population, is likely to have 
more variability than white populations in various genes, due to African admixture.  In 
addition, stronger LD is expected in admixed populations than in more ethnically 
homogenous populations [578,675].  This was observed in the LD analyses in our study 
when comparative analyses between the South African Coloured and other populations 
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were done.  LD, which refers to the linkage of alleles at different sites along the 
chromosome, is an important tool in disease susceptibility studies, since it can be used 
to identify the functional markers that contribute to the disease without genotyping 
every known polymorphism in the gene region.  This feature of admixed populations is 
another advantage of using the South African Coloured population in association 
studies. 
 
In spite of its strengths as discussed above, this research had certain limitations: 
1) The polymorphisms selected for genotyping in this study were all located in or 
around protein-coding genes, based on the dogma that most DNA that determines 
phenotype and form is expressed as proteins.  However, DNA sequences in introns or 
intergenic regions that do not encode proteins or cis-acting regulatory elements are also 
transcribed in humans and have biological functions [676].  In addition, the existence of 
numerous intercalated transcripts spanning the majority of the genome has been 
established [677].  Therefore the view of the genome as having a limited set of loci 
transcribed independently is oversimplified.  Since these mechanisms are not currently 
understood, we did not include polymorphisms located in intergenic DNA in our 
research at this stage.  
 
2) A hypothesis that genetic polymorphisms are not the only inherited features of DNA 
which may influence disease susceptibility has been considered for several years [678].  
Epigenetic mechanisms, such as DNA methylation, RNA interference and histone 
acetylation, regulate the transcription rate and/or tissue-specific expression of certain 
genes without altering the primary nucleotide sequence of the DNA.  These DNA 
features have been shown to be transmitted to subsequent generations, but they may also 
be influenced by the environment [678].  However, this inheritance is not as stable as 
DNA-based inheritance and it is not completely elucidated.  It has been shown that 
M.tuberculosis may interfere with epigenetic regulation [679].  Therefore, once the 
inheritance is understood, it is possible that these epigenetic mechanisms may be found 
to play a role in host susceptibility to TB.  However, this was not studied here. 
 
3) Due to the high incidence of latent TB infection in the control community where 
sample collection was done [680], the possible associations of the SNPs with TB were 
tested in disease progression only.  It is not clear whether a different set of genes may be 
involved in infection versus progression to disease, as has been supposed for solute 
carrier family 11, member 1 gene (SLC11A1) [213].  It is therefore still possible that the 
polymorphisms studied here are associated with primary infection in the South African 
Coloured population.   
 
4) Certain polymorphisms could not be genotyped during this research, due to 
limitations of the genotyping methods, such as the SNPlex™ Genotyping System. 
 
5) The number of families for the TDTs was not large enough to have the same power 
as the case-control association studies.  This complicated the interpretation of the 
results, since TDTs were used as a secondary means to judge the validity of the 
significant association results found for the case-control studies.  It is unlikely that the 
discrepant results in the TDTs were due to population stratification, as this was 
excluded in previous work on this population [176].  However, this does not mean that 
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the family-based study design is not a good validation study.  If the number of families 
is equal to the number of cases available, TDTs will have enough power to replicate 
associations found in case-controls studies [280] as shown previously by Valentonyte et 
al [289] and others. 
 
6) TB is a complex disease and several genes may make small contributions to the 
disease outcome.  It is possible that our study did not have enough power to detect these 
small effect sizes, especially for SNPs that had allele frequencies less than 5% in the 
South African Coloured population.  However, very few low frequency SNPs (n = 15) 
were studied. 
 
7) During this research we did not make use of all available single-SNP tests.  Since it is 
not known what amount of disease-susceptibility polymorphisms are dominant, 
recessive or additive, the design of optimal analyses is not possible and it is up to the 
researcher to decide which test is more suited for analysis of the available data [74].  
Our research tested the null hypothesis of no association between rows and columns of 
the 2 x 3 table among cases and controls.  Other single-SNP tests not considered in this 
study include the Cochran-Armitage test, logistic regression and linear regression.  
However, any statistical analysis can only give an indication of a genetic association.  
The functional validation of reported associations is therefore necessary.   
 
8) Statistical genetics should include correction for multiple testing and this was done in 
this study, either by Bonferroni correction as suggested by Nicodemus et al [76] or by 
permutation testing.  However, the possibility exists that these tests may be too stringent 
and that correcting for multiple tests may lead to the exclusion of a true susceptibility 
variant.   
 
Future work would include the replication of the associations found in this study.  This 
should preferably be done in a population that is ethnically distinct from the South 
African Coloured population.  In addition, the combined effect of TB susceptibility 
genes should be studied and functionality of the associated polymorphisms should be 
tested.  A genome-wide association (GWA) study in this unique TB population would 
provide a wealth of data if markers that represent the most common variation in the 
South African Coloured population and which cover the whole genome are determined.  
Ideally, such an experiment should be done using genome-wide SNP arrays [681]. This 
microarray-based method allows access to large amounts of genetic information.  A 
SNP array that allows genotyping of more than 900 000 SNPs [682] was recently 
released.   Alternatively, mapping by admixture linkage disequilibrium (MALD), could 
be considered [683].  This method employs the strong LD in admixed populations, such 
as the South African Coloured population, to localise disease gene polymorphisms 
which have different allele frequencies in the parental populations of the admixed 
population.  The parental populations should differ in the incidence of the disease 
studied [578].  Such a study in the South African Coloured population will therefore be 
feasible, since it is known that at least two of the parental populations, namely 
Europeans and African blacks, have different incidences of TB. 
 
The idea that TB is not only influenced by the bacterium, but also by both genetic and 
environmental factors, was restated by Rene Dubos 55 years ago [684].  Dubos was also 
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of the opinion that medical solutions alone would not prevent or cure TB.  It is obvious 
that this has been the case so far.  However, Dubos did not consider the possible effect 
of research in the field of human genetic susceptibility to TB.  Even though this research 
is years from being clinically applied, it is likely that in the coming era of personalised 
medicine, which may arrive faster than we imagine, it will be possible to test individuals 
for their susceptibility to a number of diseases with a genetic component, including TB.  
This would allow identification of more vulnerable individuals in the population who 
may need different vaccination strategies or prolonged treatment when exposed to 
M.tuberculosis. 
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A.1. BUFFERS AND SOLUTIONS 
19.1 g di-sodium tetraborate decahydrate 20X Sodium boride buffer  
(SB buffer): 500 ml dH2O 
  
93.06 g EDTA.2H2O 
Approximately 10 g NaOH pellets 
Add 400 ml distilled water 
Adjust the pH to 8.0 using the NaOH pellets.  
Make up to 500 ml 
EDTA: 
Autoclave and store at room temperature 
  
10 g Bacto-tryptone 
10 g NaCl 
5 g Bacto yeast 
Add 1 liter of water 
Luria broth (LB): 
Autoclave 
  
1.9 g Bacto-agar added to 1 l of autoclaved LB 
400 µl 20mg/ml X-Gal 
250 µl 100mM ampicillin 
LB/ampicillin/X-Gal plates: 
Plates were poured and stored at 4 degrees 
  
5 g tryptone 
1.25 g yeast extract 
0.125 g NaCl 
Make up to 250 ml 
Autoclave 
2.5 ml 0.25M KCl 
1.25 ml 2M MgSO4 
Super Optimal Broth (SOB): 
25 µl 5M NaOH 
  
  
12.5 ml SOB 
200 µl glucose 
SOB with added glucose 
(SOC): 
100 µl 1mM MgCl2 
  
1.21 g Tris-HCl  
0.372 g EDTA 
Add approximately 800ml distilled water and mix.   
Adjust the pH to 8.0 with concentrated HCl 
Make up to a final volume of 1 liter  
TE: 
Autoclave 
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A.4. SOFTWARE 
Cocaphase ..... MRC Human Genome Mapping Project  UK 
GeneMapper v3.5.1 ..... Applied Biosystems Germany 
GeneMapper v3.7 ..... Applied Biosystems South Africa 
Haploview v3.3 ..... Daly lab, Broad Institute USA 
LIMS ..... IKMB Germany 
Nanodrop v3.0.1 ..... Inqaba Biotechnology South Africa 
Sequencher v4.2 ..... Gene Codes Corporaration USA 
SDS 2.0 ..... Applied Biosystems Germany 
SGCaller ..... IKMB  Germany 
 
A.5. ONLINE RESOURCES 
BLAST ..... www.ncbi.nlm.nih.gov/BLAST 
CHIP Bioinformatics ..... snpper.chip.org/bio/snpper-enter 
dbSNP ..... www.ncbi.nlm.nih.gov/SNP 
Genetic Power Calculator ..... pngu.mgh.harvard.edu/~purcell/gpc/ 
HapMap ..... www.hapmap.org 
Human BLAT search ..... genome.ucsc.edu/cgi-bin/hgBlat 
myScience Environment ..... myscience.appliedbiosystems.com 
SNPInspector ..... www.genomatix.de/products/SNPInspector 
PubMed ..... www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed 
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A.6. POLYMORPHISMS DETECTED DURING BTNL2 SEQUENCING 
TABLE A1. SNPs detected during BTNL2 sequencing. 
Allele  
frequencies 
Exon  
amplified 
SNP  
location 
Chromosome 
6 
position 
rs-number 
Allele   Cases Controls 
G 0.587 0.417 
Promoter 32,485,094 rs9268504 
C 0.413 0.583 
G 0.542 0.354 
Promoter 32,485,039 rs9268503 
A 0.458 0.646 
G 0.541 0.583 
Promoter 32,484,910 rs9268502 
A 0.484 0.417 
C 0.458 0.646 
Promoter 32,484,860 rs9268501 
A 0.542 0.354 
G 0.604 0.5 
Promoter 32,484,766 rs3763317 
A 0.396 0.5 
G 0.938 0.896 
5' UTR 32,484,724 rs3763316 
A 0.063 0.104 
C 0.979 0.979 
Intron 32,484,632 rs3763315 
A 0.021 0.021 
G 0.458 0.271 
1 
Intron 32,484,596 rs3763314 
A 0.542 0.729 
G 0.042 0 
Exon 32,482,843 none 
A 0.958 1 
C 0.833 0.87 
Intron 32,482,618 rs3763308 
T 0.167 0.13 
T 0.938 0.891 
Intron 32,482,600 rs3763307 
A 0.063 0.109 
C 0.104 0.065 
2 
Intron 32,482,573 rs2395159 
T 0.896 0.935 
G 0.979 1 Exon  
boundary 
32,481,042 none 
A 0.021 0 
C 0.979 1 
Exon 32,481,037 none 
T 0.021 0 
C 0.826 0.833 
Exon 32,480,941 BTNL2_ex3_101 
T 0.174 0.167 
G 0.977 1 
Exon 32,480,940 none 
A 0.023 0 
A 0.167 0.167 
3 
Exon 32,480,841 BTNL2_ex3_201 
T 0.833 0.833 
A 0.833 0.813 
Intron 32,477,681 rs3834855 
- 0.167 0.188 
C 0.167 0.188 
Intron 32,477,621 rs3763306 
T 0.833 0.813 
G 1 0.979 
4 
Intron 32,477,579 none 
A 0 0.021 
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Allele  
frequencies 
Exon  
amplified 
SNP  
location 
Chromosome 
6 
position 
rs-number 
Allele   Cases Controls 
G 0.022 0.022 
Intron 32,472,192 rs2076527 
A 0.978 0.978 
T 0.977 0.978 
Intron 32,472,172 rs2076528 
G 0.023 0.022 
C 0.021 0.042 
Intron 32,472,168 none 
T 0.979 0.958 
G 0.979 0.979 
Exon 32,472,035 PM15830 
A 0.021 0.021 
G 0.979 0.979 
Exon 32,472,030 PM15835 
A 0.021 0.021 
A 0.979 0.979 
Exon 32,472,024 PM15841 
T 0.021 0.021 
G 0.021 0.021 
Exon 32,471,989 PM15876 
A 0.979 0.979 
G 0.979 0.979 
Exon 32,471,951 PM15914 
A 0.021 0.021 
G 0.25 0.271 
Exon 32,471,933 rs2076529 
A 0.75 0.729 
G 0.979 0.979 
Exon 32,471,866 PM15999 
A 0.021 0.021 
G 0.938 0.896 
Exon 32,471,822 rs9268480 
A 0.063 0.104 
G 0.25 0.271 Exon  
boundary 
32,471,794 rs2076530 
A 0.75 0.729 
C 0.021 0.021 
Intron 32,471,768 PM16097 
T 0.979 0.979 
C 0.958 0.979 
Intron 32,471,764 PM16101 
T 0.042 0.021 
C 0.818 0.854 
5 
Intron 32,471,752 ss38346939 
T 0.182 0.146 
G 0.833 0.854 
Intron 32,470,908 rs12528939 
A 0.167 0.146 
C 0.833 0.854 
Intron 32,470,810 rs17202435 
T 0.167 0.146 
C 0.886 0.909 
Exon 32,470,723 BTNL2_ex6_58 
T 0.114 0.091 
G 0.864 0.864 
Exon 32,470,719 BTNL2_ex6_62 
A 0.136 0.136 
C 0.833 0.854 
Exon 32,470,681 BTNL2_ex6_100 
A 0.167 0.146 
G 0.13 0.109 
Exon 32,470,680 BTNL2_ex6_101 
A 0.87 0.891 
6 
Exon 32,470,647 BTNL2_ex6_134 C 0.167 0.146 
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Allele  
frequencies 
Exon  
amplified 
SNP  
location 
Chromosome 
6 
position 
rs-number 
Allele   Cases Controls 
A 0.833 0.854 
T 0.167 0.146 
Exon 32,470,617 BTNL2_ex6_164 
C 0.833 0.854 
C 0.188 0.146 
Intron 32,470,431 PM17434 
T 0.813 0.854 
G 0.958 0.938 
Intron 32,470,425 none 
A 0.042 0.063 
G 0.833 0.909 
Intron 32,470,411 PM17454 
T 0.167 0.091 
C 0.771 0.813 
Intron 32,470,394 rs2076534 
A 0.229 0.188 
C 0.826 0.848 
Intron 32,470,310 PM17479 
T 0.174 0.152 
C 0.063 0.042 
Intron 32,469,872 none 
T 0.938 0.958 
G 0.958 0.958 
Intron 32,469,834 none 
A 0.042 0.042 
C 0.958 0.958 
Intron 32,469,820 none 
T 0.042 0.042 
G 0.042 0.042 
Intron 32,469,819 none 
A 0.958 0.958 
G 0.896 0.938 
Exon 32,469,799 rs3129953 
A 0.104 0.063 
A 0.958 0.958 
Exon 32,469,787 none 
G 0.042 0.042 
C 0.958 0.958 
Exon 32,469,740 none 
T 0.042 0.042 
G 0.958 0.958 
Exon 32,469,730 none 
A 0.042 0.042 
C 0.958 0.958 
Exon 32,469,727 none 
G 0.042 0.042 
C 1 0.958 
Intron 32,469,672 rs17202428 
T 0 0.042 
C 0.958 0.958 
Intron 32,469,655 rs17202414 
T 0.042 0.042 
C 0.958 0.958 
Intron 32,469,591 rs17202407 
T 0.042 0.042 
A 0.958 0.958 
Intron 32,469,590 rs17208769 
G 0.042 0.042 
G 0.958 0.958 
7 
Intron 32,469,588 rs17208762 
A 0.042 0.042 
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amplified 
SNP  
location 
Chromosome 
6 
position 
rs-number 
Allele   Cases Controls 
A 0.188 0.146 
Exon 32,469,108 rs3817972 
G 0.813 0.854 
G 0.729 0.729 
Exon 32,469,089 rs3817973 
A 0.271 0.271 
A 0.833 0.854 
Exon 32,469,058 rs17208699 
C 0.167 0.146 
A 0.826 0.833 
Intergenic 32,469,013 rs3817974 
G 0.174 0.167 
T 0.864 0.891 
Intergenic 32,469,008 rs3817975 
A 0.136 0.109 
A 0.167 0.146 
Intergenic 32,468,981 rs3817976 
G 0.833 0.854 
A 0.864 0.891 
Intergenic 32,468,965 rs3817977 
C 0.136 0.109 
A 0.143 0.13 
Intergenic 32,468,964 rs3817978 
G 0.857 0.87 
C 0.979 0.979 
Intergenic 32,468,961 rs3817979 
T 0.021 0.021 
A 0.167 0.146 
Intergenic 32,468,948 rs3817980 
G 0.833 0.854 
C 0.833 0.854 
Intergenic 32,468,933 rs17202316 
T 0.167 0.146 
G 0.188 0.146 
Intergenic 32,468,923 rs3817981 
A 0.813 0.854 
C 0.042 0.104 
Intergenic 32,468,893 rs13198563 
T 0.958 0.896 
C 0.792 0.813 
8 
Intergenic 32,468,827 rs17208671 
A 0.208 0.188 
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